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ABSTRACT OF DISSERTATION

THE INTRANASAL DELIVERY OF DNSP-11 AND ITS EFFECTS IN ANIMAL MODELS
OF PARKINSON’S DISEASE
A major challenge in developing disease altering therapeutics for the treatment of
Parkinson’s disease (PD) has been the delivery of compounds across the blood-brain
barrier (BBB) to the central nervous system (CNS). While direct surgical infusion has
been utilized to deliver compounds to the brain that don’t cross the BBB, issues of poor
biodistribution in the CNS due in part to properties of the molecules being delivered
and/or infusion device protocols have limited the widespread success of this invasive
approach. To avoid the issues of surgically delivering compounds to the CNS, numerous
studies have examined the use of intranasal administration as a non-invasive delivery
method. The data presented in this dissertation examines intranasal administration of
dopamine neuron stimulating peptide-11 (DNSP-11), a small, amidated peptide with
neuroprotective and restorative properties, and its effects on the nigrostriatal system in
animal models of PD.
Here we demonstrate that severely lesioned 6-hydroxydopamine (6-OHDA) F344
rats repeatedly administered DNSP-11 intranasally exhibited a decrease in damphetamine-induced rotation, dopamine (DA) turnover, and an increase in tyrosine
hydroxylase positive neuronal sparing. Additionally, tracer studies indicated rapid
distributed throughout the CNS and CSF following a one-time bilateral intranasal dose of
125
I-labeled DNSP-11. These results demonstrate that DNSP-11 can be delivered to the
CNS intranasally, and maintains its neuroactive properties on the nigrostriatal system in
a rat model of PD.
In a dose escalation study of DNSP-11, we evaluated the efficacy of repeated
intranasal administration in awake, vertically chaired trained, 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) hemiparkinsonian rhesus macaques using an atomizer
system over a 10-week period. Here we report that animals did not exhibit observable
adverse effects at the DNSP-11 concentrations examined, bilateral increases in fine
motor performance of the upper limbs, and changes in tissue levels of DA and its
metabolites. Finally, tracer studies indicated signal present throughout the CNS and CSF
following a one-time bilateral intranasal dose of 125I-labeled DNSP-11. These studies
support the efficacy of the repeated intranasal administration of DNSP-11 in awake
rhesus macaques over 10-weeks, while also enhancing motor performance and striatal
neurochemistry in a non-human primate model of PD.

KEYWORDS:

6-OHDA rat, MPTP non-human primate, intranasal, DNSP-11

Mallory J. Stenslik
October 30, 2015

THE INTRANASAL DELIVERY OF DNSP-11 AND ITS EFFECTS IN ANIMAL MODELS
OF PARKINSON’S DISEASE

By

Mallory Joan Stenslik

Dr. Luke H. Bradley
Director of Dissertation

Dr. Wayne A. Cass
Director of Graduate Studies

October 30, 2015

ACKNOWLEDGEMENTS

First and foremost I would like to thank my mentor, Dr. Luke H. Bradley, for his
confidence in my abilities, project, and his unwavering support throughout my time as a
graduate student. He has shaped me into the scientist I’ve hoped to become, and will
always be a guiding post as I navigate through life and my career. I would also like to
thank Dr. Greg A. Gerhardt, an irreplaceable individual on my committee that has
shaped me as a scientist, who has always believed in my abilities, and never lost sight of
what we were trying to accomplish with my project. Thank you both for teaching me the
art of experimental design and helping me succeed, for which I am forever grateful.
I would also like to thank my committee members Dr. Guoying Bing, Dr. Franca Cambi,
Dr. John Slevin, and Dr. Don Gash for their input on my projects, especially Dr. Patrick
Sullivan and Dr. Wayne Cass for the one-on-one time they have spent in lab with me
teaching me their craft. Their expertise in mitochondria and HPLC respectively has
played a vital role in the development and success of my project. I would also like to
thank Dr. Bjorn Bauer for serving as the outside examiner on my committee.
Special thank you to Dr. Richard Grondin for his advice throughout my graduate
school career, and all of the time he has spent helping me grow as a scientist. To the
Gerhardt lab, especially Francois Pomerleau M.Sc., Pete Huettl M.S., and Dr. Jorge
Quintero thank you for your help and advice with everything. I would also like to thank
Dr. Jadwiga Turchan-Cholewo for her work in developing our understanding of DNSP11, Dr. Yi Ai for her help with immunohistochemistry, and Dr. Zhiming Zhang for his
neurosurgical expertise. To Matt Hazzard and Tom Dolan of the University of Kentucky
Academic Technology Group for the medical illustrations included in this body of work,
and Dr. Anders Anderson of the University of Kentucky Magnetic Resonance Imaging
and Spectroscopy Center for his assistance with autoradiography, thank you. I would
also like to thank April Evans, Ryan Weeks, and Eric Forman for all of their assistance in
lab. To my girls, Dr. Heather Yonutas, Dr. Meagan Littrell, Dr. Erin Miller, April Evans,
Stacey Reid, Robin Lindsay, Kathryn Bickel, and Avalon Sandoval, thank you for your
friendship.
I would also like to thank and dedicate this work to my family Colleen, Tom, Cara,
and Robert Stenslik, my grandparents, and Tarah Sperando for all of their love and

iii

support. Lastly to Mathew Strike, the love of my life, thank you for your friendship,
support, and unwavering confidence in me.

iv

Table of Contents

ACKNOWLEDGEMENTS ............................................................................................... iii
List of Tables ................................................................................................................ viii
List of Figures ................................................................................................................. ix
CHAPTER ONE: INTRODUCTION ................................................................................. 1
Introduction to Parkinson’s disease (PD) .................................................................... 1
Dopamine Synthesis and Metabolism ......................................................................... 3
Toxin-Induced Animal Models of PD ........................................................................... 5
Options for the Symptomatic Treatment of PD ............................................................ 8
Levodopa (The Gold Standard of Treatment for PD) ............................................... 8
Deep Brain Stimulation (DBS) ................................................................................. 9
Disease Modifying Approaches for the Potential Treatment of PD .............................10
Glial Cell Line-Derived Neurotrophic Factor (GDNF) ..............................................10
Dopamine Neuron Stimulating Peptide-11 (DNSP-11)............................................12
Delivery of Protein Biotherapeutics to the CNS for the Treatment of Parkinson’s
Disease ......................................................................................................................14
The Blood-Brain Barrier (BBB) ...............................................................................14
Convection Enhanced Delivery (CED) ....................................................................15
Viral Vectors ...........................................................................................................16
Intranasal Delivery ..................................................................................................17
Chapter One: Figures ................................................................................................19
Dissertation Overview ................................................................................................24
CHAPTER TWO: Materials and Methods ...................................................................... 25
RAT STUDIES ...........................................................................................................25
Reagents ................................................................................................................25
Ethics Statement ....................................................................................................25
Intranasal Administration of DNSP-11 ....................................................................25
Dose Response in Normal Rats (HPLC-EC neurochemical analysis) .....................26
Unilateral, 3-site, 6-OHDA Striatal Lesion ...............................................................27
d-Amphetamine-Induced Rotation in 6-OHDA-Lesioned Rats ................................27
DA and DA Metabolite levels in the Striatum of 6-OHDA Lesioned Rats.................28

v

Tissue Processing for TH+ Neurons in the SN of 6-OHDA Lesioned Rats ..............28
TH+ Neurons and Fiber Density in 6-OHDA Lesioned Rats....................................29
Modification (R9K) of DNSP-11 for 125I Tracer Studies ...........................................29
Distribution Studies (Gamma Counting & Autoradiography) in Normal Rats ...........29
125

I-Labeled DNSP-11 Mitochondrial Import Assay .................................................30

NON-HUMAN PRIMATE STUDIES............................................................................32
Reagents ................................................................................................................32
Ethics Statement ....................................................................................................32
Animals and MPTP administration ..........................................................................32
Atomizer Design and Calibration ............................................................................33
Vertical Chair Training and Acclimation to Atomizer ...............................................34
Experimental Timeline ............................................................................................35
Intranasal Administration Procedure .......................................................................35
Cage-Side Observations and Body Weight Measurements ....................................36
monkey Movement Assessment Panel (mMAP) .....................................................36
Videorecording for EthoVision Analysis ..................................................................37
Tissue

Processing

for

Neurochemical

Analysis,

Gamma

Counting

and

Autoradiography .....................................................................................................38
Neurochemical Analysis of Dopamine, Serotonin, and Metabolite Levels in the
Striatum ..................................................................................................................39
Gamma Counting and Autoradiography Analysis ...................................................39
CHAPTER THREE: Methodology and Effects of Repeated Intranasal Delivery of DNSP11 in a Rat Model of PD ................................................................................................ 41
Introduction ................................................................................................................41
Methods and Materials ...............................................................................................42
Ethics Statement ....................................................................................................42
Materials.................................................................................................................43
Intranasal Administration of DNSP-11 ....................................................................43
Dose Response in Normal Rats (HPLC-EC Neurochemical Analysis) ....................44
Unilateral, 3-site, 6-OHDA Striatal Lesion ...............................................................44
d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats.................................45
Cylinder Forepaw Asymmetry Test .........................................................................45
DA and DA Metabolite Levels in the Striatum of 6-OHDA Lesioned Rats ...............46
Tissue Processing for TH+ Neurons in the SN of 6-OHDA Lesioned Rats ..............46
vi

TH+ Neurons and Fiber Density in 6-OHDA Lesioned Rats....................................47
Modification (R9K) of DNSP-11 for 125I Tracer Studies ...........................................47
Distribution Studies (Gamma Counting & Autoradiography) in Normal Rats ...........48
125

I-Labeled DNSP-11 Mitochondrial Import Assay .................................................49

Statistical Analysis ..................................................................................................50
Results.......................................................................................................................50
Dose Response of DNSP-11 in Normal Rats ..........................................................50
d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats.................................51
Cylinder Forepaw Asymmetry Test in 6-OHDA Lesioned Rats ...............................51
Tissues Levels of DA and DA Metabolites in the Striatum of Unilateral 6-OHDALesioned Rats ........................................................................................................52
TH+ Neurons and Fiber Density .............................................................................52
Distribution Studies Following Intranasal Administration .........................................53
Discussion .................................................................................................................54
Chapter Three: Figures and Tables ...........................................................................58
CHAPTER FOUR: Methodology and Effects of Repeated Intranasal Administration in
Awake Hemiparkinsonian Rhesus Macaques ................................................................ 75
Introduction ................................................................................................................75
Materials and Methods ...............................................................................................77
Materials.................................................................................................................77
Non-Human Primates and MPTP Administration ....................................................77
Atomizer Design and Calibration ............................................................................78
Vertical Chair Training and Acclimation to Atomizer ...............................................79
Daily Intranasal Administration of DNSP-11 in NHPs..............................................80
Experimental Timeline ............................................................................................81
Cage-Side Observations and Body Weight Measurements ....................................81
monkey Movement Assessment Panel (mMAP) .....................................................81
Videorecording for EthoVision Analysis ..................................................................82
Tissue

Processing

for

Neurochemical

Analysis,

Gamma

Counting

and

Autoradiography .....................................................................................................83
Neurochemical Analysis of Dopamine, Serotonin, and Metabolite Levels ...............84
in the Striatum ........................................................................................................84
Statistical Analysis ..................................................................................................85
Results.......................................................................................................................86
vii

Body Weight and Cage-Side Observations.............................................................86
Changes in Motor Performance ..............................................................................86
Neurochemical Changes in the Left (Unlesioned) Hemisphere ...............................87
Neurochemical Changes in the Right (Lesioned) Hemisphere ................................89
Gamma Counting and Autoradiography..................................................................91
Discussion .................................................................................................................92
Chapter Four: Figures and Tables .............................................................................98
CHAPTER FIVE: Major Conclusion and Future Directions .......................................... 140
References .................................................................................................................. 144
Vita .............................................................................................................................. 175

List of Tables
Table 3.1. Average Tissues Levels of DA and DA Metabolites in Normal Rats after
Repeated Intranasal Administration of DNSP-11. ..........................................................64
Table 3.2. Average Tissues Levels of DA and DA Metabolites in Unilaterally 6-OHDA
Lesioned Rats after Repeated Intranasal Administration of DNSP-11. ..........................65
Table 3.3. The Effects of Repeated Intranasal Administration of DNSP-11 on TH + Fiber
Density in the SNpr in Unilateral 6-OHDA Lesioned Rats. .............................................69
Table 3.4. Tissue 125I Levels in Normal Rats After a One-Time Bilateral Dose. ..............70
Table 4.1. Average Tissue Levels of DA and Metabolites for Both the Left (Unlesioned)
and Right (Lesioned) Hemispheres. ............................................................................109
Table 4.2. Average DA Turnover Rations in Both the Left (Unlesioned) and Right
(Lesioned) Hemispheres..............................................................................................110
Table 4.3 Lesion Severity Groupings in DNSP-11 and Vehicle Treated NHPs.............111
Table 4.4 The Average Tissue Level of 5-HT, 5-HIAA, NE, and 5-HIAA/5-HT Turnover in
Both the Left (Unlesioned) and Right (Lesioned) Hemispheres. ..................................112
Table 4.5.

125

I Signal in the CNS and Peripheral Samples 60 Minutes After the Start of

the First Intranasal Dose..............................................................................................134

viii

List of Figures
Figure 1.1 The Indirect and Direct Pathways ................................................................. 19
Figure 1.2 Classic DA Synthesis, Release, and Metabolism .......................................... 20
Figure 1.3 DNSP-11 Sequence ..................................................................................... 21
Figure 1.4 Transport Mechanism after Intranasal Administration ................................... 22
Figure 3.1 Diagram for Intranasal Administration in Rats ............................................... 58
Figure 3.2 Experimental Timeline for Rat Studies .......................................................... 59
Figure 3.3 HPLC-EC Studies of DA Turnover in Normal Rats ........................................ 61
Figure 3.4 d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats ....................... 62
Figure 3.5 Cylinder Test in 6-OHDA Lesioned Rats ....................................................... 63
Figure 3.6 HPLC-EC Studies of DA Turnover in 6-OHDA Lesioned Rats ...................... 66
Figure 3.7 Representative Sections for TH+ Neuronal Cell Counts in 6-OHDA Lesioned
Rats ............................................................................................................................... 67
Figure 3.8 TH+ Neuronal Cell Counts in 6-OHDA Lesioned Rats .................................. 68
Figure 3.9 One-Time 125I-Labeled DNSP-11 Intranasal Dose in Normal Rats ................ 71
Figure 3.10 Modified (R9K) DNSP-11 Study In Vitro...................................................... 73
Figure 3.11 Import of 125I-Labeled DNSP-11 in Isolated CNS Mitochondria ................... 74
Figure 4.1 Experimental Timeline for Dose Escalation Study of Intranasally Administered
DNSP-11 in NHPs ......................................................................................................... 98
Figure 4.2 Diagram for Intranasal Administration in NHPs ............................................. 99
Figure 4.3 Atomizer System for Intranasal Administration in NHPs .............................. 100
Figure 4.4 Brain Slabs and Tissue Punch Sites for Neurochemical Analysis ............... 101
Figure 4.5 Body Weight Measurements in NHPs ......................................................... 102
Figure 4.6 Fine (Hand) Motor Performance in DNSP-11 Treated NHPs ...................... 104
Figure 4.7 Coarse (Arm) Motor Performance in DNSP-11 Treated NHPs .................... 105
Figure 4.8 Fine (Hand) Motor Performance in Vehicle Treated NHPs .......................... 106

ix

Figure 4.9 EthoVision Analysis in Vehicle versus DNSP-11 Treated NHPs ................. 107
Figure 4.10 Ethovision Analysis of DNSP-11 Treated NHPs........................................ 108
Figure 4.11 Average Tissue Levels of DA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 113
Figure 4.12

Average Tissue Levels of DOPAC at Individual Tissue Punch Sites in

Vehicle versus DNSP-11 Treated NHPs ...................................................................... 115
Figure 4.13 Average Tissue Levels of HVA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 117
Figure 4.14 Ratio of DOPAC/DA at Individual Tissue Punch Sites in Vehicle versus
DNSP-11 Treated NHPs .............................................................................................. 119
Figure 4.15 Ratio of HVA/DA at Individual Tissue Punch Sites in Vehicle versus DNSP11 Treated NHPs ......................................................................................................... 121
Figure 4.16 Ratio of [(DOPAC+HVA)/DA] at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 123
Figure 4.17 Average Tissue Levels of DA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 125
Figure 4.18 Average Tissue Levels of DOPAC at Individual Tissue Punch Sites in
Vehicle versus DNSP-11 Treated NHPs ...................................................................... 126
Figure 4.19 Average Tissue Levels of HVA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 127
Figure 4.20 Ratio of DOPAC/DA at Individual Tissue Punch Sites in Vehicle versus
DNSP-11 Treated NHPs .............................................................................................. 128
Figure 4.21 Ratio of HVA/DA at Individual Tissue Punch Sites in Vehicle versus DNSP11 Treated NHPs ......................................................................................................... 129
Figure 4.22 Ratio of [(DOPAC+HVA)/DA] at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs .................................................................................. 130
Figure 4.23 Neurochemical Ratios in a Mild Lesion Model After DNSP-11 Treatment . 132
Figure 4.24 125I Signal in Brain Biopsy Tissue Punches Throughout the CNS .............. 133
Figure 4.25 Autoradiography Analysis of 125I Signal in the Rostral Regions of the CNS135
x

Figure 4.26 Corresponding Brain Slabs for Autoradiography Analysis for Rostral Regions
of the CNS ................................................................................................................... 136
Figure 4.28 Corresponding Brain Slabs for Autoradiography Analysis for Caudal Regions
of the CNS ................................................................................................................... 138

xi

CHAPTER ONE: INTRODUCTION

Introduction to Parkinson’s disease (PD)
Parkinson’s disease (PD) is a progressive neurodegenerative disease which is
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta
(SNpc), the subsequent depletion of dopamine (DA) in the striatum, and the presence of
intracytoplasmic inclusion bodies containing α-synuclein (Lewy bodies), for which there
is currently no cure (Lang and Lozano, 1998a, Lang and Lozano, 1998b). The first
complete clinical description of PD, by James Parkinson in 1817, who described several
patients with a shaking palsy (Parkinson, 2002). Almost 200 hundred years after this first
clinical description of PD, great strides have been made in establishing both the genetic
and/or environmental links to the disease (Olanow and Tatton, 1999, Betarbet et al.,
2000, Lücking et al., 2000, Fernandez-Espejo, 2004, Abou-Sleiman et al., 2006, Farrer,
2006, Hardy et al., 2006, Lin and Beal, 2006, Büeler, 2009, Shulman et al., 2011,
Wirdefeldt et al., 2011, Lopert and Patel, 2015). Currently, PD prevalence is estimated at
1 million people in the United States and 7 to 10 million people worldwide (Foundation,
2003); in the United States approximately 60,000 new cases (incidence) are reported
each year (Foundation, 2003). It is estimated that the financial burden associated with
PD in the United States which includes: treatment costs, social security payments, and
loss of income is estimated to be $15-25 billion dollars per year (Foundation, 2003,
Kowal et al., 2013). As age has been shown to be the greatest risk factor for the
development of PD (Bennett et al., 1996, Morens et al., 1996, Alves et al., 2008), and
then the subsequent increase in the aging population (Kowal et al., 2013), the discovery
of disease altering therapies and more efficient CNS drug delivery methods is
imperative.
Currently, it is thought that only 5-10% of PD patients have a genetic form of the
disease which leads to its early on set (Olanow and Tatton, 1999, Alves et al., 2008).
Twin studies in monozygotic twins have illustrated that there is an increased risk in the
development of PD before the age of 50, implicating a strong genetic linkage to the
disease (Tanner et al., 1999). To date, 5 genes have been definitively linked to the
inherited early (SNA, Parkin, PINK1, DF-1) or late (LRRK2) on-set form of PD (Olanow
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and Tatton, 1999, Lücking et al., 2000, Büeler, 2009). Specifically, mutations found in
the genes and the loci of -synuclein (SNCA) at PARK1 & 4, Parkin at PARK2, PTENinduced putative kinase-1 (PINK1) at PINK6, DJ-1 at PARK7, and leucine-rich induced
putative kinase-1 (LRRK2) at PARK8 are found to be autosomally inherited in either a
dominant (SNCA and LRRK2) or recessive (Parkin, DJ-1, PINK1, ATP13A2) fashion
(Olanow and Tatton, 1999, Hardy et al., 2006, Büeler, 2009, Bekris et al., 2010). While
the disease mechanisms of action vary among these mutations (Abou-Sleiman et al.,
2006, Lin and Beal, 2006, Büeler, 2009), in regards to pathology, mutations in PARK1/4
(SNCA), PARK8 (LRRK2) and PARK2 (Parkin) are associated with Lewy body formation
and SNpc dopaminergic cell loss (Gasser, 2001, Hardy et al., 2006).
The remaining approximate 90% of PD cases are thought to be idiopathic, and
are usually diagnosed after the age of 65 (Olanow and Tatton, 1999, Abou-Sleiman et
al., 2006), making age the largest predictor/risk factor for a PD diagnosis (Bennett et al.,
1996, Morens et al., 1996, Alves et al., 2008). PD has also been linked to numerous
environmental toxins including but not limited to paraquat (Costello et al., 2009, Tanner
et al., 2011), rotenone (Betarbet et al., 2000, Sherer et al., 2003, Tanner et al., 2011),
trichloroethylene (TCE) (Gash et al., 2008, Liu et al., 2010, Zaheer and Slevin, 2011)
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al., 1983,
Langston et al., 1984). Such toxins have been associated with either heavy rural farming
areas (Gorell et al., 1998, Dinis-Oliveira et al., 2006, Tanner et al., 2011), industrial
settings (Gash et al., 2008) and famously in drug addicts taking a synthetic heroine
contaminated with MPTP (Langston et al., 1983, Langston et al., 1984). As with many of
these toxins, studies have revealed that there is a decrease in mitochondrial energetics
by approximately 20-40% in the SNpc of PD patients, specifically complex I inhibition of
the electron transport chain (Dawson and Dawson, 2003, Lin and Beal, 2006).
Generally, the mechanisms of neurotoxicity associated with mitochondrial inhibition of
the electron transport chain in PD can include oxidative damage through the production
of reactive oxygen species (ROS), free radical formation and inflammation (Parker et
al., 1989, Fahn and Cohen, 1992, Beal, 2001). While other environmental risk factors do
exist, the focus of this dissertation will be based on those that affect the mitochondrial
transport chain as it pertains to the inhibition of complex I activity.
Typically, motor deficits associated with PD manifest when approximately 50-60
% of the neuromelanin containing dopaminergic neurons in the SNpc are lost, and
approximately 80-85 % of dopamine (DA) is depleted in the striatum (Abou-Sleiman et
2

al., 2006, Wirdefeldt et al., 2011). In PD, the dopaminergic nigrostriatal connections from
the SNpc to the putamen are lost, leading to the deregulation and dysfunction of both the
direct and indirect pathways (Albin et al., 1989, Olanow and Tatton, 1999, Abou-Sleiman
et al., 2006, Wirdefeldt et al., 2011) (Figure. 1.1). The dysregulation and dysfunction of
both pathways can lead to any combination of the hallmark motor signs and symptoms
of PD which include bradykinesia, rigidity, resting tremor, stooped posture, dysphagia,
micrographia, dysarthria and decreases in facial expressions (Hoehn and Yahr, 1998).
Non-motor symptoms may also develop before motor deficits which include the loss of
olfaction, sleep disorders, gastrointestinal dysmotility, and cardiac issues (Braak et al.,
2004, Ross et al., 2008). In the later stages of PD, non-motor symptoms including
depression and cognitive decline become more prominent (Cummings, 1992, Singaram
et al., 1995, Braak et al., 2004, Remy et al., 2005).
To understand the hallmark motor system associated with PD it is important to
understand both the direct (striatonigral) and indirect (striatopallidal) pathways which
play a vital role in the initiation of motor movement (Albin et al., 1989) (Figure 1.1).
Normally, dopaminergic projections from the SNpc play a vital role in both the direct
(striatonigral) and indirect (striatopallidal) pathways involved in the initiation of motor
movements (Albin et al., 1989) (Figure 1.1). The two main classes of DA receptors
involved in located in the dorsal striatum, specifically the putamen, act to modulate the
release of glutamate from the medium spiny neurons, which make up approximately 95
% of the striatum (Figure 1.1) (Bentivoglio and Morelli, 2005, Lobo, 2009). Specifically,
D1 receptors play an excitatory role in the direct pathway, while D2 receptors found in the
indirect pathway path an inhibitory role (Albin et al., 1989) (See Figure 1.1 for details on
the indirect and direct pathways).

Dopamine Synthesis and Metabolism

The hallmark motor deficits associated with PD causally relate to the diminution
of the dopaminergic neuronal population of the nigrostriatal system. While DA synthesis
and release are important, its degradation into its primary metabolites 3,4dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) are key to the
understanding of the neurochemical analysis presented in this dissertation (Meiser et al.,
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2013). Therefore, the main focus of this section will be on the degradation of DA (Please
refer to Figure 1.2 for this section).
The classic pathway of DA synthesis within the CNS occurs in the cytosol of
catecholaminergic neurons, where either L-phenylalanine or L-tyrosine are hydroxylated
by phenylalanine hydroxylase or tyrosine hydroxylase (TH) (Daubner et al., 2011) (Fig.
2). The conversion of L-tyrosine to L-dihydroxyphenylalanine (L-dopa) by TH, the cofactor tetrahydrobiopterin (BH4), and O2 is the major rate-limiting enzymatic step in DA
synthesis (Dunkley et al., 2004, Daubner et al., 2011, Meiser et al., 2013) (Fig. 1.2). The
enzymatic activity of TH is highly regulated because it is the major rate limiting step in
DA synthesis (Zigmond et al., 1989). Short term regulation of TH can occur through the
phosphorylation of one or more of its four serine residues (8, 19, 31 and 40), allosteric
regulation, and/or inhibitory feedback loops (Zigmond et al., 1989, Kumer and Vrana,
1996, Dunkley et al., 2004). Conversely, the long term regulation of TH can occur
through changes in gene expression, transcription, translation, and/or RNA splicing
(Dunkley et al., 2004, Daubner et al., 2011).
The next step in DA synthesis is the conversion of L-DOPA to DA by aromatic
amino acid decarboxylase (AADC) which utilizes B6 (pyridoxal phosphate) as a co-factor
(Kuhn and Lovenberg, 1983) (Figure. 1.2). While not a rate-limiting step in DA synthesis,
AADC like TH is also regulated by gene expression and/or protein modulation (Zhu and
Juorio, 1995, Berry et al., 1996). After the completion of DA synthesis, the
neurotransmitter is taken into synaptic vesicles by vesicular monamine transporter
(VMAT2) (Erickson et al., 1992, Caudle et al., 2008) (Figure 1.2). Upon the release of
DA into the synaptic cleft, it is cleared by its reuptake into the pre-synaptic terminal
mainly through the high-affinity dopamine transporter (DAT) (Figure. 1.2), especially in
certain areas of the striatum that contain large amount of DAT (Aquilonius et al., 1987,
Cass et al., 1993).
Major enzymes involved in the degradation of DA include monoamine oxidase
(MAO) and catechol-o-methyl transferase (COMT) (Elsworth and Roth, 1997).

Two

forms of MAO exists: MAO-A and MAO-B (Elsworth and Roth, 1997). As there are two
different animal models presented in this dissertation, the understanding of speciesspecific differences in DA metabolism are imperative (Garrick and Murphy, 1980). In
humans and non-human primates (NHPs) the majority of DA metabolism has been
shown to occur through MAO-B, while in rats it is MAO-A (Garrick and Murphy, 1980,
Youdim and Riederer, 1993, Smeyne and Jackson-Lewis, 2005). These differences in
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DA metabolism become important when choosing an appropriate toxin and animal
model (see animal models of Parkinson’s diseases).
Both MAO-A and B are located on the outer mitochondrial membrane in the CNS
but have been found in peripheral tissues as well (Meiser et al., 2013) (Figure. 1.2). In
the CNS, MAO-A is important for the metabolism of free cytosolic DA, while MAO-B and
COMT are important for extraneuronal metabolism of DA, for example in glia (Westerink,
1985, Männistö et al., 1992, Youdim and Bakhle, 2006, Meiser et al., 2013) (Figure.1.2).
MAO metabolism of DA occurs by oxidative deamination with the production of 3, 4dihydroxyphenylacetaldehyde (DOPAL) and hydrogen peroxide (Elsworth and Roth,
1997, Eisenhofer et al., 2004, Meiser et al., 2013) (Figure 1.2). For all practical
purposes, DOPAL is immediately converted to 3,4-dihydroxyphenylacetic acid (DOPAC)
through either alcohol dehydrogenase (ADH) or aldehyde dehydrogenease (ALDH); this
energetically favorable pathway makes DOPAC a major metabolite of DA metabolism
(Elsworth and Roth, 1997, Eisenhofer et al., 2004). COMT metabolism of DA leads to
the intermediates 3-methoxytyramine (3-MT) and 3-methoxy-4-hydroxyacetaldehyde by
MAO and ALDH respectively, and the production of another major metabolite of DA
metabolism, homonvanillic acid (HVA) (Meiser et al., 2013; Moussa et al., 2006).
In PD, the surviving dopaminergic neurons act to increase the synthesis and
release of DA to compensate for the large depletions of the DA neurotransmitter, due to
cell death and the functional loss of dying neurons (Bernheimer et al., 1973, Olanow and
Tatton, 1999). This increase in synthesis and metabolism often presents as an increase
in tissue levels of DA metabolites and/or an increase in the ratios of DA and its active
metabolites, DOPAC and HVA (Bernheimer et al., 1973, Olanow and Tatton, 1999). In
human PD incidences and animal models of PD, increases in DA turnover
[(DOPAC+HVA)/DA] are often proportional to the degree of DA depletion, which will be
discussed later in this chapter (Bernheimer et al., 1973, Zigmond et al., 1990). This
makes the measurement and analysis of tissue levels of DA and its metabolites an
important indicator of dopaminergic function and/or dysfunction.

Toxin-Induced Animal Models of PD

Two widely utilized and characterized animal models of PD require the delivery of
a neurotoxin to the nigrostriatal system: 6-hydroxydopamine (6-OHDA) in rats or MPTP
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(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in non-human primates (NHPs). Both of
which are neurotoxins that mimic the cellular loss associated with the dopaminergic
neuronal population and dysfunction of the remaining nigrostriatal system (Kirik et al.,
1998, Dauer and Przedborski, 2003, Schober, 2004, Smeyne and Jackson-Lewis, 2005,
Cicchetti et al., 2009, Blesa et al., 2012). While both of these animal models mimic the
loss dopaminergic neurons, they do so without the formation of Lewy bodies (Schober,
2004).
One of the most widely used rat models of Parkinson’s disease involves the
direct injection of 6-OHDA into the nigrostriatal dopaminergic system, as it is unable to
readily cross the blood-brain barrier (BBB) after systemic delivery (Ungerstedt, 1968,
Cicchetti et al., 2009). Typical injection sites of 6-OHDA include the striatum, medial
forebrain bundle (MFB) and substantia nigra pars compacta (SNpc) (Perese et al., 1989,
Przedbroski et al., 1995). Depending on both the site of the injection and concentration
of toxin delivered, the model can be tailored to induce a moderate (>90 %), severe (9095 %) or a total/massive (>95-99%) lesion in regards to the depletion of DA in the
striatum (Schwarting and Huston, 1996a, Schwarting and Huston, 1996b). In PD
patients, the greatest loss of DA occurs in the striatum, specifically the putamen. For the
purpose of this dissertation we selected a severe unilateral striatal lesion model,
focusing on the dorsal lateral striatum of the rat which is equivalent to that of the
putamen in humans (Kish et al., 1988, Kirik et al., 1998, Olanow and Tatton, 1999,
Olanow, 2004).
In terms of its mechanism of neurotoxicity, 6-OHDA shares a similar structure to
both dopamine (DA) and noradrenaline, only differing by the placement of a hydroxyl
group, 6-OHDA gains access to neurons using these neurotransmitters through their
cell-specific dopamine transporters (DAT) (Blum et al., 2001) (Figure 1.2). After entering
the cell, free radicals and hydrogen peroxide begin to accumulate in the cytosol as 6OHDA is rapidly oxidized. These cytotoxic compounds then begin to break down the cell
membrane through oxidative stress, reductions in striatal glutathione (GSH) and
superoxide dismutase (SOD), inhibition of complex I activity in mitochondria, and
increase in levels of malondialdehyde (Sachs and Jonsson, 1975; Cleeter et al., 1992;
Betarbet et al., 2002; Kumar et al., 1995). After 6-OHDA infusion, the loss of
dopaminergic neurons progresses rapidly unlike that observed in PD patients, where
effects typically peak at 2 weeks while becoming stable by week 4 (Kirik et al., 1998).
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Arguably the most important and relevant pre-clinical animal model of PD
involves the administration of the neurotoxin, MPTP, in non-human primates (NHPs)
(Blum et al., 2001, Schober, 2004, Cicchetti et al., 2009). MPTP was first discovered
incidentally after drug addicts injected a “synthetic” heroin containing the contaminant
MPTP, later found to be responsible for the destruction of dopaminergic neurons
(Langston et al., 1983, Langston et al., 1984). Since its discovery, MPTP neurotoxicity
in NHPs, like humans, has been shown to cause a loss of the dopaminergic neurons of
the SNpc and a subsequent depletion of striatal DA (Langston et al., 1984, Beal, 2001,
Blum et al., 2001, Ding et al., 2008, Cicchetti et al., 2009). MPTP as a model of PD in
NHPs is unique in that NHPs have similar cardinal motor symptoms which are present in
PD patients, including but not limited to rigidity and bradykinesia (Bankiewicz et al.,
1986, Petzinger and Langston, 1998, Przedborski et al., 2001, Ding et al., 2008).
Being a lipophilic molecule, MPTP is capable of crossing the blood-brain barrier
(Markey et al., 1984) and can be given systemically (Schober, 2004), for example,
through the internal carotid artery (Ding et al., 2008). MPTP is taken up by glia and is
readily converted to MPP+ by monoamine oxidase B (MAO-B) (Nicklas et al., 1985,
Nicklas et al., 1987). MPP+ is then taken up by the dopamine transporter (DAT) where it
accumulates in the cytosol of dopaminergic

neurons (Gainetdinov et al., 1997)

(Figure.1.2). As the mitochondrial membrane potential lends to the mitochondrial matrix
having a large negative charge (Ramsay et al., 1986, Ramsay and Singer, 1986), MPP+
is readily taken up into mitochondria (Ramsay et al., 1986, Ramsay and Singer, 1986).
MPP+ has been shown to inhibit complex I (NADH:ubiquinone oxidoreductase) leading
to a reduction in ATP production and subsequent depletion of energy in the cell (Nicklas
et al., 1985, Mizuno et al., 1987, Nicklas et al., 1987). Inhibition of the electron transport
chain at complex I has been shown to increase the production of ROS and other free
radicals, which are thought to be one of the main contributing factors to dopaminergic
cell death (Smeyne and Jackson-Lewis, 2005).
MPTP is capable of crossing the blood-brain barrier (Markey et al., 1984) and
can be given systemically (Schober, 2004). In NHPs, MPTP can be administered by
either multiple intraperitoneal or subcutaneous injections (Petzinger and Langston,
1998). NHPs then present with severe bilateral PD features and often have difficulty
eating or drinking, needing L-dopa therapy to improve the NHPs health and well-being
(Petzinger and Langston, 1998). To remove the need of L-dopa treatment for severe PD
features, a unilateral model in NHPs was developed by administering MPTP via the
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intracarotid artery, which limits PD features to one side (Bankiewicz et al., 1986). Please
refer to the review on MPTP models of Parkinson’s disease in non-human primates
(NHPs) for greater detail in modes of administration (Przedborski et al., 2001).
Traditionally, the standard MPTP concentration (0.4 mg/kg) administered
unilaterally by the intracarotid artery, renders a severe stable lesion to the nigrostriatal
system, mimicking the later stages of PD (Bankiewicz et al., 1986). Typically, a 99 %
reduction in putaminal DA and 87 % loss of TH+ neurons in the SNpc is observed using
this MPTP concentration (Ding et al., 2008). To model the earlier stages of PD, a new
model was developed by Ding and co-authors who administered a MPTP concentration
of (0.12 mg/kg) unilaterally by the intracarotid artery (Ding et al., 2008). NHPs receiving
this dose usually exhibit a 98 % reduction in putaminal DA and a 68 % loss of TH+
neurons in the SNpc (Ding et al., 2008). In both models, PD features are present;
however, milder in the early stage model (Ding et al., 2008).
While outside of the scope of this dissertation, it should be noted that the mode
of MPTP administration, concentration, and age of the NHPs can greatly affect the
stability of the lesion; which can lead to a partial “recovery” in NHPs which receive a less
severe lesion (Crossman et al., 1987, Schneider et al., 1987, Kurlan et al., 1991,
Moratalla et al., 1992, Albanese et al., 1993, Rose et al., 1993, Petzinger and Langston,
1998). Studies have shown that in both the early and late stage models, younger NHPs
(<10 years) tend to need a higher MPTP dose to produce stable PD features (Ovadia et
al., 1995, Ding et al., 2008). In the early stage model developed by Ding an co-authors,
middle aged NHPs (10-19 years) developed stable PD features by 3 months which
persisted for at least 1 year after MPTP administration (Ding et al., 2008).

Options for the Symptomatic Treatment of PD

Levodopa (The Gold Standard of Treatment for PD)
Sinemet (levodopa/carbidopa) is the current gold standard for the symptomatic
treatment of PD. Levodopa can be administered orally, as L-dopa is readily transported
across the blood-brain barrier (BBB) by the large-neutral amino-acid transport 1 (LAT-1)
(Alexander et al., 1994, Geier et al., 2013). Levodopa is given in combination with
carbidopa which acts as a competitive inhibitor of aromatic-amino-decarboxylase
enzyme (AADC) in peripheral tissues (Nutt et al., 1985), where AADC converts levodopa
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to dopamine which cannot cross the BBB (Nutt et al., 1985). The utilization of carbidopa
allows for a lower concentration of levodopa to be used by increasing its brain
bioavailability (Nutt et al., 1985). Even when the standard Sinemet tablet (25 mg
carbidopa/ 100 m levodopa) is given, the half-life is only about 90 minutes increases
(Nutt et al., 1985). By increasing the amount of levodopa able to reach the CNS,
peripheral side effects including dyskinesias can be minimized or occur to a lesser
degree (Olanow and Obeso, 2000, Olanow, 2004).
A major issue in using Sinemet as a monotherapy is just that, there is a
progressive loss of its major cellular target. Chronic levodopa treatment for PD can then
lead to the development of motor fluctuations and dyskinesias 5-10 years after the start
of treatment (Olanow, 2004). Current treatments paradigms now resort to combination
therapies in the later stages of PD which revolve around; (1) retarding the metabolism of
available dopamine through the use of MAO (selegiline, rasagiline) or COMT inhibitors
(tolcapone, entacapone), or (2) using DA receptor antagonists (pramipexole and
ropinirole) (Pelusio, 1993, Horstink et al., 2006, Corvol et al., 2011, Fox et al., 2011,
Riederer and Laux, 2011, Schapira, 2011, Seppi et al., 2011, Stowe et al., 2011).

Deep Brain Stimulation (DBS)

Deep brain stimulation (DBS) is an FDA approved surgical procedure for the
treatment of essential tremor, dystonia, and an alternative approach for the symptomatic
treatment of PD (Coffey, 2009, Lozano and Lipsman, 2013). DBS uses an implantable
neurostimulation system with microelectrode leads that can be implanted into different
regions of the basal ganglia system by stereotactic neurosurgery, powered by an
implantable neurostimulator located in upper chest (Coffey, 2009, Marks Jr, 2010,
Lozano and Lipsman, 2013, Horne et al., 2015). For the treatment of PD, microelectrode
leads have been traditionally implanted (unilaterally or bilaterally) in the GPi, STN, or
Vim (Marks Jr, 2010, Lozano and Lipsman, 2013). However, lead implantation in either
the GPi and STN show the greatest improvements in motor deficits including rigidity
akinesia, tremor, motor fluctuations, and dopamine-related involuntary movements that
are responsive to levodopa treatment (Trottenberg et al., 2005, Zhang et al., 2006a,
Vidailhet et al., 2007, Isaias and Tagliati, 2008, Lozano and Lipsman, 2013). Conversely,
PD patients suffering from tremor-dominant motor deficits have been shown to respond
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better to implantation of the electrical leads into the Vim (Savica et al., 2011, Lozano and
Lipsman, 2013).
For stereotactic neurosurgical implantation of the microelectrode leads,
microelectrode recordings (MER) are used to determine placement in the targeted nuclei
(Sierens and Bakay, 2004). While different teams debate between the use of either
microelectrode recordings, semi-microelectrode recordings, microstimulation, and/or
macrostimulation for physiological mapping, most teams agree that electrophysiological
mapping is an important component for optimal implantation of an electrode (Gross et
al., 2006). For a detailed overview of DBS and its electrophysiological principals see
reviews by Sierens and co-authors and Gross and co-authors (Sierens and Bakay, 2004,
Gross et al., 2006, Marks Jr, 2010).
DBS is a powerful option for the treatment of the cardinal motor symptoms
associated with PD; however, patients without a definitive PD diagnosis or that are unresponsive to levodopa treatment, are not candidates for DBS (Marks Jr, 2010).
Additionally, other PD symptoms including micrographia, gait disturbances, and
cognitive impairment are generally unresponsive to DBS (Hely et al., 1999, Hely et al.,
2005, Lozano and Lipsman, 2013). While promising, these are costly and invasive
neurosurgical procedures that ultimately do not halt the progressive neurodegeneration
associated with PD (Marks Jr, 2010).

Disease Modifying Approaches for the Potential Treatment of PD

Glial Cell Line-Derived Neurotrophic Factor (GDNF)

Since the purification of nerve growth factor (NGF) by Levi-Montalcini and Cohen
in the 1970’s, the trophic-factor field has grown tremendously (Levi-Montalcini and
Angeletti, 1968, Levi-Montalcini, 1987, Barde, 1989). For the past almost 50 years
numerous other classes of neurotrophic factors have been discovered including the
neurotrophin family, fibroblast growth factor family, neurokine family, transforming
growth factor- family, epidermal growth factor family, epidermal growth factor family,
and the insulin-like growth factor family (Siegel and Chauhan, 2000, Thorne and Frey,
2001). Throughout the advancement of the field, numerous neurotrophic factors have
shown great potential for the treatment of many neurodegenerative diseases, as they
10

can have robust neuroprotective and/or restorative properties in targeted areas of CNS
(Hefti et al., 1989, Lindsay et al., 1994, Siegel and Chauhan, 2000, Thorne and Frey,
2001, Aron and Klein, 2011).
GDNF, a 33-45 kDa neurotrophic factor (Lin et al., 1994), and a member of the
transforming growth factor-β (TGF-β) superfamily (Airaksinen and Saarma, 2002), was
first isolated and purified because of its effects on dopaminergic neurons in vitro (Lin et
al., 1993). GDNF has been shown to bind to the GFRα-1 receptor, forming a receptor
complex (GDNF-GRFα-1) that can interact with the extracellular RET domain, a tyrosine
kinase (Airaksinen and Saarma, 2002). RET has been shown to activate numerous
signaling

cascades

including

extracellular

signal-regulated

kinase

(ERK),

phosphatidylinositol (PI3K/AKT), p38 mitogen activated protein kinase (MAPK), which
have been shown to promote cellular survival and growth (Worby et al., 1996, Trupp et
al., 1999, Airaksinen and Saarma, 2002).
Since its discovery in 1993 by Lin and co-authors (Lin et al., 1993), GDNF has
been shown to have robust effects on the nigrostriatal system in both normal and aged
rats (Hebert et al., 1996, Hebert and Gerhardt, 1997, Salvatore et al., 2004) and nonhuman primates (NHPs) (Gash et al., 1995, Grondin et al., 2000, Maswood et al., 2002,
Ai et al., 2003a, Grondin et al., 2003a). More importantly, GDNF has been shown to be
both neurorestorative and neuroprotective on dopaminergic neurons in both rat (Hoffer
et al., 1994, Bowenkamp et al., 1995, Kearns and Gash, 1995, Kearns et al., 1997, Fox
et al., 2001) and NHP (Gash et al., 1996, Zhang et al., 1997, Grondin et al., 2002b,
Maswood et al., 2002, Grondin et al., 2003a, Gash et al., 2005) models of PD. As a
consequence of these studies which highlighted behavioral improvements, modulation of
nigrostriatal tissue levels of DA, DOPAC and HVA, and the ability to both protect and
restore dopaminergic neurons of the nigrostriatal system in 6-OHDA and/or MPTP toxin
models of PD, GDNF advanced to clinical trials (Grondin and Gash, 1998).
Due to GDNFs large molecular size (Lin et al., 1994) and inability to cross the
blood-brain barrier, it has been traditionally administered by either direct infusion into the
nigrostriatal system (Kearns and Gash, 1995, Kearns et al., 1997, Fox et al., 2001,
Maswood et al., 2002, Grondin et al., 2003a) or by intraventricular infusion (Gash et al.,
1996, Grondin et al., 2003a). Based on early studies which showed efficacy for the
delivery of GDNF in hemiparkinsonian NHPs via intraventricular delivery (Gash et al.,
1996, Zhang et al., 1997), the first round of clinical trials examined GDNF’s delivery in
this manner (Kirik et al., 2004). However, intraventricular infusion of GDNF failed to
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show improvements in Unified Parkinson’s Disease Rating Scale (UPDRS) scores, and
also raised concerns of efficacy, as adverse side-effects were also apparent (Kordower
et al., 1999, Nutt et al., 2003).
Re-evaluation of the failed phase 1 clinical trial, found that intraventricular
infusion was not sufficient in delivering GDNF to targeted regions of the basal ganglia
system (Kordower et al., 1999, Nutt et al., 2003). Therefore, new delivery methods were
examined, and targeted intraputamenal infusion of GDNF by pump and catheter was
found to be efficacious in NHPs (Grondin et al., 2002a, Ai et al., 2003a, Gash et al.,
2005). GDNF was then reintroduced in two small open-labeled clinical trials, which
showed that after intraputamenal infusion of GDNF by pump and catheter in PD patients,
there were improvements in UPDRS scores, and was well tolerated without major
adverse side effects (Gill et al., 2003, Slevin et al., 2005). However, in a larger
randomized clinical trial, intraputamenally delivery GDNF did not show a significant
improvement in UPDRS scores compared to placebo (Lang et al., 2006, Sherer et al.,
2006). Additionally, safety issues concerning cerebellar toxicity in NHPs (Hovland et al.,
2007) and neutralizing antibodies found in some PD patients (Tatarewicz et al., 2007)
ended its further testing in humans.
Since the decision to not advance GDNF in clinical trials as a disease altering
treatment option for PD patients, it has been suggested that poor biodistribution to
targeted regions of the brain, in part due to its high affinity heparin-binding domains and
large molecular size, played a major role in its failure (Salvatore et al., 2006). To
circumvent these issues associated with surgically delivering compounds to the CNS,
numerous studies have examined the use of non-invasive intranasal administration, as
an alternative delivery method for the potential treatment of PD and other
neurodegenerative diseases (Gozes et al., 2000, Gozes, 2001, Thorne and Frey, 2001,
Ross et al., 2004, Thorne et al., 2004b, Lagreze et al., 2005, Hanson and Frey, 2008,
Thorne et al., 2008, Dhuria et al., 2009c, d, 2010, Chapman et al., 2013, Laukova et al.,
2014, Migliore et al., 2014, Stenslik et al., 2015).

Dopamine Neuron Stimulating Peptide-11 (DNSP-11)

The delivery of compounds across the blood-brain barrier (BBB) to the central
nervous system (CNS) has consistently been a major challenge in the treatment of
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Parkinson’s disease (PD) and other neurodegenerative diseases (Thorne and Frey II,
2001, Salvatore et al., 2006, Anitua et al., 2008, Aron and Klein, 2011). For this reason
there has been a major push to develop smaller molecules with neuroprotective and/or
restorative properties that can be used in a less invasive delivery regimen, such as
intranasal administration (Bradley et al., 2010, Kelps et al., 2011, Fuqua et al., 2014).
Our team was the first to shown that dopamine neuron stimulating peptide-11
(DNSP-11), an 11-amino acid amidated peptide (PPEAPAEDRSL-amide) derived from
the GDNF pro-domain, has similar but distinct neurotrophic-like actions as GDNF
(Bradley et al., 2010) (Figure. 1.3). We have shown in vitro that DNSP-11 protects
against gramicidin (monocovalent cation ionophore and mitochondrial depolarizing
agent) cytotoxicity in dopaminergic cell lines; and unlike GDNF, protects against
staurosporine (non-selective protein kinase inhibitor) cytotoxicity (Rüegg and Gillian,
1989, Nicholls and Budd, 2000, Goldstein et al., 2005, Bradley et al., 2010). We have
also published that DNSP-11 protects against 6-OHDA as measured by decreases in
both TUNEL and caspase-3 activity in MN9D cells (Bradley et al., 2010).
Pull-down assays of DNSP-11 in the SN of F344 rats indicate its binding to
numerous proteins involved with chaperones, the cytoskeleton, neuronal development
and

translation,

metabolism,

and

most

notably

glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) (Bradley et al., 2010). The binding of DNSP-11 leading to a
decrease in s-nitrosylation of GAPDH may explain some aspects of its anti-apoptotic
properties (Bradley et al., 2010, Kelps, 2013), a known drug target for PD (Kragten et al.,
1998, Carlile et al., 2000, Tatton, 2000, Tatton et al., 2003, Hara et al., 2005, Hara et al.,
2006). Additional pull-down assays in MN9D cells indicate that DNSP-11 was able to
activate ERK1/2 signaling through a novel mechanism that does not involve the binding
of the GFRα-1 receptor (Bradley et al., 2010, Fuqua et al., 2014)
Early studies in F344 rats indicated that DNSP-11 was actively taken up into the
SNpc and SNpr within 30 minutes, and persisted for at least 180 minutes after a single
direct infusion into the SN (Bradley et al., 2010). In in vitro studies of FITC-labeled
DNSP-11 we have shown that it is actively taken up by mitochondria within 15 minutes in
MN9D cells (Turchan-Cholewo, 2015). Similarly, assays utilizing

125

I-labeled DNSP-11

(PPEAPAEDKSL-amide) support the rapid internalization of DNSP-11 in isolated CNS
mitochondria from young F344 rats, by mechanisms that could involve either classic or
non-classic import mechanisms into mitochondria (Turchan-Cholewo, 2015). These
studies support that DNSP-11 is rapidly internalized into isolated CNS mitochondria.
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In F344 rats, carbon fiber microelectrodes coupled with high speed
chronoamperometry, were used to examine DA in the rat striatum at 1, 2, and 4 weeks
following a single direct infusion of the peptide into the SN (Fuqua et al., 2014). These
studies indicated an increase in evoked potassium release at 2 weeks in the dorsal
striatum (Fuqua et al., 2014), an equivalent area in PD patients which exhibits the
highest levels of DA depletion (Bernheimer et al., 1973, Hornykiewicz, 1975, Gerfen et
al., 1987, Hornykiewicz, 1998, Joel and Weiner, 2000). DNSP-11’s neuroactive
properties were further examined in a severe 6-OHDA MFB rat lesion model of PD
(Fuqua, 2010, Fuqua et al., 2014). Rats that were given a single direct infusion of DNSP11 into the lesioned SN exhibited a decrease in apomorphine induced-rotation up to 4
weeks post-infusion, increases in DA, DOPAC and HVA as measured by striatal
microdialysis, and in tissue levels of DA and DOPAC in the striatum as measured by
HPLC-EC (Fuqua, 2010, Fuqua et al., 2014). These studies indicated that DNSP-11,
administered by direct infusion, exhibits neuroactive properties in a severe 6-OHDA rat
model, that mimics the later stages of PD (Kirik et al., 1998). Due to DNSP-11’s small
molecular size, protection from neuronal death in vitro, and neuroprotective and
restorative properties on the nigrostriatal system, we hypothesized that it would a viable
candidate to delivery non-invasively by intranasal administration in two pre-clinical
animal models of PD.

Delivery of Protein Biotherapeutics to the CNS for the Treatment of Parkinson’s
Disease

The Blood-Brain Barrier (BBB)

The blood brain-barrier (BBB) has continuously been a major issue when
developing biotherapeutics to treat CNS disorders and diseases (Thorne and Frey,
2001). While the BBB is restrictive in the molecules it “allows” to cross; O2, CO2, ions,
and small lipophilic molecules are able to pass by way of para or transcellular
mechanisms (Hawkins and Davis, 2005, Abbott et al., 2006, Chen and Liu, 2012). Other
larger molecules that would not ordinarily by-pass the BBB including amino acids,
hormones, antibodies, and most notably dopamine can be transported through
membrane receptor transporters via transcytosis or carrier mediated transport; for
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example, by GLUT-1 for the transport of glucose (Oldendorf, 1971, Cecchelli et al.,
2007, Banks, 2009). In the following review of pharmacological approaches used for the
delivery of potential treatments for PD are discussed; and how the BBB has shaped the
way potential biotherapeutics, such as neurotrophic factors and neuroactive peptides,
are delivered to the CNS is discussed.

Convection Enhanced Delivery (CED)

Biotherapeutics have traditionally been delivered to the CNS by direct
intraparenchymal infusion utilizing convection enhanced delivery (CED) or high-flow
microinfusion (Kateb and Heiss, Grondin et al., 2002b, Ai et al., 2003b, Slevin et al.,
2005). This section will focus on CED as a means for delivering GDNF directly to the
brain (Slevin et al., 2005, Slevin et al., 2006b, Slevin et al., 2007); even though CED has
been used to delivery other biotherapeutics through viral vectors for the treatment of PD
(Bobo et al., 1994, Bankiewicz et al., 2000, Muramatsu et al., 2002, Kaplitt et al., 2007,
Eberling et al., 2008, Christine et al., 2009).
CED was first developed at the National Institutes of Health (NIH) by Oldfield and
co-authors to aid in increasing the diffusion and/or the volume of distribution (Vd) of
various molecules through bulk flow; as changes in tissue heterogeneity in different
regions of the brain parenchyma greatly affect the diffusion of different molecules (Bobo
et al., 1994). However, the rate of infusion delivery, cannula size, concentration of the
biotherapeutic, and pre-infusion sealing around the cannula opening are critical variables
that can influence the effectiveness of CED delivery (Chen et al., 1999, Hardy et al.,
2013)

Additionally, numerous studies have shown that biotherapeutics and other

molecules tend to diffuse along myelinated axons, termed anisotropic diffusion; and
depending on the compounds properties and targeted brain region of interest, diffusion
rates and patterns of distribution can vary greatly (Syková and Nicholson, 2008).
In the three clinical trials involving the intraputamenal infusion of GDNF via CED
in PD patients, differences in catheter port size, single versus multiport-port catheters,
rate of infusion, and concentration may have played a critical role in its failure to
advance (Sherer et al., 2006). Similarly, GDNF’s high affinity heparin binding domains
and large molecular weight, have been shown to be confounding factors in its
development at a potential therapeutic treatment option for PD (Salvatore et al., 2006).
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While improvements in CED have been made they do not circumvent the issue of using
invasive neurosurgical procedures for potentially

delivering

disease altering

biotherapeutics, such as GDNF, to the brain (Salvatore et al., 2006), limiting the potential
patient population to individuals in the late-stages of PD.

Viral Vectors

As previously discussed, the chronic treatment of PD by the direct delivery of
GDNF via CED using an implanted pump and catheter system in patients presents
numerous challenges (Kirik et al., 2004). To enhance the therapeutic potential of
neurotrophic factors, such as GDNF for the treatment of PD, scientists have examined
the use of viral vectors by their direct infusion into the brain (Bensadoun et al., 2000,
Björklund et al., 2000, Kordower et al., 2000, Eslamboli et al., 2005). While numerous
studies have examined the delivery of tyrosine hydroxylase (TH), aromatic L-amino acid
decarboxylase (AADC), and brain-derived neurotrophic factor (BDNF) to targeted
regions of the brain using viral vectors as potential disease altering treatments for PD
(Kaplitt et al., 1994, Klein et al., 1998, Bankiewicz et al., 2000, Kordower et al., 2000,
Latchman and Coffin, 2000, Kaplitt et al., 2007) the focus of this dissertation will be of
that utilizing GDNF.
In both animal and patient studies utilizing viral vectors for the delivery of GDNF
to the brain, three classes have been utilized including the adenovirus, adenoassociated virus (rAAV), and lentivirus (rLV) (Björklund et al., 2000). From these studies,
the use of viral vectors (Choi-Lundberg et al., 1997, Mandel et al., 1997, Choi-Lundberg
et al., 1998, Mandel et al., 1999, Bensadoun et al., 2000, Kordower et al., 2000, Kirik et
al., 2004, Eslamboli et al., 2005). Highlights from these studies include both the
protection and/or restoration of dopaminergic neurons in animal models of PD,
prolonged expression of GDNF after vector delivery, and clinical relevant increases in
the Unified Parkinson’s Disease Rating Scale (UPDS) scores in late-stage PD patients
(Choi-Lundberg et al., 1997, Mandel et al., 1997, Choi-Lundberg et al., 1998, Mandel et
al., 1999, Bensadoun et al., 2000, Kordower et al., 2000, Kirik et al., 2004, Eslamboli et
al., 2005, Christine et al., 2009).
However, numerous challenges are associated with this methodology including
the immune response, and the ability to achieve a stable gene transfer into the desired
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cellular populations, have been major concerns (Wood et al., 1996, Thomas et al.,
2003). Also, differences in the viral vector used for the delivery of GDNF can be
problematic in terms of their packaging capacity and safety (Björklund et al., 2000).

Intranasal Delivery

The search for alternative non-invasive delivery method is now underway as a
means to circumvent the issues associated with the neurosurgical interventions for the
delivery of neurotrophic factors, discussed earlier in this chapter, which have greatly
hindered their potential use for the treatment of PD (Slevin et al., 2005, Salvatore et al.,
2006, Sherer et al., 2006). Intranasal administration of neurotrophic factors such as
GDNF, proteins, and smaller peptides to the CNS, has therefore, become an attractive
avenue (Gozes et al., 2000, Gozes, 2001, Thorne and Frey, 2001, Ross et al., 2004,
Thorne et al., 2004b, Thorne et al., 2008, Lochhead and Thorne, 2012, Migliore et al.,
2014). Almost 30 years after the first examinations of a direct nose-to-CNS route of the
intranasally administered wheat germ agglutinin-horse radish peroxidase (WGA-HRP)
and unbound horse radish peroxidase (HRP), the field has grown tremendously
(Broadwell and Balin, 1985, Shipley, 1985, Baker and Spencer, 1986).
A basic appreciation of the anatomy is helpful in understanding the proposed
mechanisms (both rapid and slow) of transport of different molecules to the CNS after
intranasal administration. The olfactory system is comprised of olfactory sensory
neurons (OSNs) that traverse the cribriform plate as they travel to the olfactory bulbs
(Figure. 1.4) (Thorne and Frey, 2001, Dhuria et al., 2010, Lochhead and Thorne, 2012).
It has been shown that there is a direct nose-to-CNS route via anterograde axoplasmic
transport after wheat germ agglutinin-horse radish peroxidase (WGA-HRP) and unbound
horse radish peroxidase (HRP) were administered intranasally in both rats and mice
(Broadwell and Balin, 1985, Shipley, 1985, Baker and Spencer, 1986). In these studies,
the anterograde axoplasmic transport to different regions of the CNS, after intranasal
administration, took approximately 4-6 hours (Broadwell and Balin, 1985, Shipley, 1985,
Baker and Spencer, 1986).
The rapid transport of different compounds can be explained through both
periventricular and/or perivascular delivery after intranasal administration. The olfactory
ensheathing cells (OECs) are a particular subset of Schwann cells that are specific for
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and cover the OSNs (Figure.1.4.) (Thorne and Frey, 2001, Dhuria et al., 2010, Lochhead
and Thorne, 2012). The OECs surrounding the olfactory sensory neurons create a
perineural fluid filled space that allows for various molecules to gain access to the CSF
via the olfactory subarachnoid space (Figure.1.4) (Thorne and Frey, 2001, Dhuria et al.,
2010, Lochhead and Thorne, 2012). Additionally, infusion of tracers into the CSF, and
after intranasal administration have both been shown in the nasal lymphatic system and
cervical lymph nodes. (Bradbury et al., 1983; Johnston et al., 2004; Kida et al., 1993;
Walter et al., 2006). The nasal epithelium is also highly innervated by branches
(ophthalmic-V1 and maxillary-V2) of the trigeminal nerve (Thorne and Frey, 2001, Dhuria
et al., 2010, Lochhead and Thorne, 2012). Tracer studies of IGF-1 have indicated its
rapid transport to the CNS by the trigeminal nerves, suggestive of perineural transport
along said branches (Thorne et al., 2008).
Both the respiratory and olfactory regions of the nasal cavity are highly
innervated by branches of the maxillary, ophthalmic and facial arteries, especially in that
of the respiratory region (Thorne and Frey, 2001, Dhuria et al., 2010, Lochhead and
Thorne, 2012). Numerous studies have also shown that perivascular spaces surrounding
the vasculature, found in the lamina propria (basement layer to the olfactory epithelium),
can transport molecules to the CNS by bulk flow and diffusion through pulsations of the
arterial blood supply (Gozes et al., 2000, Gozes, 2001, Thorne and Frey, 2001, Ross et
al., 2004, Thorne et al., 2004b, Thorne et al., 2008, Lochhead and Thorne, 2012,
Migliore et al., 2014, Stenslik et al., 2015). Through the unique anatomy of the olfactory
system, intranasal administration, offers a rapid mechanism for the transport of different
molecules to the CNS, making it an attractive less invasive alternative for the delivery of
potential disease altering biotherapeutics (Thorne and Frey, 2001, Dhuria et al., 2010,
Lochhead and Thorne, 2012). For a detailed review of the mechanisms of transport
after intranasal delivery please refer to Dhuria and co-authors, Lochhead and coauthors, and/or Thorne and co-authors (Thorne and Frey, 2001, Dhuria et al., 2010,
Lochhead and Thorne, 2012).

Copyright © Mallory Joan Stenslik 2015
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Chapter One: Figures

Figure 1.1 The Indirect and Direct Pathways
Classically, dopaminergic projections from the SNpc play an important role in both the
direct (striatonigral) and indirect (striatopallidal) pathways involved in the initiation of
motor movement (Albin et al., 1989). Two main classes of DA receptors are located in
the dorsal striatum (putamen) which modulate the release of glutamate from the medium
spiny neurons, which make up approximately 95 % of the striatum. Specifically, D1
receptors play an excitatory role in the direct pathway, while D 2 receptors found in the
indirect pathway path an inhibitory role (Albin et al., 1989). In PD the dopaminergic
nigrostriatal connections from the SNpc to the putamen are lost, leading to the
deregulation and dysfunction of both the direct and indirect pathways (Albin et al., 1989,
Olanow and Tatton, 1999, Abou-Sleiman et al., 2006, Wirdefeldt et al., 2011).
Dysregulation of both pathways can lead to any combination of the hallmark motor
symptoms of PD which include bradykinesia, rigidity, resting tremor, stooped posture,
dysphagia, micrographia, dysarthria and decreases in facial expressions (Hoehn and
Yahr, 1998).
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Figure 1.2 Classic DA Synthesis, Release, and Metabolism
Classic DA synthesis, release and metabolism in a representative dopaminergic neuron
and the metabolism of MPTP and 6-OHDA. (A) L-tyrosine is converted to Ldihydroxyphenylalanine (L-dopa) by tyrosine hydroxylase and then to dopamine (DA) by
the aromatic amino acid decarboxylase (AADC) in the cytosol. DA is then packaged into
the synaptic vesicles by the vesicular monoamine transporter (VMAT2) and released into
the synapse upon neuronal activation. Free DA in the synaptic cleft can be taken back
up by the dopamine transporter (DAT), or metabolized by monoamine oxidase (MAO) to
3,4-dihydroxyphenylacetic acid (DOPAC) and then to homovanillic acid (HVA) by
catechol-o-methyltransferase (COMT). Alternatively, DA in the cleft can be converted to
3-methoxytyramine (3-MT) by COMT and then 3-MT to HVA by MAO-B. (B) 6hydroxydopaine (6-OHDA) is transported into the neuron by DAT where it then
accumulates into the cytosol. (C) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is
taken up by glial cells ad rapidly converted to 1-methyl-4-phenylpyridinium (MPP+) and
transported out of the cell. MPP+ is then taken up by catecholaminergic neurons through
DTA. Figure modified from (Littrell, 2011).
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Figure 1.3 DNSP-11 Sequence
DNSP-11 (PPEAPAEDRSL-amide) is theoretically cleaved from the pro-region of glial
cell-lined derived neurotrophic factor (GDNF). Figure taken directly from (Bradley et al.,
2010).
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Figure 1.4 Transport Mechanism after Intranasal Administration
(A) The respiratory and olfactory regions of the nasal cavity contain an epithelium layer
that contains sustentacular cells, basal cells and olfactory sensory neurons (OSNs) while
the lamina propria contains the axons of the OSNs, blood vessels, bowman’s glands,
nerve bundles from the OSNs, and trigeminal nerve axons. (B) The OSNs come
together as nerve bundles and are surrounded by olfactory ensheathing cells, and travel
up through the cribriform plate where they synapse mitral and tufted cells in the
glomeruli layer. (C) Representative section of the epithelium of the olfactory region.
Arrows indicate mature OSN that are fluorescently labeled by an anti-olfactory marker
protein (OMP). The nerve bundle (*) that contains the axons of the OSN is found in the
lamina propria region. (D) A representative section of the olfactory bulb. Again, OMP is
used to label the axonal projections from the OSN as they synapse on the mitral and

22

tufted cells in the glomeruli layer. Figure 1.4A & B modified from (Dhuria et al., 2010)
and C and B from Mallory Stenslik and Dr. Britto Nathan, Eastern Illinois University.
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Dissertation Overview

In recent years, the prospect of utilizing neurotrophic factors, such as glial celllined derived neurotrophic factor (GDNF) have been examined as potential disease
altering biotherapeutics for the treatment of Parkinson’s disease (PD). Large compounds
that are typically unable to cross the blood-brain barrier (BBB) have been traditionally
delivered by direct surgical infusion into the CNS using a pump and catheter system.
However, issues associated with the molecular properties of different compounds and
infusion devices have stalled the widespread use of this potential disease altering
treatment option. To circumvent the issues that surround this invasive delivery
technique, interest in the intranasal administration of compounds to the CNS has
increased. Recently our group has shown that DNSP-11, an 11-amino acid, amidated
peptide, has neuroprotective and restorative properties on dopaminergic neurons both in
vivo and in vitro. Contained in this dissertation I describe the methodology and effects of
the repeated intranasal administration of DNSP-11 on the nigrostriatal system in both
rodent and non-human primate models of PD. These foundational studies pave the way
for further investigation into the intranasal administration of DNSP-11 as a potential
biotherapeutic option for the treatment of PD.
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CHAPTER TWO: Materials and Methods
RAT STUDIES

Reagents

All chemicals were either purchased from Sigma-Aldrich (St. Louis, MO) or
Fisher Scientific (Fisher Chemical Fairlawn, NJ). DNSP- 11 was synthesized and purified
to >98% purity by Genscript (Piscataway, NJ) for all studies. The modified DNSP-11
sequence (R9K) was synthesized by AAPPTec (Louisville, KY) and iodinated (125I) via
the Bolton–Hunter method by PerkinElmer (North Billerica, MA) and purified to ≥93% by
reverse phase HPLC. DNSP-11 was dissolved in vehicle (0.9% saline, Hospira, INC.,
Lake Forest, IL) for all in vivo studies in which it has previously been shown to be stable
(Kelps et al., 2011).

Ethics Statement

All animal procedures were approved by the University of Kentucky Institutional
Animal Care and Use Committee in agreement with AAALAC guidelines.

Intranasal Administration of DNSP-11

For all in vivo studies, male F344 rats between 3 and 8 months old were utilized.
Rats were obtained from Harlan Laboratories Inc. (Indianapolis, IN) and were housed on
a 12 h light/dark cycle with water and food provided to rats ad libitum. For all intranasal
studies, rats were initially lightly anesthetized using an induction chamber and then
transferred to a nose cone where they continued to receive light isoflurane anesthesia
(1.0–3.0% with 1.0% oxygen) for the duration of the dosing period, typically lasting a
total of 20 min. While in a supine position, each rat received a total volume of 50 µl of
either vehicle or a mixture of DNSP-11 in an equivalent volume of vehicle. Prior to each
intranasal dose, the rats were removed from a nose cone and the tip of an Oxford
Benchmate pipette (range: 10–50 µl) was placed at the tip of the rat’s nare (Figure 3.1A).
A total of 12.5 µl was administered to each nare in 3–4 µl droplets allowing the rat to
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inhale the solution over the course of approximately 30–45 s (Figure 3.1). After
administering 12.5 µl to the first nare (time = 0), the solution was allowed to absorb for 5
min prior to dosing the opposite nare. This regimen was repeated a total of 4 times
alternating between nares (2 times per nare) (Thorne et al., 2004b, Dhuria et al., 2010).
For all intranasal experiments, excluding tracer studies, researchers were blinded to
intranasal treatments for all in vivo experiments, excluding tracer studies.

Dose Response in Normal Rats (HPLC-EC neurochemical analysis)

Previous studies in rodents have indicated that generally <1% of compounds
administered intranasally enter the CNS (Gozes et al., 2000, Thorne and Frey, 2001,
Thorne et al., 2004b, Dhuria et al., 2010, Lochhead and Thorne, 2012). To take into
account lower levels of delivery to the CNS, we examined half-log steps above and
below a 10-fold increase from the most effective DNSP-11 dosage (30 µg) determined
from previous infusion studies in rodents (Lundblad et al., 2002, Bradley et al., 2010,
Fuqua et al., 2014). In this study, rats received either 100 µg (n=6), 300 µg (n=6) or
1000 µg (n=6) DNSP-11 in vehicle or vehicle alone (n = 9), 5 days a week for 3 weeks
under light isoflurane (1.0–3.0% with 1% oxygen) anesthesia (Figure 3.2A). At 3 weeks,
rats were euthanized under heavy isoflurane anesthesia (5.0% with 1% oxygen), and the
brain was removed, submerged in ice-cold saline and then placed in a brain mold (on
dry ice) where 2 mm sections of the entire striatum at the optic chiasm and SN were
harvested and frozen at −80oC for neurochemical analysis.
For HPLC-EC analysis, pre-weighed (wet weight) tissue samples from the SN
and striatum were thawed and immediately processed, as described previously (Cass et
al., 2003). A total of 50 µl of filtrate (in mobile phase) was injected onto an HPLC
column. Retention times of DA standards and dihydroxybenzylamine (DHBA), which was
used as an internal standard, were used to identify peaks and used to determine tissue
levels (DA, DOPAC, HVA) found in each brain sample represented as ng/g wet weight of
the tissue sample (Cass et al., 2003).
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Unilateral, 3-site, 6-OHDA Striatal Lesion

Rats were intranasally pre-treated daily with either 300 µg (selected from the
dose response study) of DNSP-11 in vehicle, or vehicle alone, for 7 days prior to 6OHDA lesion. On the day of surgery, rats received intranasal treatment (DNSP-11 or
vehicle) approximately 60 min prior to 6-OHDA infusion under isoflurane anesthesia
(Figure 3.1A & B). Rats were then placed in a stereotaxic frame and received isoflurane
(1.0–2.0% with 1% oxygen) throughout the duration of surgery. Using previously
published procedures and stereotaxic coordinates (Kirik et al., 1998, Lundblad et al.,
2002) to target the dorsal striatum, injection sites for 6-OHDA infusion included: ((1) AP:
+1.0, ML: −3.0, DV: −5.0); (2) AP: −0.1, ML: −3.7, DV: −5.0; (3) AP: −1.2, ML: −4.5, DV:
−5.0)). Each injection site received 10 µg/2.5 µl of the 6-OHDA in 0.2 % ascorbic acid
saline solution for a total dose of 30 µg/7.5 µl using a 26 gauge Hamilton syringe.
Designated blinded intranasal treatments continued post-6-OHDA infusion, 7 days a
week for a total of 5 weeks (35 ± 3 days) (Figure 3.2B).

d-Amphetamine-Induced Rotation in 6-OHDA-Lesioned Rats

Prior to rats entering the study (n=29), an exclusion criterion was used to test for
baseline hemisphere asymmetry with d-amphetamine (2.5 mg/kg, i.p.). Rats were
excluded (n = 8) from entering the study if baseline rotation exceeded ≥160 turns per
hour in either direction (clockwise and/or counterclockwise). After 6-OHDA infusion, rats
(n = 21) received d-amphetamine (2.5 mg/kg, i.p.) at both 2 and 4 weeks to assess
lesion severity (Figure 3.2B). Rats were placed in automated rotometer bowls and
clockwise rotations were recorded over the course of 24 intervals that lasted 300 s (5
min) each using SDI Rotation (San Diego, CA USA). For analysis, only the peak 60 min
rotation time was used after the first 15 min had elapsed (Hudson et al., 1993, Hoffer et
al., 1994). On the day of testing, rats were not anesthetized and/or given their
designated blinded intranasal treatment.
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DA and DA Metabolite levels in the Striatum of 6-OHDA Lesioned Rats

At 5 weeks post-6-OHDA lesion, rats were heavily anesthetized with isoflurane
(5.0% with 1% oxygen) and transcardially perfused using approximately 200 ml of icecold saline. The brain removed, placed in an ice-cold saline bath and then placed in an
ice-cold brain mold (on dry-ice) where 2 mm thick sections were taken and the entire
striatum was removed. Tissue was then flash frozen utilizing dry ice and stored at

−80o

C for later HPLC-EC analysis. For HPLC-EC analysis, tissue samples were processed in
the same manner as previously discussed except a total of either 50 or 25 µl of filtrate in
mobile phase was injected onto the HPLC column. If analytes were undetectable at
these injection volumes, samples were run on a C18 column (4.6 mm × 75 mm, 3 µm
particle size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan) with a
more sensitive limit of detection was used (Hall et al., 1989).

Tissue Processing for TH+ Neurons in the SN of 6-OHDA Lesioned Rats

After the striatum was removed for later HPLC-EC analysis the midbrain was
blocked off and immersioned fixed in a 4% paraformaldehyde solution for 24 h. Tissue
was then submerged in increasing sucrose concentrations (15 & 30%) and frozen at
−80oC. Frozen serial coronal sections (30 µm) were cut on a sliding microtome and
stored in cryprotectant solution (30% sucrose, 30% ethylene glycol in 100 mM sodium
phosphate buffered saline (NaPBS), pH 7.2)) at −20◦C (Kearns and Gash, 1995).
For staining purposes, every sixth series free floating serial coronal section was
stained for tyrosine hydroxylase (TH) as previously published with minor adjustments (Ai
et al., 2003a). Sections were treated with the primary antibody against TH overnight
(1:10,000; Millipore, Billerica, MA) and then incubated in biotinylated horse anti-mouse
secondary antibody (1:5,000; Vector, Burlingame, CA) for 1h at controlled room
temperature (21–22◦C). Tissue was then incubated with avidin–biotin–peroxidase
complex using an Elite ABC Vectastain kit (Vector; Burlingame, CA) and TH
immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB) with nickel
enhancement.
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TH+ Neurons and Fiber Density in 6-OHDA Lesioned Rats
TH+ neurons were counted at three different levels: −5.24 mm, −5.60 mm and
−5.96 mm with respect to bregma using BioQuant Image Analysis System (BioQuant,
Nashville, TN USA) (Watson, 1986). The oculomotor nerve root was used to determine
the borders of the substantia nigra pars compacta (SNpc) from the ventral tegmental
area (Kearns and Gash, 1995). The degree of dopaminergic sparing on the ipsilateral
side to the lesion was determined by comparing the average total number of TH+
neurons at each level examined in rats treated with either DNSP-11 or vehicle.
The substantia nigra pars reticulata (SNpr) was also examined to determine TH+
fiber density (total area of the SNpr with TH+ immunereactive staining) and measured
using BioQuant Image Analysis Software at all three levels for rats (n=5 vehicle; n=6
DNSP-11) that were perfused, free of background staining due to remnants of blood
vessels. Data were average for each section for statistical analysis. One rat was
removed from all TH+ neuronal counts and fiber density analysis, as tissue depth was
inconsistent because of sectioning problems with the microtome.

Modification (R9K) of DNSP-11 for 125I Tracer Studies
To determine DNSP-11’s viability after modification (R9K), MN9D cells were
cultured in DHEM and supplemented with 10% Fetal Bovine Serum (FBS, Hyclone), 50
U/ml penicillin and streptomycin. For protection studies, cells were plated on 24-well
poly-D-lysine in DHEM with 1% (v/v) penicillin-streptomycin. The cells were grown at 37
o

C in 5% CO2. The dUTP nick-end labeling (TUNEL) assay was performed as previously

reported (Bradley et al., 2010). MN9D cells were administered STS (1 µM) and treated
with either the original and/or modified (R9K) DNSP-11 peptide (10 nM). The percent
from control was determined by the ratio of apoptotic versus total cells.

Distribution Studies (Gamma Counting & Autoradiography) in Normal Rats

Rats were administered a one-time dose of

125

I-labeled DNSP-11 (50 µl/50 µCi-

300 µg DNSP-11) while under light isoflurane anesthesia (Figure 3.1A & B). At 30 (n=4),
60 (n=3) and 360 (n=3) min after the start of the first intranasal dose (time = 0), CSF was
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immediately collected (Figure 3.2C). For CSF collection, a modified version presented by
(Nirogi et al., 2009) was used. Rats were placed upright and the back of the head was
shaved while a piece of gauze was placed under the neck angling the rat’s head
downward 45 degrees. The rat was then deeply anesthetized with isoflurane (5.0% with
1% oxygen) and the foramen magnum was located using the wings of the atlas and
occipital protuberance as landmarks. A 23 gauge needle (affixed to a short length of
tubing connected to a 1.0 ml syringe) was inserted at the midline center point and 100–
120 µl of CSF was removed. The flexible tubing attached to the syringe allowed for the
syringe to be clamped off using hemostat forceps as a fail-safe prior to blood
contaminating the CSF sample.
Prior to transcardial perfusion, 500 µl of blood was removed via aortic puncture
and rats were then perfused with 200 ml of ice-cold saline. The brain was removed, the
olfactory bulbs were removed at the frontal cortex, and the brain was then placed into a
brain mold (on wet ice). Eleven 2 mm thick coronal slabs were then harvested and all
brain, CSF, and blood samples were immediately analyzed by gamma counting (Cobra II
Auto-Gamma, Packard). Both brain and CSF samples were only quantified by gamma
counting if no blood was visible. To determine normalized concentrations of tracer found
in each sample, the counts per minute (CPM) values for all samples (brain, CSF, blood)
were divided by the CPM value determined for the total

125

I-labeled dose (50 µl/50 µCi–

300 µg DNSP-11) which was then normalized by the weight (mg) or volume (µl) of the
wet sample.
For autoradiography analysis, one rat was administered a one-time

125

I-labeled

DNSP-11 (50 µl/50 µCi–300 µg DNSP-11) and euthanized 60 min after the start of the
first intranasal dose. The rat was transcardially perfused with 200 ml of ice-cold saline
and 200 ml of 4% paraformaldehyde. Frozen sagittal brain sections were taken using a
cryostat (0.5 mm thick). Sections were then exposed for 21 days on a GE phosphor
screen (Thorne et al., 2004b), and analyzed for radioactive signal (Typhoon 9400, GE
Health Care).
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I-Labeled DNSP-11 Mitochondrial Import Assay

To examine

125

I-labeled DNSP-11’s uptake into mitochondria, total mitochondria

were isolated as previously reported (Sauerbeck et al., 2011) with minor adjustments.
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Mitochondria were isolated from all anatomical brain regions excluding the cerebellum
due to differences in basal mitochondrial bioenergetics. Animals were asphyxiated with
C02, decapitated where the brain was removed and placed in ice cold isolation buffer
(215 mM mannitol, 75 mM sucrose, 0.1% BSA, 1mM EGTA and 20 mM HEPES at pH
7.2). Mitochondria were isolated from all anatomical brain regions except for the
cerebellum due to differences in basal mitochondrial bioenergetics (Sauerbeck et al.,
2011). Samples were homogenized and centrifuged at 1300 x g for 3 minutes at 40C.
Supernatants were collected and centrifuged at 13,000 x g for 10 minutes at 40C. The
pellets were combined and resuspended in 500 µl of isolation buffer and placed in a
nitrogen bomb for 10 minutes. Samples were then placed on a Ficoll separation column
(consisting of both 10 and 7.5% Ficoll layers). Samples were then centrifuged at 100,000
x g for 30 minutes at 40C. The mitochondrial pellet was resuspended in isolation buffer
with EGTA and centrifuged at 10,000 x g for 10 minutes at 40C to remove any Ficoll from
the purified mitochondria. The mitochondrial pellet was then resuspended in isolation
buffer without EGTA and yielded a final concentration of approximately 20 mg/ml.
To examine classic import of

125

I-DNSP-11 into healthy mitochondria, For all

import assays approximately 20 µg/µl of purified mitochondria were resuspended in 200
µl of respiration buffer. To drive active transport in healthy mitochondria, the first set of
the tubes received respiration buffer which contained sucrose (50 mM), ATP (10 mM),
ADP (8 mM). The second group of tubes received mitochondrial toxins which included
FCCP (25 µM), Oligomycin (10 µM), Antimycin A (250 µM) in normal respiration buffer. A
third set of tubes were boiled in a dry-bath incubator at 1000C for 40 minutes in normal
respiration buffer. All tubes were treated with

125

I-DNSP-11 (0.42 µM) while control tubes

contained purified mitochondria and normal respiration buffer only. Healthy and toxin
treated tubes were incubated in a water bath at 370C for 30 minutes. All tubes were then
centrifuged at 10,000 x g for 10 minutes. The pellet was then resuspended in 200 µl of
isolation buffer and centrifuged at 10,000 x g for 10 minutes. This step was repeated
again to remove residual

125

I-DNSP-11. All samples were quantified for counts per

minute (CPM) by gamma counter (1 min.; preset energy range 15 to 17 KeV;
CobraIIAuto-Gamma, Packard) (Turchan-Cholewo, 2015).
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NON-HUMAN PRIMATE STUDIES

Reagents

Unless stated otherwise, all chemicals were of reagent grade and purchased
from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Fisher Chemical Fairlawn, NJ).
DNSP-11 used for intranasal administration was synthesized and purified to >98 %
purity by Genscript (Piscataway, NJ). The modified DNSP-11 sequence (R9K) for
iodination was synthesized by Mimotopes (Richmond, VA) and found to be > 98 % by
reverse phase high performance liquid chromatography (HPLC). The modified peptide
sequence (R9K) was found to be > 98 % by reverse phase HPLC after iodination ( 125I)
by the Bolton-Hunter method synthesized by PerkinElmer (North Billerica, MA). For
intranasal administration, DNSP-11 was dissolved in vehicle (0.9 % saline, Hospira, Inc.
Lake Forest, IL) prior to each dosing.

Ethics Statement

All animal procedures were approved by the University of Kentucky Institutional
Animal Care and Use Committee in agreement with AAALAC guidelines.

Animals and MPTP administration

Six female rhesus macaques (Macaca mulatta) between the ages of 10-18 years
and weighing between 4-8 kg were used in the present study (n=3 per group). As this
was a pilot study to examine the repeated intranasal delivery of DNSP-11 in a higher
order animal, we examined different concentrations of DNSP-11 by dose-escalation in
three animals to minimize the number of NHPs utilized. The other three NHPs received
vehicle for the duration of the study and served as controls. All NHPs were obtained
from Covance (Alice, TX, USA) and individually housed in the animal facility at the
University of Kentucky School of Medicine. All NHPs were maintained on a 12 hour
light/dark cycle, with food provided once daily and water available ad libitum.
Veterinarians skilled in the health care of NHPs supervised the care of all NHPs. The
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animal facility strictly follows the guidelines set by the National Institutes of Health, and
are fully accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC). NHP protocols were strictly followed by
researchers and approved by the University of Kentucky Institutional Animal Care and
Use Committee (IACUC).
All

NHPs

were

administered

1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine

hydrochloride (MPTP) to mimic the early stage of PD (Ding et al., 2008). MPTP (0.12 –
0.17 mg/kg, Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% sterile saline (0.2
mg/ml, Baxter) and administered through the right internal carotid artery at rate of 2
ml/min under sterile surgical conditions as previously described (Ding et al., 2008). All
NHPs were clinically monitored for at least 3 months post-MPTP to insure lesion stability
prior to the start of intranasal administration (Grondin et al., 2002b, Ding et al., 2008).

Atomizer Design and Calibration

Our atomizer was modified from a similar set up utilized by Deadwyler and coauthors examining intranasal delivery of Orexin-A in NHPs (Deadwyler et al., 2007).
Briefly, the atomizer (DeVilbiss model number: DV-151; Summit Medical, St. Paul, MN)
was connected to a Picospritzer III (Parker; Pine Brook, NJ), which regulated the
duration and pressure of the intranasal spray burst, driven by medical grade N2 at 40 psi
(Figure 4.3). A volume of 207 µl of DNSP-11 + 10 % at various concentrations was used
to allow for maximum delivery with two nasal sprays (1 x per nare) (Dhuria et al., 2010,
Djupesland, 2013).The Picospritzer III settings were set at a 1-1.5 second duration
(display should read, 010 or 015) and the pressure gauge on the Picospritzer III itself
was set at 16 PSI (Figure 4.3).
After determining the pressure and volume parameters for our atomizer system,
Test sprays were collected in 1.5 ml LoBind Eppendorf tubes (Sigma-Aldrich), and an
ELISA used to confirm we were delivery the designated concentration of DNSP-11 per
spray burst. Briefly, 96 wells plates were coated with 100 µl of a 100 mM carbonate
coating buffer (0.015 M Na2CO3 and 0.035 M NaHCO3 in 500 ml dH2O, pH=9.6) plus the
samples sprays overnight at 4oC. Plates were rinsed with washing solution (PBS +
0.05% Tween 20) and incubated in blocking buffer (PBS + 0.1% BSA) for 1 hr at room
temperature. The plate was then rinsed with washing solution and the primary polyclonal
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(DNSP-11) antibody (1:2000 dilution) was added and incubated at 4oC overnight. The
plate was rinsed with washing solution and the secondary antibody added (peroxidase
labeled anti-rabbit IgG (H+L); 1:10,000) and allowed to incubate for 1 hr at room
temperature.
A Vectastain Elite ABC kit (Vector Laboratories; Burlingame, CA) was used for
further processing of the samples. At room temperature, 5 ml of reagent A (H2O2) and 5
ml of reagent B (3, 3’, 5, 5’-tetramethylbenzide) (TBM) were mixed and kept out of light
until use. The plate was rinsed with the washing solution and the reagent mixture was
added to each well and allowed to incubate for 20 min (in the dark). The reaction was
quenched by the addition of 50 µl of stop solution (IM sulfuric acid). The plate was
immediately read using an optical density of 450 nm on a Spectramax 340 PC
(Molecular Devices; Sunnyvale, CA) using SoftMax Pro software (Molecular Devices;
Sunnyvale, CA).

Vertical Chair Training and Acclimation to Atomizer

Prior to training, the animal handler worked closely with the NHPs so as to make
them comfortable with the individual performing vertical chair training. For vertical
chairing, all NHPs were fitted with a hard nylon collar (Primate Products). Collars are
equipped with a metal hinge used to secure the NHP to the vertical chair. In the first few
training sessions, the pole to be attached to the NHP’s collar was introduced to all
NHPs. The few next training sessions consisted of attaching the pole to the collar,
without removing the NHP from its home cage. Once the NHP was successful
acclimated to the pole and collar method of transport, the next few training sessions
involved removing the NHPs from their home cages to become acclimated with the room
while attached to the pole.
After the NHP was trained on the pole and collar method of transportation, a
custom-fabricated vertical NHP chair was introduced into the room for acclimation
(Andersen et al., 2002, Zhao et al., 2010). Once the NHP was properly acclimated with
the vertical chair in the room, training sessions escalated to slowly maneuvering the
NHP into the vertical chair, again using the pole and collar method of transport. At this
point, the head restraint apparatus and chin stabilizer (foam wedge placed under the
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NHP’s chin) were introduced. This step is important as it restrains the NHP’s head and
angles it to approximately 450 (Figure 4.2A & B).
After the NHPs were trained the pole and collar method of transport and vertical
chairing, they were introduced to the atomizer while sitting in the chair. Training sessions
then progressed to dosing each NHP with saline using the atomizer, strictly following the
daily intranasal dosing procedure that would later be used for this study. In total,
acclimation to the pole, vertical chair, and atomizer lasted approximately 2-4 weeks with
training progression based on each individual NHP. Individual training sessions typical
lasted approximately 10-30 mins for one individual NHP, depending on willingness to
perform the tasks for that day. During training sessions, NHP’s were rewarded with
preferred foods.

Experimental Timeline

The experimental timeline for the present study utilized various increasing
concentrations (0, 0.3, 1.0, 3.0, and 10.0 mg) of DNSP-11 in vehicle that were
administered 4 consecutive days a week, with increases in dose every 2 weeks over the
course of a 10 week period (Figure 4.1). A dose escalation allowed us to examine (1) the
efficacy of different doses of DNSP-11 to monitor adverse side effects and (2) to
determine if different doses had an effect on behavioral measures/outcomes including
mMAP and Ethovision analysis.

Specifically, mMAP testing and body weight

measurements occurred every off day of the end of a dosing week, while video
recordings occurred every 2 weeks, after mMAP testing and marked the ending of a
dosing period (Figure 4.1).

Intranasal Administration Procedure

For daily intranasal dosing, each NHP was removed from their home cage using
the pole and collar method of transportation, and guided into a custom-fabricated NHP
vertical chair modified for intranasal delivery (Andersen et al., 2002, Zhao et al., 2010)
(Figure 4.2A & B). The NHP was then transported to an adjacent room and allowed to
acclimate to its surroundings for at least 5 minutes. During the acclimation period, the
NHP was rewarded with different types of positive reinforcement (e.g. television, music
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and/or approved NHP food). Following acclimation, the NHP’s head was placed in a
head frame box with a chin stabilizer to elevate the NHP’s head by approximately 45o
degrees (Figure 4.2A & B).
The atomizer was then primed (~ 3 sprays) prior to each test spray. A test spray
was then made into a pre-weighed 1.5 ml protein LoBind eppendorf tube (Sigma-Aldrich,
St. Louis, MO) to determine if the atomizer was delivering the correct volume. If at that
point the atomizer was not delivering the proper volume, slight adjustments to the
pressure (psi) or burst time (sec) were made. The NHP was then administered the first
of two nasal sprays, which was allowed to absorb for 5 minutes between sprays while
the NHPs head was still in the angled (450) position. After the 5 minute period, the
process was repeated and another spray administered in the opposite nare (Figure
4.2B). If the NHP moved or sneezed during the dosing process (which rarely occurred),
another spray was given based on whether or not the majority (< 50 %) of fluid was
ejected into the nasal cavity. After dosing was completed the NHP was returned to its
home cage. The 1.5 ml protein LoBind eppendorf tubes (Sigma-Aldrich, St. Louis, MO)
containing test sprays were then re-weighed and transferred to a -20oC freezer for
storage (Kelps et al., 2011).

Cage-Side Observations and Body Weight Measurements

NHPs were video recorded (approximately 5 min) using a SONY Handy camera
in the NHP’s home cage approximately 60 minutes after each intranasal administration
(Figure 4.1). Cage-side observations and video recordings allowed us to (1) monitor the
NHP’s general health after dosing (i.e. nasal irritation, lack of appetite, vomiting, seizures
and/or general malaise), and (2) record changes that may occur. Body weight
measurements were taken at the end of the dosing week after behavioral tests were
performed (Figure 4.1).

monkey Movement Assessment Panel (mMAP)

Our previously described mMAP was used to quantify functional recovery of the
upper limbs (motor performance) by way of food retrieval from a level platform placed in
a receptacle chamber equipped with photocells interfaced to a computer (Gash et al.,
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1999, Grondin et al., 2000, Zhang et al., 2000, Maswood et al., 2002, Grondin et al.,
2003a). Prior to the start of the study, each NHP was trained in their homecage to use
the mMAP device using preferred foods. After training, baseline fine (hand) and coarse
(arm) motor speeds were established over 3 to 4 separate testing sessions. Our group
has previously published that the rhesus macaque generally reaches a plateau level of
performance on the platform task by the third to forth mMAP training session (Zhang et
al., 2000). After chair training and acclimation to the atomizer, a new mMAP baseline for
fine (hand) and coarse (arm) motor speed was established to ensure that a typical
chairing and intranasal dosing session would not influence behavioral task the next day.
During mMAP testing sessions, each NHP performed a total of 12 retrieval trials
using miniature marshmallows, alternating between the right and left limbs (6 trials per
upper limb). Again, mMAP testing occurred at the end of each dosing week (NHPs were
not dosed on behavior days). For analysis, both fine (hand) and coarse (arm) motor
performance were average together for each 2 week dosing period. Additionally,
atomizer baseline mMAP testing and vehicle mMAP testing were averaged for both fine
(hand) and coarse (arm).

Videorecording for EthoVision Analysis

The details of this procedure have been previously described in great deal by
Walton and co-authors (Walton et al., 2006). Briefly, the EthoVision video-tracking
system measures different parameters which include distance traveled (cm), movement
speed (cm/sec) and vertical activity (sec) that are quantified from video-recordings using
EthoVision Pro Software (version 2.3, Noldus Information Technology, Asheville, NC)
(Walton et al., 2006). Prior to the start of the study, 2-3 videotaping sessions were
conducted to determine each NHPs baseline distance traveled (cm) and movement
speed (cm/sec) (Walton et al., 2006).
For video-recordings, NHPs were transferred to videotaping cages located in a
separate room in the animal facility, specifically designed to be used in EthoVision
analysis (Walton et al., 2006). NHPs were allowed to habituate to their surroundings,
and given water ad libitum and a small amount of produce as a reward. All videotaping
sessions began in the afternoon (between 1 and 2 pm) and consisted of two 30 minute
recording periods with two food pick up tasks in between using a Sony HandyCam
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Vision Camera (SONY P6-120 MPL). The food pick up task consisted of each NHP
retrieving 6 mini-marshmallows from each receptacle (total of 12), where the NHP was
forced to used either the right or left upper limb to retrieve the reward. The videorecorded food pick-up tasks were used to score motor performance to assess UPDRS
severity (Zhang et al., 2006b).

Tissue Processing for Neurochemical Analysis, Gamma Counting and
Autoradiography

At the end of the 10-week dosing period all six NHPs were anesthetized with an
initial dose of ketamine hydrochloride (10-20 mg/kg, Fort Dodge) and then placed under
light isoflurane anesthesia (2 % with 1 % oxygen) in a supine position with the head tilted
back 45o where they received a final intranasal administration of vehicle or DNSP-11 at
the highest dose of 10 mg (5 mg per nare). One NHP was administered a final dose of
125

I-labeled DNSP-11 (5 mCi/10 mg DNSP-11, 2.5 mCi/5 mg per nare), using the

modified (R9K) sequence used in our intranasal rat tracer studies (Stenslik et al., 2015).
For the duration of the 60 minute period, the NHPs remained under light isoflurane
anesthesia (2% with 1% oxygen) while in the supine position. The NHP which received
the radioactive dose remained under a fume hood to lessen the likelihood of exposure to
aerosolized radioactive material. In that NHP, approximately 1 ml blood was collected
from the saphenous vein every 15 min post dosing with radiolabeled DNSP-11 (t=0).
Approximately 60 minutes post dosing with vehicle or DNSP-11, all NHPs were laid on
their side and CSF (approximately 0.5 ml) was removed via lumbar puncture. The NHPs
were then deeply anesthetized (5 % isoflurane with 1 % oxygen) and immediately given
a fatal dose of sodium pentobarbital (250-300 mg, intravenously, Vortech, Dearborn,
Michigan, MI). NHPs were then transcardialy perfused with ice-cold heparinized saline (4
ml per 4 L of saline, Baxter). In the NHP which received the radioactive dose,
approximately 5 ml of urine was aspirated from the bladder, the olfactory bulbs (right &
left), trigeminal nerves (right & left), and pituitary gland were also removed and kept on
wet ice for immediate gamma counting analysis.
The brains were immediately processed into 2 mm-thick coronal slabs using a
brain mold that was refrigerated (4o C) in normal saline prior to use. Sections containing
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the striatum were laid flat on a piece of foam padding and placed over dry-ice. Multiple 2
mm-diameter biopsy punches were taken for neurochemical analysis from the caudate
nucleus (n=4-5 per hemisphere), putamen (n=9 per hemisphere), nucleus accumbens
(n=1 per hemisphere), and globus pallidus (n=2-3 per hemisphere) (Figure 4.4). Tissue
punches were then placed in pre-weighted tubes, weighed, flash frozen with dry-ice, and
stored at -70oC.
Tissue punches for gamma counting analysis spanned the frontal, motor and
occipital cortices (6 punches per cortical areas hemisphere), caudate nucleus (4
punches per hemisphere), putamen (6 punches per hemisphere), globus pallidus (2
punches per hemisphere), nucleus accumbens (1 punch per hemisphere), amygdala (1
punch per hemisphere), and the cerebellum (6 punches per hemisphere) (Figures 4.26 &
4.28). Tissue punches and other samples were placed in pre-weighted tubes, weighed
and placed on wet-ice for immediate gamma counting analysis. For analysis, tissue
punches were combined (left and right hemisphere) for a particular region to determine
the average CPM per mg of wet-tissue weight.

Neurochemical Analysis of Dopamine, Serotonin, and Metabolite Levels in the
Striatum
For HPLC-EC analysis, tissue samples were processed for dopamine (DA), 3,4 –
dihydroxy-phenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-HT), 5hydroxyindoleacetic acid (5-HIAA) and norepinephrine (NE) and detected using an
isocratic HPLC system (Bechman, Inc., Fullerton, CA) that was coupled to a dualchannel electrochemical array detector (ESA, Inc., 5100A, E1 +0.35 mV and E2 -0.25
mV

with

a

5011

dual

analytical

cell).

The

separation

of

the

compounds

(neurotransmitters and metabolites) was done using a C18 column (4.6 mm x 75 mm, 3
µm particle size, ODS Hypersil; Keysonte Scientific) with mobile phase (citrate-acetate,
pH 4.0) (Hall et al., 1989).

Gamma Counting and Autoradiography Analysis

To determine the amount of

125

I signal present (counts per minute, CPM),

samples were analyzed using a Perkin-Elmer (Packard) Cobra II Gamma Counter
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(preset energy range 15 to 75 KeV). Each sample (100 µl for fluid and wet weight (g) for
tissue) was place in a 12 x 75 mm polypropylene disposable culture tube (Fisher
Scientific, Pittsburgh, PA), and counts per minute (CPM) values were determined over a
1 minute period. CPM values for the olfactory bulbs (left and right), trigeminal nerves (left
and right), and tissue punches for specific regions were combined to determine the
average signal. CPM values were then normalized (CPM/mg of wet-tissue weight) to the
weight of each sample. For autoradiography analysis, brain slab were placed in a GE
autoradiography cassette and exposed to film for 24 hours, and then visualized using a
Typhoon 9400 phosphoimager (GE Health Care).
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CHAPTER THREE: Methodology and Effects of Repeated Intranasal Delivery of
DNSP-11 in a Rat Model of PD

Introduction

Neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF)
have shown great promise in treating an array of neurodegenerative diseases such as
Parkinson’s disease (PD) (Gash et al., 1996, Gill et al., 2003, Peterson and Nutt, 2008).
However, as with many protein biotherapeutics, neurotrophic factors are unable to cross
the blood-brain barrier due to their large size and poor bioavailability following both oral
and systemic administration (Chapman et al., 2013). To directly target the central
nervous system (CNS), neurotrophic factors such as GDNF have been delivered by
direct intraparenchymal infusion (Lin et al., 1993, Grondin et al., 2002b, Gill et al., 2003,
Slevin et al., 2005). However, its poor biodistribution after surgical implantation of a
catheter into the brain, likely due to GDNF’s high affinity heparin-binding domains, has
resulted in failed phase II clinical trials (Gill et al., 2003, Lang et al., 2006, Salvatore et
al., 2006, Slevin et al., 2006a). To overcome the challenges associated with the invasive
delivery of neurotrophic factors and other large molecules, numerous studies have
shown that intranasal administration is effective in delivering compounds including but
not limited to peptides to the CNS (Thorne and Frey, 2001, Ross et al., 2004, Thorne et
al., 2004b, Dhuria et al., 2009a, Dhuria et al., 2010, Migliore et al., 2014). Therefore, the
discovery and development of smaller molecules with neuroprotective or restorative
properties that can be used in a less invasive delivery regimen, such as intranasal
administration, is an attractive therapeutic strategy for treating neurodegenerative
diseases (Bradley et al., 2010, Kelps et al., 2011, Fuqua et al., 2014).
Dopamine neuron stimulating peptide-11 (DNSP-11) is a synthetic, amidated 11amino acid neuroactive peptide derived from the human GDNF pro-domain (Immonen et
al., 2008, Bradley et al., 2010, Kelps et al., 2011, Fuqua et al., 2014). In both E14
primary neurons derived from the ventral mescencephalon of Sprague Dawley rats and
dopaminergic neuron cell lines, our team demonstrated that DNSP-11 is able to promote
neuronal growth, differentiation, and activate the phosphorylation of ERK1/2 as well as
providing protection against apoptosis and cell death through mechanisms not directly
involving its binding to the GFRα-1 receptor (Bradley et al., 2010, Kelps et al., 2011,
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Fuqua et al., 2014). Furthermore, following a single intranigral infusion of DNSP-11 our
team has shown that DNSP-11 increases levels of dopamine (DA) and its active
metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic (HVA), and
increases potassium evoked release in the striatum of normal Fischer 344 (F344) rats
(Bradley et al., 2010, Fuqua et al., 2014), while decreasing apomorphine-induced
rotation in a unilateral 6-hydroxydopamine (6-OHDA) rodent model of PD (Bradley et al.,
2010). Based on DNSP-11’s in vitro and in vivo bioactivity (Bradley et al., 2010, Fuqua et
al., 2014), lack of heparin binding sites lending to increased biodistribution (Bradley et
al., 2010, Kelps et al., 2011), and stable structure allowing for long term storage (Bradley
et al., 2010; Kelps et al., 2011), we hypothesized that DNSP-11 would be an attractive
candidate to test the efficacy of repeated intranasal administration in both normal and a
unilateral 6-OHDA striatal lesion rat model that mimics the later stages of PD (Kirik et al.,
1998).
In this series of studies, we report the methodology for intranasal delivery of
DNSP-11 and demonstrate the efficacy of repeated intranasal administration of DNSP11 on the nigrostriatal system in both normal and in unilaterally 6-OHDA lesioned F344
rats, using light isoflurane anesthesia. Utilizing the optimal dosage (300 µg) determined
from our dose response study in normal rats, we investigated changes in damphetamine-induced rotation, DA turnover [(DOPAC + HVA/DA)], and tyrosine
hydroxylase (TH) positive (+) neuronal sparing in a unilateral 6-OHDA lesion model of
the striatum (Kirik et al., 1998). Additionally, we investigated DNSP- 11’s distribution in
the brain and its uptake into CSF and blood following a single intranasal dose of 125Ilabeled DNSP-11 as a function of time. Collectively, our results demonstrate for the first
time that DNSP-11 is able to be delivered to the CNS intranasally and maintains its
neuroactivity on dopamine neurons in both normal rats and unilaterally 6-OHDA lesioned
rats, after repeated intranasal administration.

Methods and Materials

Ethics Statement

All animal procedures were approved by the University of Kentucky Institutional
Animal Care and Use Committee in agreement with AAALAC guidelines.
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Materials

All chemicals were either purchased from Sigma-Aldrich (St. Louis, MO) or
Fisher Scientific (Fisher Chemical Fairlawn, NJ). DNSP- 11 was synthesized and purified
to >98% purity by Genscript (Piscataway, NJ) for all studies. The modified DNSP-11
sequence (R9K) was synthesized by AAPPTec (Louisville, KY) and iodinated (125I) via
the Bolton–Hunter method by PerkinElmer (North Billerica, MA) and purified to ≥93% by
reverse phase HPLC. DNSP-11 was dissolved in 0.9% saline (Hospira, INC., Lake
Forest, IL) for all in vivo studies in which it has previously been shown to be stable
(Kelps et al., 2011).

Intranasal Administration of DNSP-11

For all in vivo studies, male F344 rats between 3 and 8 months old were utilized.
Rats were obtained from Harlan Laboratories Inc. (Indianapolis, IN) and were housed on
a 12 h light/dark cycle with water and food provided to rats ad libitum. For all intranasal
studies, rats were initially lightly anesthetized using an induction chamber and then
transferred to a nose cone where they continued to receive light isoflurane anesthesia
(1.0–3.0% with 1.0% oxygen) for the duration of the dosing period, typically lasting a
total of 20 min. While in a supine position, each rat received a total volume of 50 µl of
either vehicle or a mixture of DNSP-11 in an equivalent volume of vehicle. Prior to each
intranasal dose, the rats were removed from a nose cone and the tip of an Oxford
Benchmate pipette (range: 10–50 µl) was placed at the tip of the rat’s nare (Figure 3.1A).
A total of 12.5 µl was administered to each nare in 3–4 µl droplets allowing the rat to
inhale the solution over the course of approximately 30–45 s (Figure 3.1B). After
administering 12.5 µl to the first nare (time = 0), the solution was allowed to absorb for 5
min prior to dosing the opposite nare. This regimen was repeated a total of 4 times
alternating between nares (2 times per nare) (Thorne et al., 2004b, Dhuria et al., 2010).
For all intranasal experiments, excluding tracer studies, researchers were blinded to
intranasal treatments for all in vivo experiments, excluding tracer studies.
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Dose Response in Normal Rats (HPLC-EC Neurochemical Analysis)

Previous studies in rodents have indicated that generally <1% of compounds
administered intranasally enter the CNS (Gozes et al., 2000, Thorne and Frey, 2001,
Thorne et al., 2004b, Dhuria et al., 2010, Lochhead and Thorne, 2012). To take into
account lower levels of delivery to the CNS, we examined half-log steps above and
below a 10-fold increase from the most effective DNSP-11 dosage (30 µg) determined
from previous infusion studies in rodents (Lundblad et al., 2002, Bradley et al., 2010,
Fuqua et al., 2014). In this study, rats received 100 µg (n=6), 300 µg (n=6) or 1000 µg
(n=6) DNSP-11 in vehicle or vehicle alone (n = 9), 5 days a week for 3 weeks under light
isoflurane (1.0–3.0% with 1% oxygen) anesthesia (Figure 3.2A). At 3 weeks, rats were
euthanized under heavy isoflurane anesthesia (5.0% with 1% oxygen), and the brain
was removed, submerged in ice-cold saline and then placed in a brain mold (on dry ice)
where 2 mm sections of the entire striatum at the optic chiasm and SN were harvested
and frozen at −80oC for neurochemical analysis.
For HPLC-EC analysis, pre-weighed (wet weight) tissue samples from the SN
and striatum were thawed and immediately processed, as described previously (Cass et
al., 2003). A total of 50 µl of filtrate (in mobile phase) was injected onto an HPLC
column. Retention times of DA standards and dihydroxybenzylamine (DHBA), which was
used as an internal standard, were used to identify peaks and used to determine tissue
levels (DA, DOPAC, HVA) found in each brain sample represented as ng/g wet weight of
the tissue sample (Cass et al., 2003).

Unilateral, 3-site, 6-OHDA Striatal Lesion

Rats were intranasally pre-treated daily with either 300 µg (selected from the
dose response study) of DNSP-11 in vehicle, or vehicle alone, for 7 days prior to 6OHDA lesion. On the day of surgery, rats received intranasal treatment (DNSP-11 or
vehicle) approximately 60 min prior to 6-OHDA infusion under isoflurane anesthesia
(Figure 3.1A & B). Rats were then placed in a stereotaxic frame and received isoflurane
(1.0–2.0% with 1% oxygen) throughout the duration of surgery. Using previously
published procedures and stereotaxic coordinates (Kirik et al., 1998, Lundblad et al.,
2002) to target the dorsal striatum, injection sites for 6-OHDA infusion included: ((1) AP:
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+1.0, ML: −3.0, DV: −5.0); (2) AP: −0.1, ML: −3.7, DV: −5.0; (3) AP: −1.2, ML: −4.5, DV:
−5.0)). Each injection site received 10 µg/2.5 µl of the 6-OHDA in 0.2 % ascorbic acid
sterile saline solution for a total dose of 30 µg/7.5 µl using a 26 gauge Hamilton syringe.
Designated blinded intranasal treatments continued post-6-OHDA infusion, 7 days a
week for a total of 5 weeks (35 ± 3 days) (Figure 3B).

d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats

Prior to rats entering the study (n=29), an exclusion criterion was used to test for
baseline hemisphere asymmetry with d-amphetamine (2.5 mg/kg, i.p.). Rats were
excluded (n = 8) from entering the study if baseline rotation exceeded ≥160 turns per
hour in either direction (clockwise and/or counterclockwise). After 6-OHDA infusion, rats
(n = 21) received d-amphetamine (2.5 mg/kg, i.p.) at both 2 and 4 weeks to assess
lesion severity (Figure 3.2B). Rats were placed in automated rotometer bowls and
clockwise rotations were recorded over the course of 24 intervals that lasted 300 s (5
min) each using SDI Rotation (San Diego, CA USA). For analysis, only the peak 60 min
rotation time was used after the first 15 min had elapsed (Hudson et al., 1993, Hoffer et
al., 1994). On the day of testing, rats were not anesthetized and/or given their
designated blinded intranasal treatment.

Cylinder Forepaw Asymmetry Test

Prior to entering the study, baseline rearing and paw placement were observed
utilizing a modified version of the cylinder test (Schallert et al., 2000). Here, an exclusion
criterion was used and rats were excluded from entering the study if paw placements
were asymmetrical. Rats used in this study did not exhibit asymmetry and were not
excluded using this criterion. On the day of cylinder testing, rats were not anesthetized
and did not receive their designated treatment so a true drug effect could be examined.
Rats were placed in a 40 cm tall x 16 cm diameter clear plexiglass cylinder for
approximately 5 minutes in a dark room. Video recordings were taken using a SONY
Handy camera for 5 minutes using a video camera to capture each rats behavior during
the animals normal dark cycle (Schallert et al., 2000, Lundblad et al., 2002). Right and
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left paw placements (forelimb use) were observed during rearing and upon landing, prior
to treatment (baseline) and at 2 and 4 weeks post 6-OHDA lesion.

DA and DA Metabolite Levels in the Striatum of 6-OHDA Lesioned Rats

At 5 weeks post-6-OHDA lesion, rats were heavily anesthetized with isoflurane
(5.0% with 1% oxygen) and transcardially perfused using approximately 200 ml of icecold saline. The brain removed, placed in an ice-cold saline bath and then placed in an
ice-cold brain mold (on dry-ice) where 2 mm thick sections were taken and the entire
striatum was removed. Tissue was then flash frozen utilizing dry ice and stored at −80◦C
for later HPLC-EC analysis. For HPLC-EC analysis, tissue samples were processed in
the same manner as previously discussed except a total of either 50 or 25 µl of filtrate in
mobile phase was injected onto the HPLC column. If analytes were undetectable at
these injection volumes, samples were run on a C18 column (4.6 mm × 75 mm, 3 µm
particle size, Shiseido CapCell Pak UG120, Shiseido Co., LTD., Tokyo, Japan) with a
more sensitive limit of detection was used (Hall et al., 1989).

Tissue Processing for TH+ Neurons in the SN of 6-OHDA Lesioned Rats

After the striatum was removed for later HPLC-EC analysis the midbrain was
blocked off and immersioned fixed in a 4% paraformaldehyde solution for 24 h. Tissue
was then submerged in increasing sucrose concentrations (15 & 30%) and frozen at
−80oC. Frozen serial coronal sections (30 µm) were cut on a sliding microtome and
stored in cryoprotectant solution (30% sucrose, 30% ethylene glycol in 100 mM sodium
phosphate buffered saline (NaPBS), pH 7.2)) at −20oC (Kearns and Gash, 1995).
For staining purposes, every sixth series free floating serial coronal section was
stained for tyrosine hydroxylase (TH) as previously published with minor adjustments (Ai
et al., 2003a). Sections were treated with the primary antibody against TH overnight
(1:10,000; Millipore, Billerica, MA) and then incubated in biotinylated horse anti-mouse
secondary antibody (1:5,000; Vector, Burlingame, CA) for 1h at controlled room
temperature (21–22◦C). Tissue was then incubated with avidin–biotin–peroxidase
complex using an Elite ABC Vectastain kit (Vector; Burlingame, CA) and TH
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immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB) with nickel
enhancement.

TH+ Neurons and Fiber Density in 6-OHDA Lesioned Rats
TH+ neurons were counted at three different levels: −5.24 mm, −5.60 mm and
−5.96 mm with respect to bregma using BioQuant Image Analysis System (BioQuant,
Nashville, TN USA) (Watson, 1986). The oculomotor nerve root was used to determine
the borders of the substantia nigra pars compacta (SNpc) from the ventral tegmental
area (Kearns and Gash, 1995). The degree of dopaminergic sparing on the ipsilateral
side to the lesion was determined by comparing the average total number of TH+
neurons at each level examined in rats treated with either DNSP-11 or vehicle.
The substantia nigra pars reticulata (SNpr) was also examined to determine TH+
fiber density (total area of the SNpr with TH+ immunoreactive staining) and measured
using BioQuant Image Analysis Software at all three levels for rats (n=5 vehicle; n=6
DNSP-11) that were perfused, free of background staining due to remnants of blood
vessels. Data were average for each section for statistical analysis. One rat was
removed from all TH+ neuronal counts and fiber density analysis, as tissue depth was
inconsistent because of sectioning problems with the microtome.

Modification (R9K) of DNSP-11 for 125I Tracer Studies
To determine DNSP-11’s viability after modification (R9K) MN9D cells were
cultured in DHEM and supplemented with 10% Fetal Bovine Serum (FBS, Hyclone), 50
U/ml penicillin and streptomycin. For protection studies, cells were plated on 24-well
poly-D-lysine in DHEM with 1% (v/v) penicillin-streptomycin. The cells were grown at
37oC in 5% CO2. The dUTP nick-end labeling (TUNEL) assay was performed as
previously reported (Bradley et al., 2010). MN9D cells were administered STS (1 µM)
and treated with either the original and/or modified (R9K) DNSP-11 peptide (10 nM). The
percent from control was determined by the ratio of apoptotic versus total cells (Figure
3.10).
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Distribution Studies (Gamma Counting & Autoradiography) in Normal Rats

Rats were administered a one-time dose of

125

I-labeled DNSP-11 (50 µl/50 µCi-

300 µg DNSP-11) while under light isoflurane anesthesia (Figure 3.1A & B). At 30 (n=4),
60 (n=3) and 360 (n=3) min after the start of the first intranasal dose (time = 0), CSF was
immediately collected (Figure 3.2C). For CSF collection, a modified version presented by
(Nirogi et al., 2009) was used. Rats were placed upright and the back of the head was
shaved while a piece of gauze was placed under the neck angling the rat’s head
downward 45 degrees. The rat was then deeply anesthetized with isoflurane (5.0% with
1% oxygen) and the foramen magnum was located using the wings of the atlas and
occipital protuberance as landmarks. A 23-gauge needle (affixed to a short length of
tubing connected to a 1.0 ml syringe) was inserted at the midline center point and 100–
120 µl of CSF was removed. The flexible tubing attached to the syringe allowed for the
syringe to be clamped off using hemostat forceps as a fail-safe prior to blood
contaminating the CSF sample.
Prior to transcardial perfusion, 500 µl of blood was removed via aortic puncture
and rats were then perfused with 200 ml of ice-cold saline. The brain was removed, the
olfactory bulbs were removed at the frontal cortex, and the brain was then placed into a
brain mold (on wet ice). Eleven 2 mm thick coronal slabs were then harvested and all
brain, CSF, and blood samples were immediately analyzed by gamma counting (Cobra II
Auto-Gamma, Packard). Both brain and CSF samples were only quantified by gamma
counting if no blood was visible. To determine normalized concentrations of tracer found
in each sample, the counts per minute (CPM) values for all samples (brain, CSF, blood)
were divided by the CPM value determined for the total

125

I-labeled dose (50 µl/50 µCi–

300 µg DNSP-11) that was then normalized by the weight (mg) or volume (µl) of the wet
sample.
For autoradiography analysis, one rat was administered a one- time

125

I-labeled

DNSP-11 (50 µl/50 µCi–300 µg DNSP-11) and euthanized 60 min after the start of the
first intranasal dose. The rat was transcardially perfused with 200 ml of ice-cold saline
and 200 ml of 4% paraformaldehyde. Frozen sagittal brain sections were taken using a
cryostat (0.5 mm thick). Sections were then exposed for 21 days on a GE phosphor
screen (Thorne et al., 2004b), and analyzed for radioactive signal (Typhoon 9400, GE
Health Care).
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I-Labeled DNSP-11 Mitochondrial Import Assay

To examine

125

I-labeled DNSP-11’s uptake into mitochondria, total mitochondria

were isolated as previously reported (Sauerbeck et al., 2011) with minor adjustments.
Mitochondria were isolated from all anatomical brain regions excluding the cerebellum
due to differences in basal mitochondrial bioenergetics (Sauerbeck et al., 2011).
Animals were asphyxiated with CO2, decapitated where the brain was removed and
placed in ice-cold isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 1mM
EGTA and 20 mM HEPES at pH 7.2). CNS samples were homogenized and centrifuged
at 1300 x g for 3 minutes at 4oC. Supernatants were collected and centrifuged at 13,000
x g for 10 minutes at 4oC. The pellets were combined and resuspended in 500 µl of
isolation buffer and placed in a nitrogen bomb for 10 minutes. Samples were then placed
on a Ficoll separation column (consisting of both 10 and 7.5% Ficoll layers). Samples
were then centrifuged at 100,000 x g for 30 minutes at 4oC. The mitochondrial pellet was
resuspended in isolation buffer with EGTA and centrifuged at 10,000 x g for 10 minutes
at 4oC to remove any Ficoll from the purified mitochondria. The mitochondrial pellet was
then resuspended in isolation buffer without EGTA and yielded a final concentration of
approximately 20 mg/ml.
To examine classic import of

125

I-DNSP-11 into healthy mitochondria, for all

import assays approximately 20 µg/µl of purified mitochondria were resuspended in 200
µl of respiration buffer. To drive active transport in healthy mitochondria, the first set of
the tubes received respiration buffer which contained sucrose (50 mM), ATP (10 mM),
ADP (8 mM). The second group of tubes received mitochondrial toxins which included
FCCP (25 µM), Oligomycin (10 µM), Antimycin A (250 µM) in normal respiration buffer. A
third set of tubes were boiled in a dry-bath incubator at 100oC for 40 minutes in normal
respiration buffer. All tubes were treated with

125

I-DNSP-11 (0.42 µM) while control tubes

contained purified mitochondria and normal respiration buffer only. Healthy and toxin
treated tubes were incubated in a water bath at 37oC for 30 minutes. All tubes were then
centrifuged at 10,000 x g 10 minutes. The pellet was then resuspended in 200 µl of
isolation buffer and centrifuged at 10,000 x g for 10 minutes. This step was repeated
again to remove residual

125

I-DNSP-11. All samples were quantified for counts per

minute (CPM) by gamma counter (1 min.; preset energy range 15 to 17 KeV;
CobraIIAuto-Gamma, Packard) (Turchan-Cholewo, 2015).
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Statistical Analysis

Prior to statistical analysis one animal was removed from the 6-OHDA study as
d-amphetamine-induced counterclockwise rotations exceeded that of clockwise rotations
and did not observe a ≤ 90% depletion of striatal DA. Neurochemical (analyte and/or DA
turnover) analyses for both normal and 6-OHDA lesioned rats were analyzed by a oneway ANOVA with Bonferroni’s post hoc test. A two-way ANOVA with repeated measures
with Bonferroni’s post hoc test was used to analyze d-amphetamine-induced rotation
and in cylinder forepaw asymmetry analysis in 6-OHDA lesioned rats. TH+ neurons of
the SNpc and fiber density of the SNpr for three different sections (rostral, middle, and
caudal) were analyzed by a two-tailed unpaired t-test comparing the ipsilateral sides to
the lesion (right hemisphere) of DNSP-11 treated rats versus vehicle. A one-way
ANOVA with Bonferroni’s post hoc test was used to analyze gamma counting data
examining the average tracer (125I) levels of each brain section (OB-combined left and
right, B2–B11), CSF and blood samples. To determine if the modest (R9K) modification
for

125

I-labeling changed DNSP-11’s protective effects in the presences of staurosporine

a One-way ANOVA with Tukey’s multiple comparison was used to test for significance.
Lastly, to examine differences in

125

I-labeled DNSP-11’s (R9K) uptake into isolated CNS

mitochondria after toxin or boiled treatments in comparison to the control treatment an
unpaired two-tailed t-test was used. Statistical significance was defined as p < 0.05 for
all analyses.

Results

Dose Response of DNSP-11 in Normal Rats

A dose-response study was carried out to determine the minimum dose of
DNSP-11that would produce consistent effects on DA neurons, following intranasal
administration in normal F344 rats. The levels of DA, DOPAC and HVA in the striatum
and SN of normal rats were measured by HPLC-EC following intranasal administration
of vehicle or DNSP-11 (100, 300, or 1000 µg) for 5 days a week, for 3 weeks. The 300
µg dosage of DNSP-11 produced significant changes in DOPAC (p < 0.05) and HVA (p
< 0.05) in the SN (Table 3.1). As changes in individual DA and/or metabolite (DOPAC &
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HVA) levels were observed, DA turnover levels were examined as a more reliable index
of changes in DA function following intranasal DNSP- 11. Rats treated with 300 µg of
DNSP-11 represented the lowest dose that produced significant increases in DA
turnover in both the striatum (25%, p < 0.05) and the SN (34%, p < 0.05), compared to
vehicle (Table 3.1, Figure 3.3A & B). The 1000 µg intranasal dose produced a significant
increase in DA turnover in the SN, but not the striatum (Table 3.1, Figure 3.3A & B),
suggesting that higher repeated intranasal dosing is either ineffective and/or region
specific in normal rats. Based on these effects, we selected the 300 µg intranasal dose
of DNSP-11 for all other subsequent in vivo experiments presented in this manuscript
(Figure 3.2B–C).

d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats

d-Amphetamine induced rotation was assessed to determine the severity of the
unilateral 6-OHDA lesion (Hudson et al., 1993, Lundblad et al., 2002). On days of damphetamine testing, rats were not intranasally dosed to mitigate effects of isoflurane
anesthesia. Analysis of d-amphetamine induced rotations following 6-OHDA lesion
showed a significant 55% decrease at 2 weeks (p < 0.05) and a 35% decrease at 4
weeks (p>0.05) in d-amphetamine induced rotation, compared to vehicle (Figure 3.4). At
week 4 of testing, attrition of the rats was observed in both the vehicle (n = 2) and
DNSP-11 (n = 4) treated groups a few hours after d-amphetamine injection.

Cylinder Forepaw Asymmetry Test in 6-OHDA Lesioned Rats

The cylinder test was used to examine forepaw asymmetry in both the DNSP-11
and vehicle treated groups at both 2 and 4 weeks post-6-OHDA lesion. The data are
presented as the percent of left paw placements on the cylinder after rearing and the
percent of total left paw landings (Figure 3.5A & B). Cylinder testing occurred on days in
which the rats were not given their specific treatment or d-amphetamine testing to
mitigate the effects of isoflurane and/or d-amphetamine. There was no statistically
significant difference between the DNSP-11 and vehicle treated groups in terms of the
percent of left paw placements at both 2 (p=0.9414) and 4 (p>0.9999) weeks post-lesion
(F(1,24)=0.09129; p=0.7651) (Figure 3.5A). Similarly, there was no statistically significant
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difference found between treatment groups at either 2 (p>0.9999) or 4 (p=0.9453) weeks
post-lesion in terms of the percent of total left paw landings (F(1,24)=1.0874; p=0.3074)
(Figure 3.5B).

Tissues Levels of DA and DA Metabolites in the Striatum of Unilateral 6-OHDALesioned Rats

To determine lesion severity in terms of neurochemical content, the entire
striatum was removed 5 weeks post 6-OHDA lesion (Figure 3.2B). It is important to note
that initial HPLC-EC analysis revealed undetectable DA, DOPAC and/or HVA levels in
some rats (n = 8). As samples were limited, those which observed undetectable levels
were run on a HPLC-EC system with a lower limit of detection. Therefore, comparisons
in analyte levels for statistical purposes were reserved to ratios instead of direct
comparisons of individual analyte levels (Table 3.2).
HPLC-EC analysis of striatal tissue revealed at least a ≥ 90% depletion of DA in
the ipsilateral side to the lesion (right hemi- sphere) compared to the contralateral side to
the lesion (left hemisphere) in all rats (Table 3.2). DNSP-11 treated rats exhibited a 39%
(p < 0.01) reduction in DA turnover in the ipsilateral side to the lesion compared to
vehicle (Table 3.2, Figure 3.6). Similarly, when comparing the ipsilateral to contralateral
sides to the lesion, vehicle treated rats exhibited a 159% (p < 0.0001) increase in DA
turnover, whereas the DNSP-11 treated rats showed a smaller 59% (p < 0.05) increase
(Table 3.2, Figure 3.6), indicating that DA turnover on the ipsilateral side to the lesion
was approaching basal levels in comparison to the contralateral sides to the lesion of
vehicle or DNSP-11 treated rats (Figure 3.6).

TH+ Neurons and Fiber Density
To further evaluate DNSP-11’s effects in a unilateral 6-OHDA lesion model. The
SN was processed for TH+ neurons and the average total number of TH+ neurons was
determined in sections representing the rostral, middle, and caudal regions (Figure 3.6).
Analysis indicated statistically significant sparing of TH+ neurons in the middle
section/region of the SNpc (29 ± 5) of DNSP-11 treated rats compared to vehicle (13 ±
2; p < 0.05; Figure 3.7A–D and 3.8). While sparing was not observed in the more rostral
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region/section (p > 0.05; Figure 3.8), there was a 44% increase in the average total
number of TH+ neurons in the caudal region/section (p > 0.05; Figure 3.8) of the SNpc in
DNSP-11 treated rats compared to vehicle. As topographical organization of the
nigrostrial system would suggest, a 6-OHDA lesion of the dorsolateral striatum would
likely exhibit greater losses of dopaminergic cell bodies at the more middle and caudal
regions of the SNpc, (Schwarting and Huston, 1996b) thereby supporting the greater
observed loss of TH+ neurons in both the middle and caudal sections of the SNpc
(Figure 3.8). Conversely, examination of the SNpr fiber density from the same tissue
sections used for cell counts exhibited no change (p > 0.05) in any of the three sections
(Table 3.3).

Distribution Studies Following Intranasal Administration

Previous tracer studies examining FITC, Gd (gadolinium) and Biotin-labeled
DNSP-11 were used to examine DNSP-11’s distribution in the olfactory system and CNS
after intranasal administration (data not shown). Do to issues of tracer sensitivity,
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I-

labeling, a classic tracer used in previously published intranasal studies was utilized and
is presented here (Gozes et al., 2000, Thorne and Frey, 2001, Ross et al., 2004, Thorne
et al., 2004b, Thorne et al., 2008, Lochhead and Thorne, 2012).
To understand the distribution of DNSP-11 following intranasal administration,
F344 rats were administered a single intranasal dose of the

125

I-labeled modified DNSP-

11(R9K) in vehicle (50 µl/50 µCi–300 µg DNSP-11) (Figure 3.9). Distribution in the CNS,
CSF, and blood were analyzed by gamma counting at 30, 60 and 360 min after the start
of the first intranasal dose (time = 0) (Figure 3.2C). Gamma counting analysis revealed
that radioactive signal was detected diffusely throughout the brain at every time point
(Table 3.4), with visibly higher signal found in the olfactory bulbs at 60 min (p > 0.05;
Table 3.4). Furthermore, qualitative autoradiography analysis supports this observation,
showing radioactive signal diffusely throughout the CNS and at visibly higher levels in
the olfactory bulbs at 60 min (Figure 3.9A & B). Cumulatively, tracer studies indicated
increased radioactive signal in the olfactory bulbs at 60 min, and both the CSF and blood
30 min after the first intranasal dose (p > 0.05; Figure 3.9A–C; Table 3.4). Furthermore,
radioactive signal was observed in targeted regions of the nigrostriatal system in brain
(B) sections (B3–7) in as little as 30 min and continuing up to 360 min thereafter (Table
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3.4; Figure 3.9A & B). Additionally,

125

I-labeled DNSP-11’s rapid uptake is further

supported by its import into isolated mitochondria after either classic and/or non-classic
import mechanism (Figure 3.11) This distribution is similar to other rodent intranasal
tracer studies showing CNS distribution in as early as 15–30 min following intranasal
administration of compounds of similar and larger molecular weight (Gozes et al., 2000,
Thorne and Frey II, 2001, Thorne et al., 2004b, Dhuria et al., 2009c, 2010, Lochhead
and Thorne, 2012)..

Discussion

A major challenge in treating neurodegenerative disorders such as PD with
neurotrophic molecules has been the delivery of large compounds across the blood
brain barrier (BBB) to the CNS (Gash et al., 1996). There has been the need for the
development of smaller molecular weight compounds capable of affecting the
nigrostriatal system and that can be used in less-invasive delivery methods such as
intranasal administration (Gozes et al., 2000, Thorne and Frey II, 2001, Thorne et al.,
2004b, Dhuria et al., 2009c, 2010, Lochhead and Thorne, 2012). As previously
discussed, our team has shown that DNSP-11 while having similar in vitro and in vivo
actions as GDNF, is also distinct in its ability to protect against cell-induced cytotoxicity
in dopaminergic neurons using a mechanism that does not involve binding to the GFRα1 receptor (Bradley et al., 2010, Fuqua et al., 2014). To the best of our knowledge, this is
the first demonstration to show that repeated intranasal administration of DNSP-11; (1)
alters DA, DOPAC, HVA, and DA turnover in the striatum and SN of normal rats, (2)
exhibits protective and/or restorative effects in a unilateral 6-OHDA striatal lesion model
of PD, and (3) can be traced after a one-time µI-labeled DNSP-11 intranasal dose to
CSF and targeted regions of the CNS (striatum and SN).
To determine efficacy, our dose response study examined the repeated
intranasal administration of various doses of DNSP-11 while using light isoflurane
anesthesia. We showed that repeated administration of 300 µg of DNSP-11 is capable of
stimulating DA turnover in both the striatum and SN in normal rats (Sonne, 2013). These
results are similar to neurochemical findings in normal rats after a single intranigral
injection of DNSP-11 (Bradley et al., 2010, Fuqua et al., 2014). Using the selected 300
µg DNSP- 11 dose, we then examined its ability to either protect and/or restore function
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in the nigrostriatal system after a unilateral 6-OHDA lesion to the dorsolateral striatum,
which mimics the later stages of PD (Kirik et al., 1998). We show that repeated
intranasal administration of DNSP-11 was able to significantly decrease d- amphetamine
induced rotation at 2 weeks (p < 0.05) by 55% and was trending on significance by 35%
at week 4 (p > 0.05). Interestingly, in a separate small group of rats (data not shown), we
observed that d-amphetamine-induced rotations also showed a decreased after 6 weeks
of DNSP-11 administration as compared to vehicle (data not shown). The observed
decrease

in

d-amphetamine-induced

rotation

suggests

either

sparing

and/or

improvement of the remaining dopaminergic terminals found in the lesioned striatal
hemisphere (Hudson et al., 1993). These results are similar to our previously published
findings that indicated DNSP-11 decreased apomorphine-induced rotation by 50% in a
unilateral MFB lesion rat model 4 weeks post infusion following a single direct intranigral
infusion (Bradley et al., 2010). In addition, we note that we switched to d-amphetamineinduced rotation measures in these studies due to the use of the Kirik and co-authors
unilateral 6-OHDA lesion model (Kirik et al., 1998), expecting more of a partial lesion of
the DA neuronal system. However, our HPLC-EC studies demonstrate that we achieved,
on average, extensive (>98%) DA lesions of the nigrostriatal pathway, supporting that
perhaps low dose apomorphine-induced rotation would have likely been a better test for
the extensive DA lesions and possible DA receptor supersensitivity that we produced
(Hudson et al., 1993). Additional studies in other models may help better characterize
the potential of intranasal DNSP-11 treatments to damaged DA neurons.
At week 4 of d-amphetamine testing, an attrition rate was observed in both the
vehicle (n = 2) and DNSP-11 (n = 4) treated groups. The d-amphetamine dose (2.5
mg/kg, i.p.) used in this study is not known to cause such an attrition rate, even at higher
doses (5.0mg/kg, i.p.) (Hudson et al., 1993). However, Datla and co-authors have shown
that isoflurane, when used as an anesthetic during 6-OHDA infusion, increased both
TH+ dopaminergic cell loss in the SNpc and striatal DA depletion as measured by
HPLC-EC compared to other anesthetics (Datla et al., 2006). Furthermore, the
concomitant repeated daily doses of isoflurane used in our study for intranasal delivery,
in addition to the 6-OHDA lesion, may have been a contributing factor to the observed
attrition and lack of a statistically significant effect of the cylinder forepaw asymmetry
test. Therefore, a “build-up toxicological-effect” is thought to be at play in our studies. We
caution to other investigators that repeated use of isoflurane anesthesia may not be the
optimum anesthetic to use for repeated intranasal administration in rats.
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As our present unilateral 6-OHDA lesion model targeted the dorsolateral striatum
(Kirik et al., 1998), neurochemical results after repeated intranasal administration of
DNSP-11 parallel previous intranigral infusion findings in that DNSP-11 was capable of
decreasing DA turnover by 35% (p < 0.01) in the ipsilateral striatum compared to vehicle
(Zigmond et al., 1990, Bradley et al., 2010, Fuqua et al., 2014). Moreover, while the
sparing of TH+ neurons in the SN was not evident in the rostral region (p > 0.05), the
caudal and middle sections did show either a trend or statistically significant (p < 0.05)
sparing of TH+ neurons, respectively (Figure 3.8).
The intranasal administration of DNSP-11 allowed for bilateral administration of
DNSP-11 as compared to prior studies, where it was administered unilaterally by direct
injection into the CNS. In contrast to the intranasal delivery of DNSP-11 in normal rats,
we saw no evidence for a similar effect on the unlesioned side in the unilateral 6-OHDAlesioned rats. This is in contrast to the contralateral effects of GDNF that we observed in
aged and MPTP-treated nonhuman primates from unilateral intracranial administration
(Gash et al., 1996, Grondin et al., 2002a). While puzzling this may relate to the effects of
the extensive unilateral 6-OHDA lesion on the nigrostriatal pathway and the fact that we
did not examine other neuronal systems that could be affected by the bilateral
administration of DNSP-11. Future studies will investigate the effects of DNSP-11 in
other model systems, such as movement impaired aged rats, which exhibit bilateral
dopamine neuron deficits.
To

better

understand

DNSP-11’s

route

of

transport

administration, we examined a one-time intranasal dose of

after

intranasal
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I-labeled DNSP-11 in

normal rats as a function of time. Numerous studies in rodents have demonstrated the
rapid up- take of radiolabeled compounds after intranasal administration which has been
contributed to (1) CSF found in the perineural spaces surrounding the olfactory sensory
neurons (OSNs) and/or (2) perivascular delivery to the CNS powered by bulk flow
through the propulsion of arterial blood and diffusion (Gregory et al., 1985, Gozes et al.,
2000, Thorne and Frey II, 2001, Hadaczek et al., 2006, Syková and Nicholson, 2008,
Dhuria et al., 2009a, Wolak and Thorne, 2013). Paralleling previous tracer studies in
rodents, we demonstrate the rapid up-take of our tracer in CSF and CNS in as early as
30min and persisting for at least 360 min after a one-time intranasal dose; with visually
higher signal of tracer found in the olfactory bulbs at 60 min and in the most caudal
section of the brainstem at 30 min (p > 0.05). These findings are again consistent with
other intranasal studies that implicate the rapid transport of different compounds by the
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OSNs to the olfactory bulbs and trigeminal nerves (Thorne et al., 2004b). While the
olfactory system is highly vascularized by facial arteries and/or through the transport by
the lymphatic system (Thorne and Frey II, 2001, Thorne et al., 2004a, Thorne et al.,
2008), it is likely that DNSP-11 would not be delivered systemically to the CNS due to a
half-life of less than 12min in rat plasma (data not shown). Collectively, these data show
diffuse signal throughout the CNS at each time point, indicating a rapid delivery
mechanism after intranasal administration to the CNS that suggesting a combination of
either perivascular and/or perineural transport (Gozes et al., 2000, Dhuria et al., 2009c,
Laukova et al., 2014).
In summary, this series of studies provides methodology for intranasal
administration of DNSP-11 and indicates (1) the efficacy of repeated intranasally
administered DNSP-11 using light isoflurane anesthesia and (2) its ability to affect the
nigrostriatal system in both normal and 6-OHDA lesioned rodents. Using a determined
bioactive dose (300 µg), repeated intranasal administration of DNSP-11 was able to
regulate DA turnover after a lesion to the dorsolateral striatum, and area equivalent to
that of the human putamen, which sees the greatest loss of DA in PD (Kirik et al., 1998).
We also observed increased sparing of TH+ neurons in specific regions of the SNpc,
which saw some of the highest losses of TH+ neurons in our rat model system.
Furthermore, our
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I-labeled study indicates sufficient biodistribution throughout the

CNS and in targeted regions of interest (striatum & SN). Collectively, this series of
experiments supports further investigation of intranasally administered DNSP-11, in
other PD model systems due to its effects on the nigrostriatal system following repeated
administration (Bradley et al., 2010, Kelps et al., 2011, Fuqua et al., 2014)(Bradley et al.,
2010; Fuqua et al., 2014; Kelps et al., 2011).
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Chapter Three: Figures and Tables

Figure 3.1 Diagram for Intranasal Administration in Rats
For all in vivo intranasal studies rats were anesthetized with isoflurane (A) and
administered either vehicle or DNSP-11 while in a supine position. (B) For intranasal
dosing a micropipetter containing 12.5 µl of either vehicle or DNSP-11 in an equivalent
volume of vehicle was administered (Stenslik et al., 2015)
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Figure 3.2 Experimental Timeline for Rat Studies
Three major studies designs were used to determine the efficacy of repeated
intranasally administered DNSP- 11’s effects on the nigrostriatal system in both normal
and unilateral 6-OHDAlesioned rats using isoflurane anesthesia. (A) To determine the
efficacy of our intranasal delivery method and adequate dosing, normal rats were
subjected to repeated intranasal administration of various doses of DNSP-11, 5 days a
week for 3 weeks (21 days). (B) Utilizing the determined dosage from experiment A, the
efficacy of intranasally administered DNSP-11’s effects on the nigrostriatal system were
examined in a unilateral 6-OHDA (right hemisphere) lesion model of PD where rats were
treated with either vehicle or DNSP-11 daily, 1 week (7 days) prior to unilateral 6-OHDA
infusion, 1 h prior to 6-OHDA infusion and 5 weeks (35 ± 3 days) post-surgery. Prior to
the start of the study baseline d-amphetamine rotation data were determined and at both
2 and 4 weeks post unilateral 6-OHDA infusion to assess lesion severity. For
experiments A and B, researchers were blinded to the treatments throughout the entirety
59

of the studies. (C) Tracer studies examined
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I-labeled DNSP-11’s distribution at 30, 60,

and 360 min after the start of the first intranasal dose in blood, CSF and the CNS
(Stenslik et al., 2015).
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Figure 3.3 HPLC-EC Studies of DA Turnover in Normal Rats
Normal rats were repeatedly administered either vehicle (open circles), 100 (red
squares), 300 (green diamonds) or 1000 (blue triangles) g of DNSP-11 intranasally 5
days a week for 3 weeks. (A) At 300 g a significant increase (p = 0.0230) in basal DA
turnover was observed compared to vehicle in the striatum. (F(3,23) = 4.520, p =
0.0124) (B) In addition, a significant increase in DA turnover was observed in the SN at
both 300 (p = 0.0129) and 1000 g (p = 0.0217) compared to vehicle (F(3,23) = 9.818, p =
0.0002). All data were analyzed using a one-way ANOVA with Bonferroni’s post-hoc test
* p < 0.05. All data are shown as mean ± SEM, n = 9 vehicle and n = 6 DNSP-11 treated
rats (Stenslik et al., 2015).
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Figure 3.4 d-Amphetamine-Induced Rotation in 6-OHDA Lesioned Rats
d-Amphetamine-induced rotation at 2 & 4 weeks post unilateral 6-OHDA lesion in rats
after repeated intranasal administration of DNSP-11 or vehicle. d-Amphetamine (2.5
mg/kg i.p.) rotation was assessed prior to 6-OHDA lesion and again at 2 and 4 weeks
post-surgery and data are presented as the number of peek clockwise turns per hour. A
significant decrease in rotation was observed at 2 weeks (* p = 0.0210) but not at 4
weeks (p = 0.1176) compared to vehicle treated rats. Data were analyzed using a twoway ANOVA with repeated measures (F(1,18) = 0.0210, p = 0.0283) with Bonferroni’s post
hoc test. Animals taken out to 6 weeks (data not shown) observed a 21% reduction in damphetamine-induced rotations in DNSP-11 (1069 ± 47; n = 3) compared to vehicle (840
± 127; n = 2) treated animals. When animals taken out to 6 weeks were added back into
the analysis, d-amphetamine-induced rotation became significant at both 2 (p = 0.0180)
and 4 (p = 0.0315) weeks post lesion (data not shown) in DNSP-11 (n = 13) compared to
vehicle (n = 12) treated rats. Data presented as mean ± SEM, n = 10 vehicle, n = 10
DNSP-11 (Stenslik et al., 2015).
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Figure 3.5 Cylinder Test in 6-OHDA Lesioned Rats
Asymmetrical forepaw placement was examined using the cylinder test at baseline (prior
to lesion) and both 2 and 4 weeks post-lesion in both the DNSP-11 and vehicle treated
groups. (A) In terms of the percent of left paw placements (effected paw) there was no
statistically significant difference at baseline (p>0.9999) or 2 (p=0.9414) and 4
(p>0.9999) weeks post-lesion between treatment groups (F(2,24)=0.09129; p=0.7651). (B)
From the same testing session the percent of total left paw landings was not statistically
significant at baseline (p=0.6696) or at 2 (p>0.9999) and 4 (p=0.9453) post-lesion
between treatment groups (F(1,24)=1.087; p=0.3074). Data are presented as the mean +
SEM and data were analyzed using a RM-Two way ANOVA with Bonferroni’s post hoc
test.
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Table 3.1. Average Tissues Levels of DA and DA Metabolites in Normal Rats after
Repeated Intranasal Administration of DNSP-11.
Individual analyte (DA, DOPAC and HVA) levels (ng/g—wet tissue weight) and DA
turnover ratios of the whole (combined hemispheres) striatum and SN of normal rats
treated with vehicle or DNSP-11 (100, 300, 1000 g) in an equivalent volume of vehicle 5
days a week for 3 weeks. In normal rats, a stimulation of the DA system is evident by
increased DA turnover in the striatum and SN for the 300 g dosage (as well as an
increase in DA turnover in the SN for the 1000 g dosage). All data were analyzed using
a one-way ANOVA with Bonferroni’s post-hoc test * p < 0.05. All data are presented as
mean ± SEM, n = 9 vehicle and n = 6 per DNSP-11 treated group (Stenslik et al., 2015).

Intranasal Treatment
Brain
Region

Vehicle

100µg

300µg

1000µg

one-way

(ng/g)

(ng/g)

(ng/g)

(ng/g)

ANOVA

12427

9043

11923

9910

P=0.0527,

+ 564

+ 1427

+ 904

+ 991

F(3,23)=2.98

1919

1257

2422

1574

P=0.0022,

+ 133

+ 174

+ 259

+ 186

F(3,23)=6.63

832

570

843

658

P=0.0555,

+ 85

+ 78

+ 63

+ 60

F(3,23)=2.92

(DOPAC+

0.220

0.216

* 0.274

0.227

P=0.0124,

HVA)/DA

+ 0.009

+ 0.017

+ 0.013

+ 0.010

F(3,23)=4.52

620

481

815

416

P=0.0186,

+ 83

+ 83

+ 83

+ 71

F(3,23)=4.07

151

103

* 269

124

P=0.0009,

+ 23

+ 20

+ 29

+ 27

F(3,23)=7.74

55

37

* 81

51

P=0.0012,

+6

+7

+7

+4

F(3,23)=7.43

(DOPAC+

0.332

0.289

* 0.443

* 0.436

P=0.0002,

HVA)/DA

+ 0.011

+ 0.017

+ 0.036

+ 0.032

F(3,23)=9.82

Analyte
DA

DOPAC
Striatum
HVA

DA

DOPAC
SN
HVA
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Table 3.2. Average Tissues Levels of DA and DA Metabolites in Unilaterally 6-OHDA
Lesioned Rats after Repeated Intranasal Administration of DNSP-11.
Individual analyte levels (ng/g—wet tissue weight) of the contralateral (unlesioned) and
ipsilateral (lesioned) striatum. DA turnover [(DOPAC + HVA)/DA] ratios were analyzed
by a one-way ANOVA with Bonferroni’s post-hoc test ** p < 0.01. Intranasal
administration of DNSP-11 resulted in a decrease in DA turnover in the lesioned
striatum, suggestive of a protective effect on the DA system. All data are presented as
mean ± SEM, n = 8 vehicle and n = 6 DNSP-11 treated (Stenslik et al., 2015).
Intranasal Treatment

Brain Region

Unlesioned

Neurochemical

Vehicle

300

Analyte

(ng/g)

DNSP-11 (ng/g)

DA

10304+1104

12299+555

DOPAC

2807+457

2422+241

HVA

759+44

861+49

µg

one-way
ANOVA

Striatum

P<0.0001

Lesioned

(DOPAC+HVA)/DA

0.341+0.047

0.257+0.024

DA

123+46

201+171

DOPAC

60+19

58+46

HVA

18+7

21+20

F(3,24)=24.56

Striatum

P<0.0001
(DOPAC+HVA)/DA

0.884+0.074
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**0.538+0.062

F(3,24)=24.56
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Figure 3.6 HPLC-EC Studies of DA Turnover in 6-OHDA Lesioned Rats
HPLC-EC studies of DA turnover [(DOPAC + HVA)/DA] in unilateral (right) 6-OHDA
lesioned rats after repeated intranasal administration of DNSP-11 or vehicle. DNSP-11
treatment significantly decreased DA turnover in the ipsilateral (right/lesioned) striatum
from 0.884 ± 0.074 to 0.538 ± 0.062 ng/g at 5 weeks in 6- OHDA lesioned rats (green
diamonds) compared to vehicle (open circles). Data were analyzed using a one-way
ANOVA (F(3,24) = 24.62, p < 0.0001) with Bonferroni’s post hoc test ** p < 0.01. Data
presented as mean ± SEM, n = 8 vehicle, n = 6 DNSP-11 (Stenslik et al., 2015).
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Figure 3.7 Representative Sections for TH+ Neuronal Cell Counts in 6-OHDA Lesioned
Rats
Representative sections used for TH+ neuronal cell counts and fiber area analysis at the
middle level (−5.60 mm) of the SNpc and SNpr. Scale bars = 200 µm in (A & B) and 100
µm in (C & D) (Stenslik et al., 2015).
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Figure 3.8 TH+ Neuronal Cell Counts in 6-OHDA Lesioned Rats
The effects of repeated intranasal administration of DNSP-11 on TH+ dopaminergic
neurons in the SNpc and fiber area of the SNpr in 6-OHDA unilaterally lesioned rats. The
total number of TH+ neurons were counted from three sections of the lesioned SNpc
after repeated intranasal administration of either vehicle or DNSP-11: Rostral (t(11) =
0.2714, p = 0.7911), Middle (t(11) = 2.703, p = 0.0205), and Caudal (t(11) = 1.223, p =
0.2468). There was no significant difference found between DNSP-11 treated rats or
vehicle in the rostral or caudal regions of the SNpc (mean ± SEM, vehicle: 23 ± 6;
DNSP-11: 25 ± 5) and (mean ± SEM, vehicle: 18 ± 1; DNSP-11: 26 ± 7). There was a
significant increase observed in the average number of TH+ positive neurons in DNSP11 treated rats compared to vehicle (* p < 0.05) in the middle region of the lesioned
SNpc (mean ± SEM, vehicle: 13 ± 2; DNSP-11: 29 ± 5). The data were analyzed by a
two-tailed unpaired t test. Data are shown as mean ± SEM (n = 7 vehicle, n = 6 DNSP11) (Stenslik et al., 2015).
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Table 3.3. The Effects of Repeated Intranasal Administration of DNSP-11 on TH + Fiber
Density in the SNpr in Unilateral 6-OHDA Lesioned Rats.
At all three levels examined for TH+ neurons in the SNpc, the SNpr was examined to
determine changes in fiber density. All data were analyzed using an unpaired t-test. All
data are presented as mean ± SEM with n = 5 vehicle treated, and n = 6 DNSP-11
treated (Stenslik et al., 2015).

Fiber Density for the Lesioned SNpr
SNpr Region

Rostral

Vehicle

DNSP-11

0.20 + 0.03

0.26 + 0.09

Unpaired T-test

t(8) = 0.4987,
p = 0.6314

Middle

0.22 + 0.07

0.41 + 0.20

t(9) = 0.8222,
p = 0.4322

Caudal

1.10 + 0.67

0.91 + 0.41

t(9) = 0.1947,
p = 0.8500
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Table 3.4. Tissue 125I Levels in Normal Rats After a One-Time Bilateral Dose.
Olfactory bulbs (combined—left and right), rostral to caudal 2 mm thick brain sections (B1–B11),
CSF and blood were processed for

125

I levels by gamma counting at 30 (n = 4), 60 (n = 3) and

360 (n = 3) post the start of the first intranasal dose (t = 0). All data were analyzed by a one-way
ANOVA with Bonferroni’s post hoc test. All data are presented as the mean ± SEM normalized
DNSP-11 levels (ng or l/mg—wet sample weight). * Denotes the time point used for intranasal
administration prior to 6-OHDA infusion (Stenslik et al., 2015).
Sample

OB

B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

30 Min

* 60 Min

360 Min

0.083+0.026

0.137+0.062

0.079+0.019

0.067+0.011

0.066+0.023

0.058+0.007

0.058+0.014

0.049+0.022

0.056+0.006

0.048+0.020

0.038+0.017

0.059+0.007

0.061+0.015

0.033+0.013

0.059+0.007

0.071+0.024

0.036+0.025

0.062+0.006

0.065+0.020

0.036+0.018

0.061+0.009

0.063+0.019

0.033+0.013

0.055+0.010

0.061+0.017

0.037+0.015

0.047+0.008

0.063+0.017

0.040+0.021

0.051+0.008

0.078+0.027

0.040+0.017

0.052+0.009

0.114+0.036

0.037+0.013

0.056+0.005

0.24+0.07

0.17+0.09

0.16+0.02

CSF

Blood

1.4+0.3

1.0+0.5

1.0+0.1
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P = 0.5346
F(2,7) = 0.6857
P = 0.9067
F(2,7) = 0.09934
P = 0.9121
F(2,7) = 0.09319
P = 0.7320
F(2,7) = 0.3263
P = 0.3341
F(2,7) = 1.287
P = 0.5445
F(2,7) = 0.6639
P = 0.4796
F(2,7) = 0.8177
P = 0.4182
F(2,7) = 0.9899
P = 0.5549
F(2,7) = 0.6415
P = 0.6168
F(2,7) = 0.5181
P = 0.4671
F(2,7) = 0.8502
P = 0.1550
F(2,7) = 2.462
P = 0.6882
F(2,7) = 0.3944
P = 0.3698
F(2,7) = 1.150

Figure 3.9 One-Time 125I-Labeled DNSP-11 Intranasal Dose in Normal Rats
Tracking of a one-time

125

I-labeled DNSP-11 dose 60 min after intranasal administration.

Normal F344 rats were given a one-time intranasal dose of

125

I-labeled DNSP-11, at 60

min blood (500 l) and cerebrospinal fluid (100–120 l) were collected from each rat and
processed by gamma counting (n = 3) and autoradiography (n = 1). (A) Representative
sagittal brain section (0.5 mm thick), exposed for 21 days on a GE phosphor screen. A
qualitative increase in radioactive signal was found in the olfactory bulbs 60 min post
intranasal administration and diffusely throughout the brain. (B) Data are shown as the
normalized DNSP-11 concentrations (ng or l/mg of wet sample weight) as analyzed by
gamma counting at 60 min. (C) Blood and CSF; the visible increase in radioactive signal
found in the olfactory bulbs at 60 min is consistent with autoradiography. Data are
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presented as the normalized DNSP-11 concentrations (ng or l/mg). Rats treated with
vehicle only were found to have CPM lower then background levels ≤50 (data not
pictured). * Denotes the olfactory bulb of a representative sagittal section of the midbrain
after autoradiography analysis (Stenslik et al., 2015).
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Figure 3.10 Modified (R9K) DNSP-11 Study In Vitro
Tunnel staining in MN9D cells suggests that at 10nM the original and modified DNSP-11
(Arg-9 for Lys) protects against 1uM of staurosporine (STS) at 12 hours. One-way
ANOVA with Tukey’s multiple comparison. Data presented as mean + SEM ***p<0.0001
compared to control and ### p<0.0001 compared to STS. (Data collected by Dr.
Jadwiga Turchan-Cholewo) (Stenslik et al., 2015).
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Figure 3.11 Import of 125I-Labeled DNSP-11 in Isolated CNS Mitochondria
A maximal amount of

125

I-DNSP-11 is internalized into isolated, functioning mitochondria

in vitro. A significant reduction of

125

I-DNSP-11 internalization is observed upon addition

of FCCP (25 µM), Oligomycin (10 µM), and Antimycin A (250 µM) and after 100 0C drybath incubation. An unpaired two-tailed t-test was used to test for significance. *p<0.05
(n=7 samples) and **p<0.01 (n=8 samples) respectively.
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CHAPTER FOUR: Methodology and Effects of Repeated Intranasal Administration
in Awake Hemiparkinsonian Rhesus Macaques

Introduction

The delivery of compounds across the blood-brain barrier (BBB) to the central
nervous system (CNS) has consistently been a major challenge in the treatment of
Parkinson’s disease (PD) and other neurodegenerative diseases (Thorne and Frey II,
2001, Salvatore et al., 2006, Anitua et al., 2008, Aron and Klein, 2011). For example,
glial cell line-derived neurotrophic factor (GDNF) has been shown to have robust effects
on the nigrostriatal system after direct, surgical intraputamenal infusion (Gash et al.,
1996, Grondin et al., 2002b, Maswood et al., 2002, Gill et al., 2003, Grondin et al.,
2003b, Patel et al., 2005, Slevin et al., 2005, Slevin et al., 2007). However, evaluation of
GDNF in phase II clinical trials was met with disappointment (Lang et al., 2006). Issues
surrounding limited biodistribution, likely due to its large molecular weight and high
affinity for heparin binding domains, have been attributed to its poor efficacy in phase II
clinical trials (Salvatore et al., 2006). To circumvent the issues of surgically delivering
compounds to the CNS, numerous studies have examined the use of non-invasive
intranasal administration as an alternative delivery method for the potential treatment of
PD and other neurodegenerative diseases (Gozes et al., 2000, Gozes, 2001, Thorne
and Frey, 2001, Ross et al., 2004, Thorne et al., 2004b, Lagreze et al., 2005, Hanson
and Frey, 2008, Thorne et al., 2008, Dhuria et al., 2009c, d, 2010, Chapman et al., 2013,
Laukova et al., 2014, Migliore et al., 2014, Stenslik et al., 2015).
Recently, our team has demonstrated in a severely lesioned 6-hydroxydopamine
(6-OHDA) rat model of PD that dopamine neuron stimulating peptide-11 (DNSP-11,
PPEAPAEDRSL-NH2), maintains its neuroactive properties (Bradley et al., 2010, Kelps
et al., 2011, Fuqua et al., 2014, Stenslik et al., 2015) after repeated intranasal delivery
using light anesthesia (Stenslik et al., 2015). The current study was designed to extend
these findings by evaluating intranasal delivery of DNSP-11 in non-human primates
(NHPs). The traditional methodology for the repeated intranasal administration of
compounds in rodents utilizes light anesthesia to keep the rodent supine for maximal
absorption to the CNS (Thorne and Frey II, 2001, Dhuria et al., 2010). To eliminate the
use of anesthetic, we developed an intranasal delivery method allowing for the repeated
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administration of DNSP-11 in non-anesthetized (awake) NHPs using a vertical chair and
atomizer system. Based on our prior work in rats administered DNSP-11 intranasally
(Stenslik et al., 2015) together with our previous in vitro studies evaluating the effect of
DNSP-11 against the neurotoxin 1-methyl-4-phenylpyridium (MPP+) (Turchan-Cholewo,
2015), we hypothesized that the repeated intranasal administration of DNSP-11 in a
dose escalating manner would promote restorative effects on the nigrostriatal system in
MPTP-lesioned hemiparkinsonian non-human primates (NHPs) modeling PD.
Here, female rhesus macaques previously rendered hemiparkinsonian via MPTP
administration through the right internal carotid artery and expressing stable symptoms
were used to examine the neuroactive properties of DNSP-11 in a species with a CNS
approaching that of humans. As a dosing paradigm had not yet been established for the
intranasal delivery of DNSP-11 in NHPs, we examined similar concentrations utilized in
our rat studies (Stenslik et al., 2015). For this initial study in NHPs, DNSP-11 was
repeatedly administered intranasally for 4 consecutive days per week over the course of
a 10-week period. The dose of DNSP-11 ranging from 0, 0.3, 1.0, 3.0, to 10.0 mg was
increased every other week. In this study, we report no clinically observable adverse
effects or morbidity following repeated intranasal administration of DNSP-11 for all
concentrations tested. Also,

125

I-labeled DNSP-11 (5 mCi/10 mg DNSP-11 in vehicle)

was shown to distribute throughout the brain and CSF following a one-time bilateral
intranasal delivery 60 minutes prior to study termination. Additionally, we report bilateral
increases in fine (hand) motor speed and neurochemical changes in tissue levels of DA,
DOPAC, HVA, 5-HT, 5-HIAA, NE, DA turnover [(DOPAC+HVA)/DA], DOPAC/DA,
HVA/DA, and 5-HIAA/5-HT. These preliminary data in hemiparkinsonian rhesus
macaques support that DNSP-11 can be repeatedly administered intranasally in nonanesthetized NHPs over an extended period of time without causing adverse effects,
while promoting changes in motor performance and striatal neurochemistry.
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Materials and Methods

Materials

Unless stated otherwise, all chemicals were of reagent grade and purchased
from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Fisher Chemical Fairlawn, NJ).
DNSP-11 used for intranasal administration was synthesized and purified to >98 % by
purity by Genscript (Piscataway, NJ). The modified DNSP-11 sequence (R9K) for
iodination was synthesized by Mimotopes (Richmond, VA) and found to be > 98 % by
reverse phase HPLC (high performance liquid chromatography).

125

I-labeled DNSP-11

was synthesized as described previously (Stenslik et al., 2015). For intranasal
administration, DNSP-11 was dissolved in vehicle (0.9 % saline, Hospira, Inc. Lake
Forest, IL) prior to each dosing week by a researcher.

Non-Human Primates and MPTP Administration

Six female rhesus macaques (Macaca mulatta) between the ages of 10-18 years
and weighing between 4-8 kg were used in the present study (n=3 per group). As this
was a pilot study to examine the repeated intranasal delivery of DNSP-11 in a higher
order animal, we examined different concentrations of DNSP-11 by dose-escalation in
three animals to minimize the number of NHPs utilized. The other three NHPs received
vehicle for the duration of the study and served as controls. All NHPs were obtained
from Covance (Alice, TX, USA) and individually housed in the animal facility at the
University of Kentucky School of Medicine. All NHPs were maintained on a 12 hour
light/dark cycle, with food provided once daily and water available ad libitum.
Veterinarians skilled in the health care of NHPs supervised the care of all NHPs. The
animal facility strictly follows the guidelines set by the National Institutes of Health, and
are fully accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC). NHP protocols were strictly followed by
researchers and approved by the University of Kentucky Institutional Animal Care and
Use Committee (IACUC).
All

NHPs

were

administered

1-metyl-4-phenyl-1,2,3,6-tetrahydropyridine

hydrochloride (MPTP) to mimic the early stage of PD (Ding et al., 2008). MPTP (0.12 –
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0.17 mg/kg, Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% sterile saline (0.2
mg/ml, Baxter) and administered through the right internal carotid artery at rate of 2
ml/min under sterile surgical conditions as previously described (Ding et al., 2008). All
NHPs were clinically monitored for at least 3 months post-MPTP to insure lesion stability
prior to the start of intranasal administration (Grondin et al., 2002b, Ding et al., 2008).

Atomizer Design and Calibration

Our atomizer was modified from a similar set up utilized by Deadwyler and coauthors examining intranasal delivery of Orexin-A in NHPs (Deadwyler et al., 2007).
Briefly, the atomizer (DeVilbiss model number: DV-151; Summit Medical, St. Paul, MN)
was connected to a Picospritzer III (Parker; Pine Brook, NJ), which regulated the
duration and pressure of the intranasal spray burst, driven by medical grade N2 at 40 psi
(Figure 4.3). A volume of 207 µl of DNSP-11 + 10 % at various concentrations was used
to allow for maximum delivery with two nasal sprays (1 x per nare) (Dhuria et al., 2010,
Djupesland, 2013).The Picospritzer III settings were set at a 1-1.5 second duration
(display should read, 010 or 015) and the pressure gauge on the Picospritzer III itself
was set at 16 PSI (Figure 4.3).
After determining the pressure and volume parameters for our atomizer system,
test sprays were collected in 1.5 ml LoBind Eppendorf tubes (Sigma-Aldrich), and an
ELISA used to confirm we were delivery the designated concentration of DNSP-11 per
spray burst. Briefly, 96 wells plates were coated with 100 µl of a 100 mM carbonate
coating buffer (0.015 M Na2CO3 and 0.035 M NaHCO3 in 500 ml dH2O, pH=9.6) plus the
samples sprays overnight at 4oC. Plates were rinsed with washing solution (PBS +
0.05% Tween 20) and incubated in blocking buffer (PBS + 0.1% BSA) for 1 hr at room
temperature. The plate was then rinsed with washing solution and the primary polyclonal
(DNSP-11) antibody (1:2000 dilution) was added and incubated at 4oC overnight. The
plate was rinsed with washing solution and the secondary antibody added (peroxidase
labeled anti-rabbit IgG (H+L); 1:10,000) and allowed to incubate for 1 hr at room
temperature.
A Vectastain Eliste ABC kit (Vector Laboratories; Burlingame, CA) was used for
further processing of the samples. At room temperature, 5 ml of reagent A (H2O2) and 5
ml of reagent B (3, 3’, 5, 5’-tetramethylbenzide) (TBM) were mixed and kept out of light
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until use. The plate was rinsed with the washing solution and the reagent mixture was
added to each well and allowed to incubate for 20 min (in the dark). The reaction was
quenched by the addition of 50 µl of stop solution (1M sulfuric acid). The plate was
immediately read using an optical density of 450 nm on a Spectramax 340 PC
(Molecular Devices; Sunnyvale, CA) using SoftMax Pro software (Molecular Devices;
Sunnyvale, CA).

Vertical Chair Training and Acclimation to Atomizer

Prior to training, the animal handler worked closely with the NHPs so as to make
them comfortable with the individual performing vertical chair training. For vertical
chairing, all NHPs were fitted with a hard nylon collar (Primate Products). Collars are
equipped with a metal hinge used to secure the NHP to the vertical chair. In the first few
training sessions, the pole to be attached to the NHP’s collar was introduced to all
NHPs. The few next training sessions consisted of attaching the pole to the collar,
without removing the NHP from its home cage. Once the NHP was successful
acclimated to the pole and collar method of transport, the next few training sessions
involved removing the NHPs from their home cages to become acclimated with the room
while attached to the pole.
After the NHP was trained on the pole and collar method of transportation, a
custom-fabricated vertical NHP chair was introduced into the room for acclimation
(Andersen et al., 2002, Zhao et al., 2010). Once the NHP was properly acclimated with
the vertical chair in the room, training sessions escalated to slowly maneuvering the
NHP into the vertical chair, again using the pole and collar method of transport. At this
point, the head restraint apparatus and chin stabilizer (foam wedge placed under the
NHP’s chin) were introduced. This step is important as it restrains the NHP’s head and
angles it to approximately 45o (Figure 4.2A & B).
After the NHPs were trained the pole and collar method of transport and vertical
chairing, they were introduced to the atomizer while sitting in the chair. Training sessions
then progressed to dosing each NHP with saline using the atomizer, strictly following the
daily intranasal dosing procedure that would later be used for this study. In total,
acclimation to the pole, vertical chair, and atomizer lasted approximately 2-4 weeks with
training progression based on each individual NHP. Individual training sessions typical
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lasted approximately 10-30 mins for one individual NHP, depending on willingness to
perform the tasks for that day. During training sessions, NHP’s were rewarded with
preferred foods.

Daily Intranasal Administration of DNSP-11 in NHPs

For daily intranasal dosing, each NHP was removed from their home cage using
the pole and collar method of transportation, and guided into a custom-fabricated NHP
vertical chair modified for intranasal delivery (Andersen et al., 2002, Zhao et al., 2010)
(Figure 4.2A & B). The NHP was then transported to an adjacent room and allowed to
acclimate to its surroundings for at least 5 minutes. During the acclimation period, the
NHP was rewarded with different types of positive reinforcement (e.g. television, music
and/or approved NHP food). Following acclimation, the NHP’s head was placed in a
head frame box with a chin stabilizer to elevate the NHP’s head by approximately 45o
degrees (Figure 4.2A & B).
The atomizer was then primed (~ 3 sprays) prior to each test spray. A test spray
was then made into a pre-weighed 1.5 ml protein LoBind eppendorf tube (Sigma-Aldrich,
St. Louis, MO) to determine if the atomizer was delivering the correct volume. If at that
point the atomizer was not delivering the proper volume, slight adjustments to the
pressure (psi) or burst time (sec) were made. The NHP was then administered the first
of two nasal sprays, which was allowed to absorb for 5 minutes between sprays while
the NHPs head was still in the angled (450) position. After the 5 minute period, the
process was repeated and another spray administered in the opposite nare (Figure
4.2B). If the NHP moved or sneezed during the dosing process (which rarely occurred),
another spray was given based on whether or not the majority (< 50 %) of fluid was
ejected into the nasal cavity. After dosing was completed the NHP was returned to its
home cage. The 1.5 ml protein LoBind eppendorf tubes (Sigma-Aldrich, St. Louis, MO)
containing test sprays were then re-weighed and transferred to a -20oC freezer for
storage (Kelps et al., 2011).
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Experimental Timeline

We

have

previously

published

that

DNSP-11

stimulates

DA

turnover

[(DOPAC+HVA)/DA] at 0.3 mg in normal rats after repeated intranasal administration in
both the striatum and substantia nigra (Stenslik et al., 2015). Taking into account the
increase in brain size between the rat and NHP brain, we examined half-log step
increases above and below the neuroactive dose determine in normal rats (Stenslik et
al., 2015). Concentrations of DNSP-11 included 0, 0.3, 1.0, 3.0, and 10.0 mg of DNSP11, in vehicle, administered 4 consecutive days a week, with increases in dose occurring
bi-weekly over the course of a 10 week period (Figure 4.1). During the study, daily cageside observations were made approximately 60 min after the start of the first intranasal
dose (t=0). Additionally, (monkey Movement Assessment Panel) mMAP testing and
body weight measurements occurred at the end of the week on the off day dosing, with
video-recording for Ethovision analysis occurred bi-weekly (Figure 4.1). A dose
escalation allowed us to examine: (1) the efficacy of different doses of DNSP-11 while
monitoring potential adverse clinical side-effects, and (2) to determine if different doses
had an effect on behavioral measures (mMAP).

Cage-Side Observations and Body Weight Measurements

NHPs were video recorded (approximately 5 min) using a Sony HandyCam
Vision Camera (SONY P6-120 MPL) in the NHP’s home cage approximately 60 minutes
after each intranasal administration (Figure 4.1). Cage-side observations and video
recordings allowed us to (1) monitor the NHP’s general health after dosing (i.e. nasal
irritation, lack of appetite, vomiting, seizures and/or general malaise), and (2) record
changes that may occur. Body weight measurements were taken at the end of the
dosing week after behavioral tests were performed (Figure 4.1).

monkey Movement Assessment Panel (mMAP)

Our previously described mMAP was used to quantify functional recovery of the
upper limbs (motor performance) by way of food retrieval from a level platform placed in
a receptacle chamber equipped with photocells interfaced to a computer (Gash et al.,
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1999, Grondin et al., 2000, Zhang et al., 2000, Maswood et al., 2002, Grondin et al.,
2003a). Prior to the start of the study, each NHP was trained in their homecage to use
the mMAP device using preferred foods. After training, baseline fine (hand) and coarse
(arm) motor speeds were established over 3 to 4 separate testing sessions. Our group
has previously published that the rhesus macaque generally reaches a plateau level of
performance on the platform task by the third to forth mMAP training session (Zhang et
al., 2000). After chair training and acclimation to the atomizer, a new mMAP baseline for
fine (hand) and coarse (arm) motor speed was established to ensure that a typical
chairing and intranasal dosing session would not influence behavioral task the next day.
During mMAP testing sessions, each NHP performed a total of 12 retrieval trials
using miniature marshmallows, alternating between the right and left limbs (6 trials per
upper limb). Again, mMAP testing occurred at the end of each dosing week (NHPs were
not dosed on behavior days). For analysis, both fine (hand) and coarse (arm) motor
performance were average together for each 2 week dosing period. Additionally,
atomizer baseline mMAP testing and vehicle mMAP testing were averaged for both fine
(hand) and coarse (arm).

Videorecording for EthoVision Analysis

The details of this procedure have been previously described in great detail by
Walton and co-authors (Walton et al., 2006). Briefly, the EthoVision video-tracking
system measures different parameters, which include distance traveled (cm), movement
speed (cm/sec) and vertical activity (sec) that are quantified from video-recordings using
EthoVision Pro Software (version 2.3, Noldus Information Technology, Asheville, NC)
(Walton et al., 2006). Prior to the start of the study, 2-3 videotaping sessions were
conducted to determine each NHPs baseline distance traveled (cm) and movement
speed (cm/sec) (Walton et al., 2006).
For video-recordings, NHPs were transferred to videotaping cages located in a
separate room in the animal facility, specifically designed to be used in EthoVision
analysis (Walton et al., 2006). NHPs were allowed to habituate to their surroundings,
and given water ad libitum and a small amount of fruit as a reward. All videotaping
sessions began in the afternoon (between 1 and 2 pm) and consisted of two 30 minute
recording periods with two food pick up tasks in between using a Sony HandyCam
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Vision Camera (SONY P6-120 MPL). The food pick up task consisted of each NHP
retrieving 6 mini-marshmallows from each receptacle (total of 12), where the NHP was
forced to use either the right or left upper limb to retrieve the reward. The video-recorded
food pick-up tasks were used to score motor performance to assess UPDRS severity
(Zhang et al., 2006b).

Tissue Processing for Neurochemical Analysis, Gamma Counting and
Autoradiography

At the end of the 10-week dosing period all six NHPs were anesthetized with an
initial dose of ketamine hydrochloride (10-20 mg/kg, Fort Dodge) and then placed under
light isoflurane anesthesia (2 % with 1 % oxygen) in a supine position with the head tilted
back 45o where they received a final intranasal administration of vehicle or DNSP-11 at
the highest dose of 10 mg (5 mg per nare). One NHP was administered a final dose of
125

I-labeled DNSP-11 (5 mCi/10 mg DNSP-11, 2.5 mCi/5 mg per nare), using the

modified (R9K) sequence used in our intranasal rat tracer studies (Stenslik et al., 2015).
For the duration of the 60 minute period, the NHPs remained under light isoflurane
anesthesia (2% with 1% oxygen) while in the supine position. The NHP which received
the radioactive dose remained under a fume hood to lessen the likelihood of exposure to
aerosolized radioactive material. In that NHP, approximately 1 ml blood was collected
from the saphenous vein every 15 min post dosing with radiolabeled DNSP-11 (t=0).
For the duration of the 60 minutes NHPs remained under light isoflurane
anesthesia (2% with 1% oxygen) in the supine position. The NHP that received the
radioactive dose remained under a fume hood to lessen the likelihood of exposure to
aerosolized radioactive material, and in 15 minute intervals ~ 1 ml of blood was collected
from the saphenous vein after the start of the first intranasal dose (t=0). At ~60 minutes,
the NHP was laid on its side and CSF (~ 0.5 ml) was removed via lumbar puncture.
All NHPs were given a fatal dose of sodium pentobarbital, prior to transcardial
perfusion with ice-cold heparinized saline (4 ml per 4 L of saline-Baxter). In the NHP that
received the radioactive dose, a total of approximately 5 ml of urine was aspirated from
the bladder, and the olfactory bulbs (right & left), trigeminal nerves (right & left), and
pituitary gland were removed and kept on wet ice for analysis.
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The brains were immediately processed into 2 mm thick coronal slabs using a
brain mold that was refrigerated (4o C) in saline prior to use. From those brain slabs,
tissue punches were taken using 2 mm diameter biopsy needles for neurochemical and
gamma counting analysis. Sections containing the striatum were placed on dry-ice and
multiple 2 mm biopsy punches were taken from the caudate nucleus (n=4-5), putamen
(n=9), nucleus accumbens (n=1), and GP (n=2-3) (Figure 4.4). Tissue punches were
then placed in pre-weighted tubes, weighed, and flash frozen with dry-ice and stored at 70oC.
Tissue bunches for gamma counting analysis spanned (rostral to caudal) the
frontal, motor and occipital cortices (6 punches per hemisphere); the caudate nucleus (4
punches per hemisphere), putamen (6 punches per hemisphere), GP (2 punches per
hemisphere), and nucleus accumbens (1 punch per hemisphere); the amygdala (1
punch per hemisphere), and the cerebellum (6 punches per hemisphere) (Figures 4.27 &
29). Tissue punches and other samples were placed in pre-weighted tubes, weighed and
placed on wet-ice.

Neurochemical Analysis of Dopamine, Serotonin, and Metabolite Levels
in the Striatum
For HPLC-EC analysis, tissue samples were processed for dopamine (DA), 3,4 –
dihydroxy-phenylacetic acid (DOPAC), and homovanillic acid (HVA), and detected using
an isocratic HPLC system (Bechman, Inc., Fullerton, CA) that was coupled to a dualchannel electrochemical array detector (ESA, Inc., 5100A, E1 +0.35 mV and E2 -0.25
mV

with

a

5011

dual

analytical

cell).

The

separation

of

the

compounds

(neurotransmitters and metabolites) was done using a C18 column (4.6 mm x 75 mm, 3
µm particle size, ODS Hypersil; Keysonte Scientific) with mobile phase (citrate-acetate,
pH 4.0) (Hall et al., 1989).
Gamma Counting and Autogradiography Analysis of 125I-labeled DNSP-11

Samples which included brain tissue punches, olfactory bulbs (right & left),
trigeminal nerves (right & left), the pituitary gland, CSF, blood and urine were processed
by gamma counting (Cobra II Auto-Gamma, Packard) to determine the amount of
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125

I

signal (counts per minute-CPM) present in each sample. CPM values for tissue
punches, olfactory bulbs and trigeminal nerves were combined to determine the average
signal. CPM values were then normalized (CPM/mg of wet-tissue weight) to the weight
of each sample. Brain slabs were placed in a GE autoradiography cassette and exposed
to film for 24 hours. Tissue exposed to film was visualized using a Typhoon 9400 (GE
Health Care).

Statistical Analysis

Changes between DNSP-11 and vehicle treated NHPs in terms of body weight
(% change from baseline), EthoVision and individual punch sites levels of DA, DOPAC,
HVA, DOPAC/DA, HVA/DA and [(DOPAC+HVA)/DA] were analyzed using a RM TwoWay ANOVA with Bonferroni’s multiple comparison test respectively. Changes in both
fine (hand) and coarse (arm) motor performance within DNSP-11 treated NHPs were
analyzed using a RM One-way ANOVA. Statistical comparisons between vehicle and
DNSP-11 concentration for mMAP (both fine and coarse motor performance) were made
using a paired two-tailed t test (PC-SAS 9.3, Cary, NC). Average levels of DA, DOPAC,
HVA, 5-HT, 5-HIAA, NE and DA, 5-HT turnover ratios were analyzed using an unpaired
two-tailed t test to examine differences in analyte and turnover ratios between DNSP-11
and vehicle treated NHPs on the contralateral side (unlesioned hemisphere) to the
lesion. As variations in lesion severity were an issue in both the DNSP-11 and vehicle
treated groups, comparisons of DA, DOPAC, HVA, DOPAC/DA, HVA/DA and
[(DOPAC+HVA)/DA] were made in NHPs (n=2 per treatment group) that were found to
have a milder lesion (80-90 % depletion of DA) of the striatum. As a small sample size
was used for neurochemical analyte and DA turnover ratios, statistical analysis between
treatment groups was not performed. Statistical significance was defined as p<0.05 for
all analyses.
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Results

Body Weight and Cage-Side Observations

Cage-side observations demonstrated that there were no major adverse side
effects such as nasal irritation/bleeding, nausea, vomiting, diarrhea or neurological
symptoms including seizures, and/or irregular motor movements (dyskinetic) in the
DNSP-11 treated NHPs. At weeks 4 (0.3 mg, p=0.0019), 7 (3.0 mg, p=0.0048) and 8
(3.0 mg, p=0.0079) DNSP-11 treated NHPs lost a statistically significant amount of body
weight compared to vehicle (Figure 4.5A). This decline in body weight was not thought to
be critical as it was < 5 % from their original weight at week 1 (vehicle treatment) (Figure
4.5A & B). From the DNSP-11 treated group, 2 out of 3 NHPs gained weight by week 10
compared to their original body weight at week 1 of vehicle treatment (Figure 4.5A & B).
The 1 DNSP-11 treated NHP that did not gain weight from week 1 of vehicle treatment,
did stabilize after its initial drop after week 2 of vehicle treatment (Figure 4.5B). While
this weight loss did occur in 1 DNSP-11 treated NHP, the weight loss was not
detrimental to its health (< 5 %).

Changes in Motor Performance

At the end of each dosing period, DNSP-11 treated NHPs were scored to
determine their individual UPDRS (unified Parkinson’s disease rating scale) scores
compared to their vehicle treatment scores (Figure 4.1). In NHPs that received DNSP-11
treatment, all scored 0 on the UPDRS after their first two weeks of vehicle treatment.
UPDRS scores did not change at any of the DNSP-11 dosages administered or as a
function of time over the course of 10 weeks.
To determine improvements in fine (hand) and course (arm) motor performance
(speed-sec), mMAP (monkey movement assessment panel) testing was performed at
the end of each dosing week (Figure 4.1). While vehicle treated NHPs exhibited no
change in mMAP testing over the 10-week period, major variations in fine motor
movement between individual NHPs was apparent (Figure 4.8A-D). As the main purpose
of mMAP testing was to determine improvements in motor performance at different
DNSP-11 dosages, statistical analysis was reserved to DNSP-11 treated NHPs.
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In terms of the left (affected) upper limb, there was a statistically significant
improvement in performance of fine (hand) motor speed at 1 (p=0.058), 3 (p=0.011) and
10 mg (p=0.034) and was trending toward significance at 0.3 mg (p=0.39) of DNSP-11
when compared to baseline vehicle treatment (F(1.1925, 3.849)=30.43; p=0.0044). Similarly,
the non-affected (right) upper limb was trending toward statistical significance when
compared to baseline vehicle treatment at 0.3 (p=0.00039), 1 (p=0.000065), 3
(p=0.000065) and 10 mg (p=0.000025) of DNSP-11 (F(1.495, 2.990)=11.96; p=0.0388).
When examining coarse (arm) motor speed of the left (affected) (F(1.522,
p=0.2962) and right (non-affected) limbs (F(1.082,

2.163)=0.3556;

3.045)=1.776;

p=0.6233), there was no

statistically significant improvement at the DNSP-11 concentrations examined.
Video-recording sessions for EthoVision analysis occurred at the end of every
two week dosing period (Figure 4.1). Analysis of EthoVision did not show a statistically
significant change in distance traveled (cm) (F(1,
(cm/sec) (F(1,

4)=0.07338;

4)=0.002964;

p=0.9592) or speed

p=0.7999) between DNSP-11 and vehicle treated NHPs

(Figure 4.9A & B). When examining only the DNSP-11 treated NHPs, there was not
statistically significant change in distance traveled (F(1.155, 2.310)=0.9620; p=0.4357) at 0.3
(p=0.2804), 1.0 (p=0.6100), 3.0 (p=0.9998) or 10.0 mg (p=0.6921) compared to their first
two weeks of vehicle treatment (Figure 4.10A). There was also no statistically significant
change in speed (F(1.7641, 3.522)=0.6484; p=0.5577) at 0.3 (p=0.0933), 1.0 (p=0.7573), 3.0
(p=0.9384) or 10.0 mg (p=0.09491) in DNSP-11 treated NHPs compared to their first two
weeks of vehicle treatment (Figure 4.10B).

Neurochemical Changes in the Left (Unlesioned) Hemisphere

A statistically significant decrease in the average tissue levels of DOPAC and/or
HVA were found in the putamen, caudate nucleus, nucleus accumbens and/or GP in
DNSP-11 treated NHPs compared to vehicle treatment (Table 4.1). A decrease in DA
turnover (DOPAC/DA) was also found in the nucleus accumbens and GP of DNSP-11
treated not human primates compared to vehicle treatment (Table 4.1). Specifically,
DOPAC tissue levels were decreased in the putamen, caudate nucleus and nucleus
accumbens by 59 % (p<0.05), 54 % (p<0.01) and 45 % (p<0.01) respectively (Table
4.1). HVA tissue levels were also decreased in the putamen, caudate nucleus and GP
by 25 % (p<0.01), 24 % (p<0.05) and 21 % (p<0.01), respectively (Table 4.1). With the
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largest decreases observed in DOPAC tissue levels a statistically significant decrease in
DA turnover (DOPAC/DA) was also found in the nucleus accumbens and GP by 14 %
(p<0.05) and 56 % (p<0.05), respectively, with levels in the putamen and caudate
nucleus trending toward significance (Table 4.2).
As average tissue levels could potentially mask important changes in regional
distribution, neurochemical tissue levels of DA, DOPAC and HVA were examined at the
tissue punch level in the putamen and caudate nucleus (Figures 4.11-16). A statistically
significant 51 % decrease in DA (p=0.0133) was found in section 8 of the caudate
nucleus at P4 (punch 4) in the more caudal region of the caudate nucleus examined in
DNSP-11 compared to vehicle treated NHPs (Figure 4.11B). Decreases in DOPAC
tissue levels were found spanning the putamen and caudate nucleus in DNSP-11
treated NHPs compared to vehicle (Figure 4.12A & B). In section 7 of the putamen there
was a statistically significant decrease in DOPAC at tissue punches P2 (p=0.0402) and
P3 (p=0.0084) by 57 % and 55 %, respectively (Figure 4.12A). A statistically significant
decrease in DOPAC, by 55 %, was also found at P6 (p=0.0208) in section 8 of the
putamen (Figure 4.12A). Statistically significant decreases in DOPAC were found at all
tissue punches taken of the caudate nucleus (Figure 4.12B). Specifically, there was a
52, 48, 59 and 60 % decrease in DOPAC at P1 (p=0.0181), P2 (p=0.0256), P3
(p=0.0022) and P4 (p=0.0043) in DNSP-11 treated NHPs versus vehicle (Figure 4.12B).
Decreases in HVA tissue levels were also found at all tissue punches taken in the
putamen and caudate nucleus (Figure 4.13A & B). Specifically, there were decreases in
P1 (p=0.00112) and P2 (p=0.0458) in section 7 of the putamen by 32 and 24 %,
respectively (Figure 4.13A). At section 8 of the putamen at P4 (p=0.0153), P5
(p=0.0043) and P6 (p=0.0289) there were also decreases in HVA at 30, 29 and 23 %,
respectively, (Figure 4.13A) in DNSP-11 versus vehicle treated NHPs. Decreases in
HVA by 26 and 39 % were all present at P3 (p=0.0447) and P4 (p=0.0042) respectively,
in section 8 of the caudate nucleus (Figure 4.13B).
DOPAC/DA, HVA/DA and [(DOPAC+HVA)/DA] turnover were also examined at
the tissue punch level in both the putamen and caudate nucleus (Figures 4.14-16). In the
caudate nucleus at P2 (p=0.0647) and P2 (p=0.0647) which spanned sections 7 and 8,
decreases in DOPAC/DA were trending toward significance in DNSP-11 treated NHPs
compared to vehicle (Figure 4.14B). No statistically significant changes in either HVA/DA
and [(DOPAC+HVA)/DA] in the caudate nucleus or putamen in DNSP-11 treated NHPs
versus vehicle were observed (Figure 4.15-16).
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Changes in 5-HT, 5-HIAA, 5-HIAA/5-HT and NE were also examined. There
were no statistically significant changes in 5-HT or NE in the putamen, caudate nucleus,
nucleus accumbens or GP in DNSP-11 treated NHPs when compared to vehicle (Table
4.4). In DNSP-11 treated NHPs there was a statistically significant decrease in 5-HIAA in
the putamen (p=0.0169), caudate nucleus (p=0.0291) and GP (0.0367) by 46, 47 and 37
%, respectively, compared to vehicle (Table 4.4). In the caudate nucleus, there was a
statistically significant (p=0.0023) decrease in 5-HT turnover (5-HIAA/5-HT) in DNSP-11
versus vehicle treated NHPs (Table 4.4).

Neurochemical Changes in the Right (Lesioned) Hemisphere

Neurochemical analysis of the right (lesioned) striatum indicated variations in
lesion severity in both the DNSP-11 and vehicle treated animals (Table 4.3). NHPs were
categorized into either mild (< 80 %), moderate (80-90 %) and/or severely (> 99 %)
lesioned groups in terms of the total DA depletion when comparing the right to left
hemispheres (Table 4.3). While statistical analysis could not be performed comparing
DNSP-11 and vehicle treated NHPs in the moderate lesion (80-90 %) group because of
a small sample size (n=2 per group); DA, DOPAC and HVA tissue levels were found to
be lower in the putamen, caudate nucleus and nucleus accumbens of DNSP-11 versus
vehicle treated NHPs (Table 4.3). In the GP, there was an observed decrease in DOPAC
and increase in HVA (Table 4.3) of DNSP-11 treated NHPs compared to vehicle control
(Table

4.3).

Additionally,

changes

in

turnover

(DOPAC/DA,

HVA/DA

an

[(DOPAC+HVA)/DA]) were unchanged in both the caudate nucleus and nucleus
accumbens; however, DA turnover ([(DOPAC+HVA)/DA]) in both the putamen and GP
were increased in DNSP-11 versus vehicle treated NHPs (Table 4.3).
To determine if there were changes in DA, DOPAC and HVA distribution,
neurochemical changes at the individual tissue punch level were examined in the
putamen and caudate nucleus (Figures 4.17-19). Again, statistical analysis was not
performed to compare DNSP-11 versus vehicle treated NHPs as regional distributions of
DA, DOPAC, HVA tissue levels and DOPAC/DA, HVA/DA and [(DOPAC+HVA)/DA]
ratios were examined in the moderately lesioned group with a small sample size (n=2)
(Table 4.3). In both the putamen and caudate nucleus there was a decrease in DA tissue
levels in the DNSP-11 versus vehicle treated NHPs (Figure 4.17A & B), most apparent
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at P1, P2, P4 and P5 in the putamen (Figure 4.17B). Both DOPAC and HVA observed
similar decreases in the DNSP-11 versus vehicle treated NHPs in the putamen (Figure
4.18A & 18A) and caudate nucleus (Figures 4.18B &19B). Large decreases in DOPAC
were apparent in the putamen at P1, P2, P3, P5 and P6 (Figures 4.18A), and in the
caudate nucleus at P2 and P3 (Figures 4.18B).
Regional

distributional

changes

in

DOPAC/DA,

HVA/DA

and

[(DOPAC+HVA)/DA] ratios were also examined (Figures 4.20-22). In DNSP-11
compared to vehicle treated NHPs, there was no change in DOPAC/DA in the putamen
(Figure 4.20A); however, there was an increase in the caudate nucleus at all tissue
punch levels (Figure 4.20B). HVA/DA in the putamen showed increases in the DNSP-11
treated NHPs compared to vehicle in the more rostral sections (7 & 8) (Figure 4.21A).
HVA/DA ratios in the caudate nucleus were also increased in the DNSP-11 treated
NHPs compared to vehicle, in particularly at P1 of the most rostral section examined
(Figure 4.21B). There was an increases in the [(DOPAC+HVA)/DA] ratio in sections 7
and 8 in the putamen most noticeable at P1 and P2, and at P1 in the caudate nucleus
(Figure 4.22A & B).
One DNSP-11 treated NHP was found to have a milder lesion (<80 %) (Table
4.3). DA tissue levels were found to be relatively unchanged in the putamen and caudate
nucleus when comparing the left and right hemispheres (Figure 4.23 A & D). There was
a decrease in DA at P2 and P3 in the putamen right (lesioned) hemisphere compared to
the left (unlesionsed) hemisphere (Figure 4.23A). In the putamen, DOPAC tissue levels
were found to be increased in the right (lesioned) compared to left (unlesioned)
hemisphere (Figure 4.23B), and remained relatively unchanged in the caudate nucleus
(Figure 4.23F). HVA tissue levels remained unchanged in both the putamen and caudate
nucleus when comparing the right (lesioned) and left (unlesioned) hemispheres (Figure
4.23C & F).
Distributional changes of DOPAC/DA, in terms of individual tissue punches, were
increased at P2 in both the putamen and caudate nucleus in the right (lesioned) versus
left (unlesioned) hemisphere (Figure 4.24A & D). Both HVA/DA and [(DOPAC+HVA)/DA]
ratios were increased at P2 and P3 in the putamen on the right (lesioned) compared to
left (unlesioned) hemisphere (Figure 4.24B & C), and remained relatively unchanged in
the caudate nucleus (Figure 4.24E & F).
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Gamma Counting and Autoradiography

In one NHP we examined the distribution of a one-time

125

I-labeled DNSP-11

dose in the CNS, CSF and blood 60 min after the start of the first intranasal dose (t=0).
Tissue punches from the frontal cortex (n=12), motor cortex (n=12), occipital cortex
(n=12), caudate nucleus (n=8), putamen (n=12), nucleus accumbens (n=2), globus
pallidus (internal & external combined) (n=4), amygdala (n=2) and cerebellum (n=2)
were analyzed by gamma counting (Figures 4.25-29).

125

I signal (cpm) was found

throughout all of the aforementioned tissue punches indicating a diffuse distribution in
the brain parenchyma, further corroborated by autoradiography analysis (Figures 4.26 &
28).

125

I signal was also found in the olfactory bulbs, trigeminal nerve, CSF, pituitary

gland and in increasing levels as measured in the blood in 15 min intervals over the
course of 60 min (Table 4.5).
Normalized data (cpm/mg-wet weight) from tissue punches indicated an increase
in

125

I signal in the caudate nucleus, putamen, nucleus accumbens and GP, our target

regions of interest (Figure 4.25). Qualitative autoradiography analysis also indicated an
increase in

125

I signal found in the internal capsule an area that innervates striatum

(Figures 4.26 & 28). Normalized data (cpm/mg-wet weight) from the olfactory bulbs and
trigeminal nerves in terms indicated higher level of

125

I signal in the olfactory bulbs in

comparison to the trigeminal nerves (Table 4.5). Normalized data (cpm/mg-wet weight)
also indicated higher

125

I signal found in the pituitary gland compared to the olfactory

bulbs and trigeminal nerves (Table 4.5).
Raw cpm values indicated the highest levels of
indication of the peripheral iodination of
free/unbound

125

I signal in the thyroid gland, an

125

I-labled DNSP-11 and are a reflection of

125

I in the periphery (Table 4.5) (Sodoyez et al., 1980).

125

I signal was also

found in the urine and in increasing levels in the blood at 15 min intervals (Table 4.5).
While DNSP-11 was found in the blood, it is unlikely that DNSP-11 would be delivered to
the CNS after intranasal administration by the systemic blood supply as the half-life of
DNSP-11 in NHP plasma has been shown to be less than 10 minutes (data not shown)
and its large size (> 500 MW for crossing the BBB).
Qualitative autoradiography analysis indicated visually higher levels of

125

I-signal

in the olfactory tracts (Figure 4.26A-G), corpus callosum (Figures 4.26E-I), internal
capsule (Figure 4.26F-E), midbrain (Figure 4.26A-C), cerebellum (Figures 4.26D-K) and
the surrounding area of the 4th ventricle (Figures 4.26C-I). While it was decided a priori
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to take tissue punches of grey matter regions to determine correlations between motor
performance and neurochemical changes, autoradiography analysis indicated visually
higher levels of

125

I-signal in numerous white matter compared to grey matter regions

(Figures 4.26 and 28).

Discussion

The blood brain-barrier (BBB) has been a major challenge when developing
potential therapies for the treatment of neurodegenerative diseases, such as PD (Slevin
et al., 2005, Salvatore et al., 2006, Sherer et al., 2006, Slevin et al., 2006a, 2007, Anitua
et al., 2008). Intranasal administration of neuroactive compounds has now become an
attractive alternative to the traditional invasive direct intraparenchymal infusion of large
molecular weight compounds to targeted regions of the CNS that are unable to cross the
BBB (Gozes et al., 2000, Thorne and Frey II, 2001, Illum, 2002, Ross et al., 2004,
Thorne et al., 2004b, Thorne et al., 2008, Dhuria et al., 2009c, Dhuria et al., 2009b,
Dhuria et al., 2010, Lochhead and Thorne, 2012). As such, there is a great need for the
development of smaller neuroactive compounds that can be delivered to the CNS after
intranasal administration. In addition to the in vitro and in vivo neuroprotective and
restorative properties of DNSP-11 (Bradley et al., 2010, Kelps et al., 2011, Fuqua et al.,
2014, Stenslik et al., 2015, Turchan-Cholewo, 2015), we have recently demonstrated
that the repeated intranasal administration of DNSP-11; (1) modulates DA, DOPAC,
HVA and DA turnover ([DOPAC+HVA)/DA] in both the striatum and SN of normal rats,
(2) exhibits neuroprotective and/or restorative effects in a 6-OHDA rat model of PD, and
(3) after a single

125

I-labeled DNSP-11 dose can be traced into the CNS and CSF in as

early as 30 minutes (Stenslik et al., 2015).
To the best of our knowledge, this is the first study to demonstrate that repeated
intranasal administration of DNSP-11 using our atomizer system; (1) is well tolerated at
all dosages over the 10-week period, (2) does not cause adverse side-effects, (3) does
not induce weight loss, (4) increases fine (hand) motor performance of the upper limbs
bilaterally, (5) elicits bilateral neurochemical changes in DA, DOPAC, HVA and DA
turnover (DOPAC/DA, HVA/DA and [(DOPAC+HVA)/DA]), (6) induces similar bilateral
changes in 5-HT, 5-HIAA and 5-HT turnover (5-HIAA/5-HT) in the striatum, and (7) can
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be traced 60 minutes after a single one-time

125

I-labeled DNSP-11 to the SN and

striatum.
Currently, there are no studies examining the effects of DNSP-11 in higher order
animal models of PD. As the intranasal administration of proteins and/or peptides in both
rats and NHPs have been shown to reach multiple regions of the CNS and peripheral
tissues, including DNSP-11 in rats (Gozes et al., 2000, Dufes et al., 2003, Banks et al.,
2004, Thorne et al., 2004b, Nonaka et al., 2008, Thorne et al., 2008, Dhuria et al.,
2009c, Stenslik et al., 2015); body weight measurements and cage-side observations
were important to determine if any adverse side-effects occurred at a particular dose or
as a function of time. At all dosages tested, there were no visible signs of overall malaise
and more importantly no NHPs were lost during the study, even at the highest dosage
(10.0 mg) tested.
Previously published studies involving the direct surgical delivery of GDNF in
normal NHPs indicated substantial weight loss (> 10 %) (Gash et al., 1995). While
statistically significant differences were observed in body weight loss at weeks 4 (0.3
mg, p=0.0019), 7 (3.0 mg, p=0.0048) and 8 (3.0 mg, p=0.0079) in DNSP-11 versus
vehicle treated NHPs, weight loss was not critical (< 5 %) (Figures 4.5A & B).
Interestingly, 2 out of the 3 NHPs in our study that received DNSP-11 in a dose
escalating manner gained weight by week 10 compared to their weight at week 1 of
vehicle treatment (Figures 4.5A & B). While 1 NHP had a non-critical initial drop off in
weight (< 5 %) at week 2, its weight stabilized over the course of the study. It cannot be
ruled out that the initial decline in weight may have been triggered by stress related to
the daily activities involved in dosing. These findings support that (1) the repeated
intranasal administration of DNSP-11 does not appear to produce a significant decline in
body weight; and (2) the vertical chairing, atomizer and dosing paradigm were not a
major sources of stress for 5 out of the 6 NHPs.
The NHPs used in the current experiment were obtained from a previous study
were they were previously rendered hemiparkinsonian by MPTP (> 2 years prior) as they
did not exhibit sufficient motor deficits. Therefore, the neuroactive properties of DNSP-11
presented here examine its potential restorative properties in a partial lesion model,
supported by neurochemical analysis of the lesioned striatum (Table 4.3). While UPDRS
(unified Parkinson’s disease rating scale) scores of DNSP-11 treated NHPs taken prior
to the start of the study were 0, we observed bilateral increases in fine (hand) upper limb
performance speeds, as measured by mMAP. The lack of UPDRS scores is further
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evident in a study presented by Pifl and Hornykiewicz, in which the range of PD features
was small in that < 92 % lesion of the putamen renders NHPs asymptomatic (Pifl and
Hornykiewicz, 2006). These increases observed in fine (hand) upper limb speed by
mMAP are similar to those in normal middle aged NHPs that received direct infusion of
GDNF into the lateral ventricle (Grondin et al., 2003a). Also, this same study in middle
aged NHPs, as analyzed by mMAP, had similar upper motor limb performance times
that matched those of our mid-aged NHPs baseline mMAP speeds established during
vehicle treatment (Figures 4.6 & 7). EthoVision analysis of both distance traveled (cm)
and speed (cm/sec) in the arena did not indicate increases in either parameter in DNSP11 versus vehicle treated NHPs (Figures 4.9 & 10). While DNSP-11 treated NHPs did
not observe increases in distance traveled or speed, there was no decline in either
parameter, even at the highest DNSP-11 dosage (10 mg) administered (Figures 4.9 &
10), further supporting the lack of adverse side-effects.
As DNSP-11 was administered intranasally, we hypothesized that there would be
neurochemical changes in tissue levels of DA, DOPAC, HVA and DA turnover
[(DOPAC+HVA)/DA] bilaterally. Statistically significant decreases in the average tissue
levels of DOPAC, HVA, and/or DOPAC/DA were present in the putamen, caudate
nucleus, nucleus accumbens and GP in the left (unlesioned) striatum (Tables. 4.1 & 2),
while DA turnover [(DOPAC+HVA)/DA] remained unchanged between the DNSP-11 and
vehicle treated NHPs (Table 4.2). The largest percent decreases in average tissue levels
were found with DOPAC, which exhibited > 45 % reduction in the putamen, caudate
nucleus and nucleus accumbens in DNSP-11 treatment compared to vehicle treated
NHPs (Table 4.1).
Neurochemical analysis of the right (lesioned) striatum indicated variability in
lesion severity in both the DNSP-11 and vehicle treated groups (Table 4.3). In NHPs that
were found to have a moderate lesion (80-90 %) of the striatum, average tissue levels of
DA, DOPAC and HVA were found to be lower in the putamen, caudate nucleus and
nucleus accumbens of DNSP-11 versus vehicle treated NHPs (Table 4.3). While
DOPAC/DA and HVA/DA were unchanged between the DNSP-11 and vehicle treated
groups, DNSP-11 treated NHPs there was a stimulatory effect in DA turnover
[(DOPAC+HVA)/DA] in the putamen and GP (Table 4.3). Bilateral decreases in average
tissue levels of DA, DOPAC, HVA and DA turnover [(DOPAC+HVA)/DA] were an
interesting finding as we have recently reported an inverse U-shaped curve at higher
doses in the striatum of normal rats (Stenslik et al., 2015). While puzzling, similar
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suppression of DA and its metabolites have been observed at higher doses of GDNF in
NHPs (Zhang et al., 1997) and rats (Hoffer et al., 1994).
To determine if there were region specific neurochemical changes in tissue levels
of DA, DOPAC and HVA in DNSP-11 versus vehicle treated NHPs, we examined
individual tissue punch sites in both the left (unlesioned) and right (lesioned) putamen
and caudate nucleus (Figures 4.11-22). In the left (unlesioned) putamen and caudate
nucleus, tissue levels of DA, DOPAC and HVA were found to be lower at all tissue
punch sites examined (Figures 4.11-13). Similarly, a decrease in DOPAC/DA ratio was
also observed at all tissue punch sites examined (Figures 4.14-16).

DA turnover

[(DOPAC+HVA)/DA] ratio was unchanged when compared to vehicle treatment at all
tissue punch sites examined (Figure 4.16). The right (lesioned) caudate nucleus and
putamen in the milder lesioned NHPs exhibited a similar suppression of DA, DOPAC
and HVA at all tissue punch sites examined in DNSP-11 versus vehicle treated groups
(Figures 4.17-19). There was an observed rostral to caudal gradient in DOPAC/DA,
HVA/DA and [(DOPAC+HVA)/DA] ratios in both the putamen and caudate nucleus
(Figures 4.20-22). In total, wide spread neurochemical changes were present in most of
the tissue punch sites examined (Figures 4.11-22). Diffuse neurochemical changes
support the use of intranasal administration to achieve wide spread effects in the
striatum as a whole. These are interesting findings as previous examinations of GDNF’s
biodistribution after delivery by CED with a pump and catheter into the putamen, has
indicated that a lack of bioavailability to areas of the striatum outside of the volume area
of distribution (Grondin et al., 2002b, Ai et al., 2003a, Salvatore et al., 2006).
There has also been evidence supporting the depletion of 5-HT in the caudate
nucleus of early stage PD (Kerenyi et al., 2003, Kish et al., 2008, Fox et al., 2009). An
examination of average neurochemical changes in 5-HT, 5-HIAA, 5-HIAA/5-HT an NE
(Table 4.4) indicated similar decreases in 5-HT, 5-HIAA and/or 5-HIAA/5-HT but not NE
bilaterally in the putamen, caudate nucleus, nucleus accumbens and GP in DNSP-11
treated NHPs compared to vehicle (Table. 4.3). Diffuse bilateral suppression in 5-HT, 5HIAA and/or 5-HIAA/5-HT supports the previous findings in DA, DOPAC, HVA and
DOPAC/DA (Figures 4.11-22 and Tables 4.1-4). Again, while puzzling previous studies
in normal rats after the repeated intranasal administration of DNSP-11 have also
indicated a reverse U-shaped curve in tissue levels of 5-HIAA and 5-HIAA/5-HT ratio in
the striatum (Sonne, 2013).
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Diffuse neurochemical changes observed in both the DA and 5-HT systems in
virtually all tissue samples analyzed, are further supported by our
tracer study.

125

I-labeled DNSP-11

125

I signal was found in all tissue punches examined (Figure 4.25), with

relatively higher levels found in our target regions of interest (caudate nucleus, putamen,
nucleus accumbens and GP) as analyzed by gamma counting (Figure 4.25). While
tissue punches of the major white matter tracks were not taken for comparison,
qualitative autoradiography analysis indicated higher levels of

125

I signal present in the

olfactory tracts, corpus callosum and internal capsule (Figures 4.25-28). This evidence
supports the idea of anisotropic delivery as

125

I signal was found heavily in these major

white matter track regions (Syková and Nicholson, 2008). While

125

I signal was present

at lower levels in grey matter regions, this may be due to its rapid cellular uptake
(Jadwiga et al. 2015). Future

125

I-labeled DNSP-11 would greatly benefit from examining

different time points after intranasal administration to determine if

125

I signal is present at

higher levels earlier than 60 minutes.
125

I signal was also found at higher levels in the olfactory bulbs, which supports a

direct nose-to CNS route after intranasal administration (Gozes et al., 2000, Dufes et al.,
2003, Banks et al., 2004, Thorne et al., 2004b, Nonaka et al., 2008, Thorne et al., 2008,
Dhuria et al., 2009a, Stenslik et al., 2015). 125I signal was also found in the CSF, another
important indicator of an intranasal route of transport; as the olfactory sensory neurons
are exposed to the subarachnoid space when they traverse the cribriform plate to
synapse in the olfactory bulbs (Thorne and Frey, 2001, Dhuria et al., 2010). Additionally,
high 125I signal was present in the pituitary gland, a circumventricular organ, which would
receive higher levels of

125

I as it is exposed to systemic blood, further implicating a direct

nose-to CNS route (Gross, 1992, Lochhead and Thorne, 2012).
In summary, this pilot study provides a methodology which allowed for the
repeated intranasal delivery of DNSP-11, in chair-trained MPTP hemiparkinsonian
rhesus macaques over an extended period of time. This study effectively eliminated the
need for the repeated use of light isoflurane anesthesia that may have affected
parameters we have previously examined in rats (Datla et al., 2006, McCormick et al.,
2011, Stenslik et al., 2015); and allowed us to examine DNSP-11s neuroactive
properties in a purely restorative model. To the best of our knowledge this is the first
study to show that repeated intranasal administration of DNSP-11 using our atomizer
system does not cause adverse side-effects or weight loss. Additionally we show that in
previously stable MPTP hemiparkinsonian rhesus macaques, bilateral enhancement of
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fine (hand) motor performance of the upper limbs and bilateral neurochemical changes
in both the DA and 5-HT systems. Behavioral measures and neurochemical findings are
further support by tracer studies of a single

125

I-labled DNSP-11 that indicated

125

I signal

in the nigrostriatal system. These studies therefore support the further examination of
intranasal administration of DNSP-11 in NHPs as a potential therapeutic intervention for
the treatment of PD.

Copyright © Mallory Joan Stenslik 2015
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Chapter Four: Figures and Tables

Figure 4.1 Experimental Timeline for Dose Escalation Study of Intranasally Administered
DNSP-11 in NHPs
Timeline for dose escalation of intranasally administered DNSP-11 in MPTP treated
hemiparkinsonian rhesus macaques. Over the course of a 10 week period, NHPs
received either vehicle or DNSP-11 (0.3, 1.0, 3.0, 10.0 mg) 4 days a week, with an
escalation in dose occurring every two weeks. During the course of the study, all
behavioral testing was performed on the 5th day of the week (non-dosing day) marking
the ending of that dosing period. Over the course of the 10 week period, mMAP testing
occurred at the end of each week with video recordings occurring at the end of each
dosing period (every 2 weeks).
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Figure 4.2 Diagram for Intranasal Administration in NHPs
Illustration of intranasal administration of DNSP-11 in MPTP treated hemiparkinsonian
rhesus macaques. (A) NHPs were placed in a vertical chair and a chin stabilizer to lift
the head 45o for administration of DNSP-11 intranasally. (B) NHPs were dosed bilateral
using an atomizer.
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Figure 4.3 Atomizer System for Intranasal Administration in NHPs
Illustration of atomizer system used for the intranasal administration of DNSP-11 in
MPTP treated hemiparkinsonian rhesus macaques. The atomizer was connected to a
Picospritzer III (Parker; Pine Brook, NJ), which regulated the duration and pressure of
the intranasal spray burst, driven by medical grade N2 at 40 psi. A volume of 207 µl of
DNSP-11 + 10 % at various concentrations was used. The time was set at ~1-1.5
second duration (display should read, 010 or 015) and the pressure gauge on the
Picospritzer III itself was set at ~16 PSI.
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Figure 4.4 Brain Slabs and Tissue Punch Sites for Neurochemical Analysis
Representative brain slabs used for tissue punches for neurochemical analysis. Sections
containing the striatum were placed on dry-ice and multiple 2 mm biopsy punches were
taken from the caudate nucleus (n=4-5), putamen (n=9), nucleus accumbens (n=1), and
globus pallidus (GP-internal and external segments) (n=2-3).
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Figure 4.5 Body Weight Measurements in NHPs
The effects of repeated intranasal administration of DNSP-11 or vehicle on changes in
body weight. As per our dose escalation all NHPs were administered vehicle the first two
weeks (Wk) 1 & 2. Escalating doses occurred every two weeks in DNSP-11 treated
NHPs; Wk 3 & 4 (0.3 mg), Wk 5 & 6 (1 mg), Wk 7 & 8 (3 mg) and Wk 9 & 10 (10 mg).
During the dosing period, NHPs were weighed at the end of a dosing period (once a
week). (A-B) Changes in body weight (percent from baseline-Wk 1) were examined. (A)
Data were analyzed using a RM Two-Way ANOVA with Bonferroni’s post hoc test
(F(1,4)=7.462; p=0.0524) and presented as the mean + SEM. At weeks 4 (**p=0.0019), 7
(**p=0.0048) and 8 (**p=0.0079) DNSP-11 treated NHPs lost on average a significantly
higher percent of body weight when compared to vehicle treated NHPs. At weeks 2
(p=0.8273), 3 (p>0.9999), 5 (p>0.9999), 6 (p=0.5900), 9 (p=0.1884) and 10 (p=0.4083)
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there was no statistically significant decrease in percent body weight found. (B) When
examining individual fluctuations in body weight (percent from baseline-Wk 1) all NHPs
(DNSP-11 and vehicle treated) were above their original baseline weights at Wk 1), only
one DNSP-11 treated NHP was consistently lower throughout the duration of the study.
However, the percent change in body weight from baseline in said DNSP-11 treated
NHP was not critical (> 5%).
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Figure 4.6 Fine (Hand) Motor Performance in DNSP-11 Treated NHPs
Changes in fine (hand) motor performances were examined, after the repeated
intranasal administration of DNSP-11, in a dose escalating manner using a monkey
movement assessment panel (mMAP). (A) In terms of the affected (left) upper limb,
there was a statistically significant increase in motor performance at 1 (*p=0.058), 3
(*p=0.011) and 10 mg (*p=0.034) and was trending on significance at 0.3 mg (p=0.39) of
DNSP-11 when compared to baseline vehicle treatment (F(1.1925, 3.849)=30.43; p=0.0044).
(B) The non-affected (right) upper limb was trending on statistical significance when
compared to baseline vehicle treatment at 0.3 (***p=0.00039), 1 (****p=0.000065), 3
(****p=0.000065) and 10 mg (****p=0.000025) of DNSP-11 (F(1.495,

2.990)=11.96;

p=0.0388). Data were analyzed using a RM-One Way ANOVA with paired two-tailed ttest comparing DNSP-11 concentrations to vehicle treatment. Data are presented as the
mean + SEM, n=3 NHPs per group.
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Figure 4.7 Coarse (Arm) Motor Performance in DNSP-11 Treated NHPs
Changes in coarse (arm) motor performances were examined, after the repeated
intranasal administration of DNSP-11, in a dose escalating manner using a monkey
movement assessment panel (mMAP). (A) When examining coarse (arm) motor speed
of the left (affected) limb, there was no statistically significant improvement in motor
performance at the DNSP-11 concentrations examined when compared to vehicle
treatment (F(1.522, 3.045)=1.776; p=0.2962). (B) The right (non-affected) limb observed no
statistically significant improvement in coarse (arm) motor performance at the DNSP-11
concentrations examined when compared to baseline vehicle treatment (F(1.082,
2.163)=0.3556;

p=0.6233). Data were analyzed using a RM-One Way ANOVA comparing

DNSP-11 concentrations to vehicle treatment. Data are presented as the mean + SEM,
n=3 NHPs per group.
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Figure 4.8 Fine (Hand) Motor Performance in Vehicle Treated NHPs
Changes in fine (hand) and coarse (arm) motor performances were examined, after the
repeated intranasal administration of vehicle using a monkey movement assessment
panel (mMAP). (A-D) Statistical analysis of mMAP was limited to that of DNSP-11
treated NHPs as individual motor scores were not consistent in vehicle treated NHPs.
Statistical analysis of mMAP was limited to that of DNSP-11 treated NHPs as individual
motor scores were not consistent in vehicle treated NHPs. Data are presented as the
mean + SEM, (n=3 NHPs per treatment group).
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Figure 4.9 EthoVision Analysis in Vehicle versus DNSP-11 Treated NHPs
The effects of escalating doses of DNSP-11 versus vehicle treatment in terms of
distanced traveled and speed over the course of 10 weeks. Distance traveled (cm) and
speed (cm/sec) was determined by examining the entire arena over the course of two
30-minute time intervals that were then averaged. (A) There was no significant
difference in distanced traveled (cm) at the dosages tested in comparison to baseline
(F(1.155, 2.310)=0.9620; p=0.4357). (B) In terms of speed (cm/sec) there was no statistically
significant difference at the dosages tested in comparison to baseline (F(1.7641,
3.522)=0.6484;

p=0.5577). All data were analyzed using a RM Two-Way ANOVA with

Bonferroni’s post hoc test and are presented as the mean + SEM, (n=3 NHPs per
treatment).
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Figure 4.10 Ethovision Analysis of DNSP-11 Treated NHPs
Distanced traveled and speed analyzed at the end of a dosing period over the course of
a 10 week period. Distance traveled (cm) and speed (cm/sec) was determined by
examining the entire arena over the course of two 30-minute time intervals that were
then averaged. (A) There was no significant difference in distanced traveled (cm) at the
dosages tested in comparison to baseline (F(1.155, 2.310)=0.9620; p=0.4357). (B) In terms of
speed (cm/sec) there was no statistically significant difference at the dosages tested in
comparison to baseline (F(1.7641, 3.522)=0.6484; p=0.5577). All data were analyzed using a
RM-One Way ANOVA with Dunnett’s multiple comparison and are presented as the
mean + SEM, (n=3 NHPs per treatment).
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Table 4.1. Average Tissue Levels of DA and Metabolites for Both the Left (Unlesioned)
and Right (Lesioned) Hemispheres.
Data were analyzed using an unpaired two-tailed t test, vehicle versus DNSP-11. Data
are presented as the mean + SEM, n=3 animals per group, *p < 0.05 and **p < 0.01.
Left (Unlesioned)

Right (Lesioned)

Hemisphere

Hemisphere

DA

DOPAC

HVA

DA

DOPAC

HVA

23801

3282

27377

2254

401

9416

+3998

+590

+698

+ 1026

+ 181

+3181

21359

1339

20429

7013

734

12976

+2343

+110 *

+1323 **

+5336

+474

+441

p=0.6261

p=0.0317

p=0.0097

p=0.4305

p=0.5499

p=0.5485

t(4)=0.5270

t(4)=0.3.24

t(4)=4.696

t(4)=0.8759

t(4)=0.6522

t(4)=0.5485

27601

3183

19906

3102

363

5962

+3785

+ 299

+1043

+1570

+ 175

+2317

22304

1449

15040

9554

795

9416

+1569

+ 183 **

+1174 *

+8009

+ 560

+4137

p=0.2657

p=0.0078

p=0.0363

p=0.4735

p=0.5027

p=0.5066

t(4)=0.1.29

t(4)=4.947

t(4)=3.097

t(4)=0.7905

t(4)=0.7357

t(4)=0.7286

12572

3705

25436

2990

829

13519

+2681

+165

+1094

+760

+ 97

+2659

11790

2024

22344

5547

1373

16327

+837

+151 **

+1460

+2523

+622

+4616

p=0.7946

p=0.0017

p=0.1654

p=0.3868

p=0.4363

p=0.6259

t(4)=0.2782

t(4)=7.510

t(4)=1.695

t(4)=0.9703

t(4)=0.8639

t(4)=0.5272

373

79

10744

175

56

4422

+17

+8

+276

+42

+9

+923

411

45

8445

193

19

5999

+ 73

+17

+335 **

+61

+9 *

+1552

p=0.6404

p=0.1473

p=0.0061

p=0.8228

p=0.0444

p=0.4320

t(4)=0.5043

t(4)=1.794

t(4)=5.298

t(4)=0.239

t(4)=2.893

t(4)=0.8729

Putamen
Vehicle

DNSP-11

Caudate
Vehicle

DNSP-11

Accumbens
Vehicle

DNSP-11

GP
Vehicle

DNSP-11
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Table 4.2. Average DA Turnover Rations in Both the Left (Unlesioned) and Right
(Lesioned) Hemispheres.
Data analyzed by an unpaired two-tailed t test, vehicle versus DNSP-11. Data are
presented as the mean + SEM, n = 3 animals per group, *p < 0.05.
Left (Unlesioned)

Right (Lesioned)

Hemisphere

Hemisphere

DOPAC/DA

HVA/DA

0.15

1.30

+0.045

+0.19

0.090
+0.010

[(DOPAC+

[(DOPAC+

DOPAC/DA

HVA/DA

1.40

0.38

22.70

23.10

+0.20

+0.21

+18.40

+18.60

1.34

1.42

0.150

1.34

12.050

+0.095

+0.10

+0.040

+0.0953

+8.32

p=0.2402

p=0.8384

p=0.9234

p=0.3338

p=0.3097

p=0.6171

t(4)=1.378

t(4)=0.2176

t(4)=0.1023

t(4)=1.098

t(4)=0.3097

t(4)=0.5413

0.13

0.85

0.98

0.44

15.32

15.76

+0.027

+0.19

+0.21

+0.32

+13.27

+13.60

0.073

0.72

0.78

0.14

3.92

4.060

+0.0088

+0.027

+0.038

+0.035

+1.64

+1.67

p=0.1045

p=0.5398

p=0.4113

p=0.4063

p=0.4421

p=0.4412

t(4)=2.092

t(4)=0.6696

t(4)=0.9165

t(4)=0.9272

t(4)=0.8523

t(4)=0.8540

0.31

2.17

2.48

0.31

4.77

6.90

+0.048

+0.36

+0.40

+0.065

+0.54

+1.92

0.17

1.90

2.07

0.25

3.39

3.64

+0.015 *

+0.070

+0.085

+0.038

+0.52

+0.53

p=0.0494

p=0.5021

p=0.3744

p=0.4927

p=0.1395

p=0.1781

t(4)=2.788

t(4)=0.7368

t(4)=0.9988

t(4)=0.7543

t(4)=1.841

t(4)=1.632

0.22

29.80

30.00

0.39

31.20

20.30

+0.032

+1.72

+1.75

+0.12

+10.50

+12.50

0.097

22.20

22.30

0.097

34.90

34.90

+0.015 *

+2.72

+2.70

+0.044

+7.19

+7.15

p=0.0223

p=0.0774

p=0.0745

p=0.0835

p=0.7875

p=0.3661

t(4)=3.623

t(4)=2.364

t(4)=2.399

t(4)=2.293

t(4)=0.2882

t(4)=1.018

HVA)/DA]

HVA/DA]

Putamen
Vehicle

DNSP-11

Caudate
Vehicle

DNSP-11

Accumbens
Vehicle

DNSP-11

GP
Vehicle

DNSP-11
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Table 4.3 Lesion Severity Groupings in DNSP-11 and Vehicle Treated NHPs
Vehicle N=2

DNSP-11 N=2

Vehicle N=1

DNSP-11

(moderate) 80-90

(moderate) 80-90

(severe) >

N=1 (mild)

%

%

99 %

< 80 %

DA

3280 + 71

1679 + 229

203

17862

DOPAC

570 + 115

257 + 22

63

1688

HVA

12573 + 673

8567 + 193

3102

21794

DOPAC/DA

0.18 + 0.025

0.18 + 0.055

0.49

0.10

HVA/DA

4.32 + 0.16

1.41 + 0.12

59.42

1.20

[(DOPAC + HVA)/DA]

4.50 + 0.19

17.18 + 11.35

60.22

1.80

DA

4614 + 733

1546 + 139

79

25570

DOPAC

526 + 109

236 + 70

36

1912

HVA

8266 + 422

5283 + 273

1343

17684

DOPAC/DA

0.12 + 0.0050

0.17 + 0.035

1.08

0.08

HVA/DA

2.05 + 0.26

5.53 + 0.63

41.87

0.72

[(DOPAC + HVA)/DA]

2.16 + 0.26

5.69 + 0.66

42.95

0.80

DA

3740 + 209

3025 + 90

1490

10592

DOPAC

915 + 78

759 + 173

657

2601

HVA

15960 + 1823

11721 + 525

8636

25540

DOPAC/DA

0.25 + 0.050

0.26 + 0.065

0.44

0.25

HVA/DA

4.25 + 0.25

3.89 +0.29

5.80

2.41

[(DOPAC + HVA)/DA]

4.98 + 0.23

4.14 + 0.39

10.73

2.66

DA

133 + 9

138 + 9

260

303

DOPAC

64 + 7

17 + 15

39

22

HVA

5313 + 421

8893 + 45

26.42

9103

DOPAC/DA

0.50 + 0.060

0.11 + 0.075

0.16

0.08

HVA/DA

41.50 + 3.08

37.11 + 11.82

10.58

30.32

[(DOPAC + HVA)/DA]

25.11 + 19.90

37.21 + 11.74

10.73

30.39

Putamen

Caudate nucleus

Accumbens

GP
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Table 4.4 The Average Tissue Level of 5-HT, 5-HIAA, NE, and 5-HIAA/5-HT Turnover in
Both the Left (Unlesioned) and Right (Lesioned) Hemispheres.
Date were analyzed using an unpaired two-tailed t test, and presented as the mean +
SEM, (n=3 animals per group), *p<0.05; **p<0.01.

Right (Lesioned) Hemisphere
Left (Unlesioned) Hemisphere
5-HT

5-HIAA

NE

(5-HIAA/5-HT)

5-HT

5-HIAA

NE

(5-HIAA/5-HT)

Vehicle

338 + 45

902 + 98

88 + 7

2.84 + 0.13

338 + 39

872 + 110

53 + 5

2.73 + 0.37

DNSP-11

388 + 105

483 + 42 *

74 + 4

1.55 + 0.46

183 + 4 *

504 + 34 *

58 + 10

3.00 + 0.22

p=0.0547

p=0.0162

p=0.0336

p=0.6908

Putamen

p=0.6812

p=0.0169

p=0.1439

p=0.5592

t(4)=0.442

t(4)=3.941

t(4)=1.814

t(4)=2.689

t(4)=3.993

t(4)=3.178

t(4)=0.4279

t(4)=0.6363

Vehicle

459 + 60

578 + 79

63 + 8

1.35 + 0.087

435 + 44

488 + 35

33 + 10

1.31 + 0.19

DNSP-11

458 + 31

309 + 20 *

51 + 11

0.72 + 0.029 **

336 + 33

336 + 16 *

35 + 5

1.23 + 0.16

Caudate
nucleus

p=0.9963

p=0.0291

p=0.4227

p=0.0023

p=0.1483

p=0.0169

p=0.8380

p=0.7670

t(4)=0.004926

t(4)=3.330

t(4)=0.8922

t(4)=6.901

t(4)=1.788

t(4)=3.945

t(4)=0.2181

t(4)=0.3172

Vehicle

258 + 32

605 + 149

83 + 2

4.29 + 1.26

268 + 12

777 + 108

53 + 9

2.89 + 0.32

DNSP-11

328 + 116

418 + 25

65 + 23

1.55 + 0.42

164 + 33 *

457 + 39 *

86 + 34

3.22 + 1.09

p=0.6761

p=0.2824

p=0.6047

p=0.0851

p=0.0421

p=0.0497

p=0.3936

p=0.7812

t(4)=0.4611

t(4)=1.241

t(4)=0.5764

t(4)=2.534

t(4)=2.948

t(4)=2.782

t(4)=0.9952

t(4)=0.2970

Vehicle

347 + 80

1394 + 142

134 + 33

4.42 + 0.80

439 + 94

1646 + 213

104 + 9

4.13 + 0.64

DNSP-11

269 + 47

882 + 86 *

112 + 28

3.43 + 0.36

293 + 43

1033 + 28 *

103 + 24

3.80 + 0.42

Accumbens

GP

p=0.4498

p=0.0367

p=0.6389

p=0.3155

p=0.2318

p=0.0462

t(4)=0.8368

t(4)=3.087

t(4)=0.5069

t(4)=1.146

t(4)=1.408

t(4)=2.854
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p=0.9708
t(4)=0.0.3888

p=0.6938
t(4)=0.4234

Figure 4.11 Average Tissue Levels of DA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) While not statistically significant at individual tissue punch sites, average DA levels
were found to be lower in DNSP-11 versus vehicle treated NHPs (F(1,4)=3.029;
p=0.1567). (B) At tissue punch P4 there was a statistically significant (*p=0.0133)
decrease in DA in DNSP-11 versus vehicle treated NHPs in the caudate nucleus
(F(1,4)=1.746; p=0.2569). Data were analyzed using a RW Two-way ANOVA with
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Bonferroni’s multiple comparison test. Data are presented as the mean + SEM, (n=3
punches per tissue punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.12 Average Tissue Levels of DOPAC at Individual Tissue Punch Sites in
Vehicle versus DNSP-11 Treated NHPs
(A) Statistically significant decreases were found at P2 (*p=0.0402), P3 (**p=0.0084), P6
(*p=0.0208), average DOPAC levels were found to be lower in DNSP-11 versus vehicle
treated NHPs (F(1,4)=10.50; *p=0.0317). (B) At tissue punch P1 (*p=0.0181), P2
(*p=0.0256), P3 (**p=0.0022) and P4 (**p=0.0043) there was a statistically significant
decrease in DA in DNSP-11 versus vehicle treated NHPs in the caudate nucleus
(F(1,4)=22.65; **p=0.0089). Data were analyzed using a RW Two-way ANOVA with
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Bonferroni’s multiple comparison test. Data are presented as the mean + SEM, (n=3
punches per tissue punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.13 Average Tissue Levels of HVA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) Statistically significant decreases were found at P1 (*p=0.0112), P2 (*p=0.0458), P4
(*p=0.0153), P5 (**p=0.0043) and P6 (**p=0.0289) average HVA levels were found to be
lower in DNSP-11 versus vehicle treated NHPs (F(1,4)=21.59; **p=0.0097). (B) At tissue
punch P3 (*p=0.0447) and P4 (**p=0.0042) there was a statistically significant decrease
in HVA in DNSP-11 versus vehicle treated NHPs in the caudate nucleus (F(1,4)=12.38;
*p=0.0245). Data were analyzed using a RW Two-way ANOVA with Bonferroni’s multiple
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comparison test. Data are presented as the mean + SEM, (n=3 punches per tissue
punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.14 Ratio of DOPAC/DA at Individual Tissue Punch Sites in Vehicle versus
DNSP-11 Treated NHPs
(A) Statistically significant decreases were not found at individual punch sites, but
DOAPC/DA ratios were found to be lower in DNSP-11 versus vehicle treated NHPs in
the putamen (F(1,4)=1.923; p=0.2378). (B) Statistically significant decreases were not
found at individual punch sites, but DOAPC/DA ratios were found to be lower in DNSP11 versus vehicle treated NHPs in the caudate nucleus (F(1,4)=4.963; p=0.0898). Data
were analyzed using a RW Two-way ANOVA with Bonferroni’s multiple comparison test.
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Data are presented as the mean + SEM, (n=3 punches per tissue punch site). Please
refer to Figure 4.4 for punch site location.
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Figure 4.15 Ratio of HVA/DA at Individual Tissue Punch Sites in Vehicle versus DNSP11 Treated NHPs
(A) Statistically significant decreases were not found at individual punch sites, but
HVA/DA ratios were found to be lower in DNSP-11 versus vehicle treated NHPs in the
putamen (F(1,4)=0.2131; p=0.6684). (B) Statistically significant decreases were not found
at individual punch sites, but DOAPC/DA ratios were found to be lower in DNSP-11
versus vehicle treated NHPs in the caudate nucleus (F(1,4)=0.6634; p=0.4611). Data
were analyzed using a RW Two-way ANOVA with Bonferroni’s multiple comparison test.
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Data are presented as the mean + SEM, (n=3 punches per tissue punch site). Please
refer to Figure 4.4 for punch site location.
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Figure 4.16 Ratio of [(DOPAC+HVA)/DA] at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) Statistically significant decreases were not found at individual punch sites, but
[(DOPAC+HVA)/DA] ratios were found to be lower in DNSP-11 versus vehicle treated
NHPs in the putamen (F(1,4)=0.01287; p=0.9151). (B) Statistically significant decreases
were not found at individual punch sites, but [(DOPAC+HVA)/DA] ratios were found to be
lower in DNSP-11 versus vehicle treated NHPs in the caudate nucleus (F(1,4)=1.037;
p=0.3661). Data were analyzed using a RW Two-way ANOVA with Bonferroni’s multiple
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comparison test. Data are presented as the mean + SEM, (n=3 punches per tissue
punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.17 Average Tissue Levels of DA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) Decreases in DA were found at all individual punch sites in DNSP-11 versus vehicle
treated NHPs. (B) Decreases in DA were found at all individual punch sites in DNSP-11
versus vehicle treated NHPs. Data are presented as the mean + SEM, (n=2 punches per
tissue punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.18 Average Tissue Levels of DOPAC at Individual Tissue Punch Sites in
Vehicle versus DNSP-11 Treated NHPs
(A) Decreases in DOPAC were found at all individual punch sites in DNSP-11 versus
vehicle treated NHPs. (B) Decreases in DOPAC were found at all individual punch sites
in DNSP-11 versus vehicle treated NHPs. Data are presented as the mean + SEM, (n=2
punches per tissue punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.19 Average Tissue Levels of HVA at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) Decreases in HVA were found at all individual punch sites in DNSP-11 versus
vehicle treated NHPs. (B) Decreases in HVA were found at all individual punch sites in
DNSP-11 versus vehicle treated NHPs. Data are presented as the mean + SEM, (n=2
punches per tissue punch site). Please refer to Figure 4.4 for punch site location.

127

Figure 4.20 Ratio of DOPAC/DA at Individual Tissue Punch Sites in Vehicle versus
DNSP-11 Treated NHPs
(A) Variations in DOPAC/HVA ratios were found at all individual punch sites in DNSP-11
versus vehicle treated NHPs in the putamen. (B) Increases DOPAC/HVA ratios were
present at all individual punch sites in DNSP-11 versus vehicle treated NHPs in the
caudate nucleus. Data are presented as the mean + SEM, (n=2 punches per tissue
punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.21 Ratio of HVA/DA at Individual Tissue Punch Sites in Vehicle versus DNSP11 Treated NHPs
(A) Variations in HVA/DA ratios were found at all individual punch sites in DNSP-11
versus vehicle treated NHPs in the putamen. (B) Variations in HVA/DA ratios were found
at all individual punch sites in DNSP-11 versus vehicle treated NHPs in the caudate
nucleus. Data are presented as the mean + SEM, (n=2 punches per tissue punch site).
Please refer to Figure 4.4 for punch site location.
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Figure 4.22 Ratio of [(DOPAC+HVA)/DA] at Individual Tissue Punch Sites in Vehicle
versus DNSP-11 Treated NHPs
(A) Variations in [(DOPAC+HVA)/DA] ratios were found at all individual punch sites in
DNSP-11

versus

vehicle

treated

NHPs

in

the

putamen.

(B)

Variations

in

[(DOPAC+HVA)/DA] ratios were found at all individual punch sites in DNSP-11 versus
vehicle treated NHPs in the caudate nucleus. Data are presented as the mean + SEM,
(n=2 punches per tissue punch site). Please refer to Figure 4.4 for punch site location.
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Figure 4.23 Neurochemical Metabolite Levels in a Mild Lesion Model After DNSP-11
Treatment
Average DA and metabolite levels at each individual tissue punch (P) site in both the
putamen and caudate nucleus in a mild lesion model (<80 % depletion of striatal DA).
(A-F) N=1 punch per tissue punch site. Please refer to Figure 4.4 for punch site location.
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Figure 4.23 Neurochemical Ratios in a Mild Lesion Model After DNSP-11 Treatment
Average DA and metabolite levels at each individual tissue punch (P) site in both the
putamen and caudate nucleus in a mild lesion model (<80 % depletion of striatal DA).
N=1 punch per tissue punch site. Please refer to Figure 4.4 for punch site location.
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Figure 4.24 125I Signal in Brain Biopsy Tissue Punches Throughout the CNS
125

I radioactive signal in brain biopsy tissue punches taken throughout the brain

parenchyma. Multiple 2 mm diameter tissue biopsy punches were taken of the frontal
cortex (n=12), motor cortex (n=12), occipital cortex (n=12), caudate nucleus (n=8),
putamen (n=9), nucleus accumbens (n=2), globus pallidus (n=4), amygdala (n=2), and
cerebellum (n=12). Data are presented as the mean + SEM.
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Table 4.5.

125

I Signal in the CNS and Peripheral Samples 60 Minutes After the Start of

the First Intranasal Dose.
125

I signal was found in all tissue, CSF, urine and blood samples. CPM values were

normalized per mg or ml of sample. Original CPM values are also presented here.

CNS Samples

CPM (Counts Per Minute)

CMP/mg or ml

Olfactory Bulbs

3434 + 789

164 + 35

Frontal Cortex

227 + 13

31 + 2

Motor Cortex

213 + 191

30 + 1

Occipital Cortex

172 + 8

27 + 0.7

Caudate

228 + 10

37 + 2

Putamen

278 + 9

41 + 1

Accumbens

259 + 1

38 + 3

GP

270 + 9

46 + 2

Amygdala

128 + 16

24 + 3

Cerebellum

232 + 11

32 + 1

Trigeminal Nerve

1133 + 517

92 + 24

Pituitary Gland

29145

274

CSF

2534

25344

Thyroid Gland

8181002

15486

Urine

1984510

19845100

15 (min)

77846

778464

30 (min)

89164

891638

45 (min)

98970

959697

60 (min)

99703

997025

Peripheral Samples

Blood Samples
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Figure 4.25 Autoradiography Analysis of 125I Signal in the Rostral Regions of the CNS
125

I signal found throughout the brain parenchyma at 60 minutes after the start of the first

intranasal dose. 2 mm thick rostral to caudal coronal brain sections from one NHP were
exposed to film for 24 hours in a GE cassette and then immediately processed using a
Typhoon 9400 (GE Health Care).

125

I present signal was present in the white tracts of

the brain including the corpus callosum, olfactory tracks and the internal capsule. Please
refer to Fig. 26 for corresponding 2 mm serial coronal brain sections. Sections G & I
punches taken for neurochemical analysis (see Figure 4.4).
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Figure 4.26 Corresponding Brain Slabs for Autoradiography Analysis for Rostral Regions
of the CNS
2 mm thick coronal brain slabs used for autoradiography analysis that correspond with
Figure 4.25. Tissue bunches for gamma counting analysis spanned the (rostral to
caudal) the frontal, motor and occipital cortices (n=6 punches per hemisphere); the
caudate nucleus (n=4 punches per hemisphere), putamen (n=6 punches per
hemisphere), GP (n=2 punches per hemisphere), and nucleus accumbens (n=1 punch
per hemisphere); the amygdala (n=1 punch per hemisphere), and the cerebellum (n=6
punches per hemisphere).
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Figure 4.27 Autoradiography Analysis of 125I Signal in the Caudal Regions of the CNS
125

I signal found throughout the brain parenchyma at 60 minutes after the start of the first

intranasal dose. 2 mm thick rostral to caudal coronal brain sections from one NHP were
exposed to film for 24 hours in a GE cassette and then immediately processed using a
Typhoon 9400 (GE Health Care).

125

I present signal was present in the white tracts of

the brain including the corpus callosum, olfactory tracks and the internal capsule. Please
refer to Figures 4.26 & 27 for corresponding 2 mm serial coronal brain sections. Section
2 punches taken for neurochemical analysis (See Figure 4.4).
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Figure 4.28 Corresponding Brain Slabs for Autoradiography Analysis for Caudal Regions
of the CNS
2 mm thick coronal brain slabs used for autoradiography analysis that correspond with
Figure 4.27. Tissue bunches for gamma counting analysis spanned the (rostral to
caudal) the frontal, motor and occipital cortices (n=6 punches per hemisphere); the
caudate nucleus (n=4 punches per hemisphere), putamen (n=6 punches per
hemisphere), GP (n=2 punches per hemisphere), and nucleus accumbens (n=1 punch
138

per hemisphere); the amygdala (n=1 punch per hemisphere), and the cerebellum (n=6
punches per hemisphere).
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CHAPTER FIVE: Major Conclusion and Future Directions

The studies contained in this manuscript are the first to definitively demonstrate
the potential of DNSP-11 administered intranasally in two different animal models of
Parkinson’s disease (PD). Our data support that the repeated intranasal administration
of DNSP-11, using a pre-determined dose that stimulates dopamine (DA) turnover
[(DOPAC+HVA)/DA] in the SN and striatum, is neuroactive in a severe unilateral 6OHDA lesion rat model of PD. We then developed a methodology to test the repeated
intranasal administration of DNSP-11 in awake, vertically chair trained rhesus
macaques. Here we show early indications that DNSP-11 is able to induce bilateral
neurochemical changes in the striatum, and increase motor performance of the upper
limbs in MPTP hemiparkinsonian rhesus macaques. In total, these detailed studies in
animal models of PD have provided a methodology for the intranasal administration of
DNSP-11 that can be further expanded upon; while supporting this approach as a
favorable alternative to the direct delivery of similar protein and peptide neuroactive
compounds to the CNS for the treatment of PD. This chapter will touch upon some of the
important questions to be addressed in order to advance intranasally administered
DNSP-11 forward as a potential treatment option for PD.
In our severe unilateral 6-OHDA rat study, DNSP-11 was repeatedly
administered intranasally using light isoflurane anesthesia (7 days a week), 1 week prior
to 6-OHDA, 60 minutes prior to 6-OHDA infusion and 5 weeks post 6-OHDA infusion
(Stenslik et al., 2015). From this study design, two major questions need to be
addressed in future experiments examining the efficacy of intranasally administered
DNSP-11 in rats. The first question stems from a study presented by Datla and coauthors showing that isoflurane compared to other anesthetics used during 6-OHDA
infusion increased both TH+ dopaminergic cell loss in the substantia nigra pars
compacta (SNpc) and striatal DA depletion as measured by HPLC-EC (Datla et al.,
2006). These data support our findings as we saw an increase in the striatal depletion of
DA and tyrosine hydrozylase (TH) neuronal cell loss in the SNpc using stereotaxic
coordinates and 6-OHDA concentrations to induce a more partial lesion of the
dopaminergic nigrostriatal system (Kirik et al., 1998, Stenslik et al., 2015). Additionally,
the choice of anesthetic repeatedly used in our study may also support the attrition
observed in both the vehicle and DNSP-11 treated rats at week 4 of d-amphetamineinduced rotation (Stenslik et al., 2015). An odd occurrence, as previous studies using the
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same d-amphetamine dose (2.5 mg/kg, i.p.) were not known to cause attrition, even at
higher concentrations (5.0 mg/kg, i.p.) (Hudson et al., 1993). For these reasons, future
studies examining the intranasal administration of DNSP-11 in rats may benefit from
changing the dosing regimen to minimize exposure to an anesthetic, or through the
development of a methodology for delivering it in awake animals. The second major
question to be addressed stems from our study design, as rats were treated with DNSP11 both pre and post 6-OHDA infusion (Stenslik et al., 2015). Therefore, future
experiments are needed to potentially unmask DNSP-11’s potential as either a
neuroprotective and/or restorative agent on the dopaminergic nigrostriatal system.
To eliminate the use of an anesthetic and test the efficacy of intranasally
administered DNSP-11 in higher order animals, we developed a methodology to
evaluate the repeated intranasal administration of DNSP-11 in awake, vertically chairtrained rhesus macaques using an atomizer system. To both minimize the number of
NHPs used in this study, a dose escalation allowed us to examine: (1) the efficacy of
different concentrations of DNSP-11 while also monitoring potential adverse clinical sideeffects, and (2) to determine if different concentrations had a behavioral effect. While the
results of this study indicate both the efficacy and safety of repeatedly delivering DNSP11 intranasally in awake rhesus macaques numerous questions need to be addressed.
First, this study design examined increasing doses of DNSP-11 as a function of
time. Both the neurochemical and behavioral findings presented here could be the result
of a “build-up” of DNSP-11’s effects on the nigrostriatal system over time versus that at
specific dosages. While we did examine doses in the NHP study that were half-log steps
above the optimal dose used in our rat studies, future experiments would benefit from
examining the repeated intranasal administration of DNSP-11 in normal (unlesioned)
rhesus macaques at specific concentrations to determine an optimal dose (Stenslik et
al., 2015).
Neurochemical evidence further supports finding an optimal dose to be
administered intranasally in NHPs, as DA and/or its metabolites DOPAC & HVA were
suppressed in the putamen, caudate nucleus, nucleus accumbens and globus pallidus in
both hemispheres of DNSP-11 treated NHPs compared to vehicle. Interestingly, DA
turnover remained unchanged in the unlesioned hemisphere of DNSP-11 treated NHPs
compared to vehicle. While puzzling, previous studies examining higher doses of GDNF
have also found a similar suppression of DA and metabolites (Zhang et al., 1997).
Additionally, the non-human primate study presented in this body of work examined the
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repeated (4 days on, 3 days off) intranasal administration of DNSP-11. Future studies
may also benefit in examining a modification to the current dosing regimen (4 days on, 3
days off) used in the present NHP study design to determine an optimal dosing
paradigm.
The second major question that needs to be addressed from the present NHP
study is to examine both DNSP-11’s potential as either a neuroprotective and/or
restorative peptide in both partial and severely MPTP lesioned rhesus macaques.
Evidence from the neurochemical data presented in this body of work, would suggest
that DNSP-11 may be restorative in NHPs which received a milder lesion. Therefore,
after determining both an optimal dose and/or dosing regimen, future studies examining
the repeated intranasal administration of DNSP-11 should focus on DNSP-11’s effects
prior to and post MPTP administration. Studies examining the neuroactive properties of
DNSP-11 administered intranasally in milder lesioned MPTP NHPs is important as the
FDA traditionally limits clinical trials to patients in the later stages of PD, due to the
invasiveness of directly delivering compounds to the CNS. Non-invasive intranasal
administration of DNSP-11 would allow for the testing of such an option in patients in the
earlier stages of PD.
Aging models would also be interesting to test the effects of intranasally
administered DNSP-11 in as well. In aging individuals, it has been shown that there is a
slowing of motor movements and other Parkinsonian like features (Kish et al., 1992,
Bennett et al., 1996, Zhang et al., 2000). It has been suggested that these Parkinsonian
features observed in aging individuals and animals (rats and non-human primates) are
likely associated with nigrostriatal dysfunction of the dopaminergic system, although
there is not a striking loss of DA neurons (Flood and Coleman, 1988, Gerhardt et al.,
1995, Emborg et al., 1998, Morris et al., 1999, Stanford et al., 2001). The data presented
in this dissertation suggests that DNSP-11, administered intranasally, has restorative
effects on the dopaminergic nigrostriatal system. Therefore, future studies could benefit
from examining the effects of intranasally administered DNSP-11 in aged animals.
The preliminary data from our tracer studies contained in this manuscript
suggest, that there is a higher level of
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I signal in the white matter tracks in comparison

to grey matter at 60 minutes after the start of the first intranasal dose (t=0). Both FITC
and
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I-labeled DNSP-11 data examining its up take in cell culture and isolated CNS

mitochondria, suggest that the peptide is internalized in as little as 15 minutes (TurchanCholewo, 2015). Therefore, future tracer studies in NHPs should examine earlier and
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later time points after intranasal administration that mirror our tracer studies in rats
(Stenslik et al., 2015). Tracer studies examining different time points could help to
determine if

125

I signal is present at higher levels, for example, in grey matter tissues

samples earlier than 60 minutes due to its rapid internalization and degradation.
Depending on the results of the experiments suggested in this chapter, the option
of enhancing DNSP-11’s delivery to the CNS after intranasal administration can be
addressed. For example, formulation changes could include the encapsulation of DNSP11 in cyclodextrins, microemulsions, or nanoparticles (Dhuria et al., 2009d), and/or with
liposomes which have been recently used to enhance GDNF’s delivery after intranasal
administration (Migliore et al., 2014). In summary, the experiments contained in this
dissertation illustrate the potential of DNSP-11 to be non-invasively administered
intranasally, as a means to circumvent the challenges associated with directly delivering
potential biotherapeutics to the CNS for the treatment of PD. Future experiments can
now utilize the detailed methodology contained in this dissertation for delivering DNSP11 intranasally in both rats and NHPs, to advance our understanding of its protective and
restorative properties on the DA nigrostriatal system as a potential candidate for the
treatment of PD.

Copyright © Mallory Joan Stenslik 2015
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